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 i 
Abstract 
Background: There is an inverse relationship between Vitamin D concentrations and 
KOA but the effects of Vitamin D supplementation on KOA symptoms are poorly 
understood. Physical activity (PA) is recommended for KOA yet evidence on how to 
sustain increased PA is limited. Online PA interventions offer advantages including 
personalisation and scalability. This pilot study explored the acceptability and feasibility 
of vitamin D and PA interventions within an older obese KOA population. 
Methods: Patients meeting our inclusion criteria (age 50-70y, BMI 30-40kg/m2, 
diagnosed symptomatic KOA ACR criteria) were recruited (March-April/September–
December 2015) from eight GP surgeries. Eligible individuals attended a study visit 
where blood samples, questionnaires, knee assessments and PA accelerometry (3-5 day 
accelerometry) were taken. Screening was performed for the 3-month pilot intervention 
study (25(OH)D 25-50nmol/L OR <60min/week moderate activity) and eligible 
participants were given either daily Vitamin D supplements (2000IU [50µg]) or access to 
an online PA programme.  Assessments were repeated 6 and 12 weeks later and a 
qualitative interview to explore participants views on acceptability of the study 
performed immediately after the 12 week visit.  
Results: Eight GP surgeries identified 791 participants of whom 45 (5.7%) were eligible 
and attended the study visit. Pilot intervention study screening yielded 17 (2.1%) 
participants; nine were allocated to each intervention group. The average compliance 
to the vitamin D intervention was 99% compliance (defined as % tablets taken) and 67% 
compliance with the PA interventions (defined as use of website beyond registration 
visit). The PA intervention resulted in a mean decrease of 107 minutes (95% CI: -259.8, 
45.0) daily sedentary time and mean increase of 4.4 minutes (95% CI -3.0, 11.8) daily 
moderate activity time. The Vitamin D intervention led to a mean increase in plasma 
25(OH)D concentration of 51nmol/L (SD: ±23.1). Feedback from interviews suggested 
recruitment and interventions were acceptable and suggestion for improvements on 
study materials were made.  
 ii 
Conclusion: Recruitment from GP surgeries and delivery of a Vitamin D and online-based 
PA intervention is feasible. Most participants were compliant to study procedures and 
data suggest improved PA and vitamin D status after the respective interventions. 
Further studies are needed to further pilot test improvements and test the effectiveness 
of the interventions. 
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Chapter 1. Introduction 
1.1 Osteoarthritis 
Osteoarthritis (OA) is the most common type of arthritis[1], incidence of which 
increases substantially with age [2]. It commonly occurs in the knee, hip, and hand 
joints and is usually associated with pain, stiffness and decreased mobility leading to 
significant functional impairment [3]. 
The pathophysiology of OA is complex and poorly understood, being multifactorial and 
involving a range of individual systemic biochemical and local biomechanical factors. 
Indeed it is still disputed whether OA is a single or multiple disorders [2]. 
Understanding of OA including the very definition of OA, has evolved substantially in 
recent decades. In this section I aim to summarise the most recent research regarding 
the pathophysiology, risk factors and burden of Knee OA (KOA). 
1.1.1 Classification and Diagnosis 
Because of a lack of a ‘diagnostic’ test for KOA, defining and diagnosing KOA using non-
invasive methods can be difficult. Therefore we must rely on readily available methods 
such as x-ray, laboratory and clinical examination findings in order to diagnose KOA in 
practice. [4] 
There have been many guidelines published to aid the diagnosis of OA for healthcare 
and research purposes. Below I have outlined some of the most common guidelines 
used for the diagnosis of KOA. 
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Table 1.1: American Rheumatology Association Diagnostic and Therapeutic Criteria 
Committee subcommittee on OA classification criteria for OA. This is split into 2 main 
sections: Primary (Idiopathic) and Secondary OA. Taken from Table 1 [4]. 
1.1.1.1 Classification of OA 
Broadly, OA can be Primary /Idiopathic (in which there is no obvious underlying cause) 
or Secondary (as a direct result of trauma, repetitive joint motion or another 
underlying disease) [4] (Table 1.1). Treatment of OA will vary according to the cause, 
which I will discuss further in Section 1.5. 
I. Idiopathic II. Secondary
A. Localised A. Post-traumatic
1. Hands: e.g. Heberden's and Bouchard's nodes (nodal), 
erosive interphalangeal arthritis (non-nodal), scapho-
metacarpel, scaphotrapezial. 
B. Congenital or developmental diseases
2. Feet :e.g., hallux valgus, hallux rigidus, contracted toes 
(hammer/cockup toes), talonavicular
1. Localised: a) Hip diseases, e.g. Legg-Calve-Perthes, 
congenital hip dislocation, slipped capital femoral 
epiphysis, shallow acetabulum, b) Mechanical and local 
factors, e.g. obesity (?), unequal lower extremity length, 
extreme valgus/varus deformity, hypermobility 
syndromes, scoliosis
3. Knee a) Medial compartment, b) Lateral compartment, 
c) Patellofemoral compartment (e.g. chondromalacia)
2. Generalised: a) Bone dysplasias, e.g. epiphyseal 
dysplasias, spondulo-apophyseal dysplasia, b) 
Metabolic disease, e.g. hemochromatosis, ochronosis, 
Gauchers disease, hemoglobinopathy, Ehler-Danlos 
disease
4. Hip: a) Eccentric (superior), b) Concentric (axial, 
medial), c) Diffuse (coxac senilis)
C. Calcium deposition disease
5. Spine (particularly cervical and lumbar): a) 
Apophyseal, b) Intervertebral (disk), c) Spodylosis 
(osteophytes), d) Ligamentous (hyperostosis [Forestier's 
disease, or DISH])
1. Calcium pyrophosphate deposisition disease                
2. Apatite arthropathy                                                                      
3. Destructive arthropathy (shoulder, knee)
6. Other single sites: e.g. shoulder, temporomandibular, 
sacroiliac, ankle, wrist, acromioclavicular 
D. Other bone and joint disorders
B. Generalised: Includes 3 or more areas listed 
above (Kellgren-Moore)
e.g. avascular nercrosis, rheumatoid arthritis, gouty 
arthritis, spetic arthritis, Pagets disease, osteopetrosis, 
osteochondritis
E. Other Diseases
1. Endocrine diseases: e.g. diabeties mellitus, 
acromegaly, hypothyroidism, hyperparathyroidism          
2. Neuropathic arthropathy (Charcot joints)                        
3. Miscellaneous e.g. frostbite, Kashin-Beck disease, 
Caisson disease
Classification for subsets of osteoarthritis
1. Small (peripheral) and spine                                                    
2. Large (central) and spine                                                            
3. Mixed (peripheral and central) and spine
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1.1.1.2 Diagnosis of KOA 
a) Kellgren and Lawrence Score  
Commonly, x-rays are used in the diagnosis and grading of KOA. The most widely 
accepted x-ray based system for grading KOA changes is the Kellgren & Lawrence (K&L) 
score [5], developed in 1957, which has been recommended by the WHO since 1961 
[4]. The K&L system aims to identify evidence of KOA and to define the severity of 
KOA. It also provides a tool to track changes in the osteoarthritic joint over time. The 
score is formed by looking for specific features of the joint, the presence of which 
indicate the presence of OA. These features are: 
(1) Osteophytes (bony outgrowths on the margin of the joint) 
(2) Cartilage/joint space narrowing 
(3) Subchondral bone sclerosis 
(4) Cyst formation  
(5) Abnormal bone shape [6] 
Depending on the amount and severity of the changes seen, a score will be assigned 
from Grade 0 (no evidence of OA) to Grade 4 (evidence of severe OA) [7]. 
Although the K&L scoring system provides an objective method of assessing KOA 
presence and severity, it has several limitations. Firstly, assigning a grade to an x-ray 
image can be quite a subjective process and can vary between interpreters. Secondly, 
the score does not take into account the fact that a large proportion of people may 
have mild to severe radiological joint changes and no symptoms of OA. Therefore, 
those identified as having KOA using the K&L system may not be those in need of any 
medical assistance.  
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b) American College of Rheumatology (ACR) Criteria  
 
Table 1.2: A summary of the Clinical, Laboratory and Radiographic ACR criteria.ESR: 
Erythrocyte Sedimentation Rate, RF: Rheumatoid Factor, SF OA: Synovial fluid signs of OA 
(clear viscous or white blood cell count <2000mm3). Adapted from [4]. 
The American College of Rheumatology (ACR) developed specific criteria for the 
diagnosis of KOA in 1986 (see Table 1.2) with the aim of clarifying the definition of KOA 
and providing a standard for defining KOA. After assessing 28 historical, 16 physical 
examination, 3 laboratory test, 10 synovial fluid and 28 radiographic features, 3 sets of 
classification criteria were developed: Clinical Examination and Laboratory Tests (e.g. 
for use in GP surgeries), Clinical Examination, Laboratory and Radiographic Tests (e.g. 
useful in clinical trials or where radiographs are available) and Clinical exam (e.g. 
population survey). The criteria aim to identify people with OA from other rheumatic 
conditions with a certain degree of sensitivity and specificity, which varies between the 
different classifications criteria developed. [4] However, a 2006 review of the use of 
ACR in identifying KOA cases in the general population found only 41% sensitivity 
(compared with the 89% originally reported) in their KOA sample for the ACR Clinical 
Criteria. These authors concluded that use of the ACR clinical criteria resulted in a high 
level of ‘false negative’ results and that the criteria may be sensitive to advanced 
disease only, therefore alternative means need to be employed for the identification 
of mild-moderate KOA [8]. 
 
Clinical and Laboratory Clinical and Radiographic Clinical 
Knee Pain                                    
AND >5 OF THE FOLLOWING:                  
- Age >50 years                                    
- <30 mins morning stiffness      
- Crepitus on active motion        
- Bony tenderness                          
- Bony enlargement                       
- No palpable joint warmth         
- ESR <40mm/hr                               
- RF <1:40                                            
- SF OA 
Knee Pain                                          
AND >1 OF THE FOLLOWING:       
- Age                                                     
- <30min morning stiffness         
- Crepitus on active motion                
- Osteophytes
Knee Pain                                          
AND >3 OF THE FOLLOWING:      
- Age                                                     
->30mins morning stiffness        
- Crepitus on active motion        
- Bony tenderness                           
- Bony Enlargement                                    
- No palpable joint warmth
92% sensitivity, 75% specificity 91% sensitivity, 86% specificity 95% sensitivity, 69% specificity
ACR Criteria for Idiopathic KOA
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c) National Institute for Health and Care Excellence (NICE) Guidelines  
In the UK, NICE (who provide evidence-based guidelines and information on health 
conditions for use in healthcare practice [9]) have produced evidence-based guidelines 
on the identification and treatment of OA. Diagnosis of OA is based on 3 criteria: 
 Age: >45yrs 
 Activity related joint pain 
 Morning stiffness in the joint <30mins 
It was concluded that radiological evidence of OA was not needed for diagnosis as x-
ray changes were not consistently linked with symptoms of OA. Therefore, a diagnosis 
of OA is to be made without further investigation if the above criteria are met. 
However, if an alternate diagnosis is possible it is recommended that further 
procedures e.g. imaging, are carried out to eliminate these alternate diagnoses [10].  
1.2 Prevalence and Incidence of OA 
1.2.1 Worldwide 
OA is common worldwide but there are relatively few large population based studies 
which makes estimating worldwide incidence and prevalence of OA difficult. Other 
factors, which make estimating OA prevalence and incidence difficult, are discussed 
further in section 1.2.3. 
 
 
 
 6 
 
 
Figure 1.1: Global burden of disease 2010 data on the total amount of available data (n= of 
studies) by geographical location for KOA prevalence estimates (top) and hip OA prevalence 
estimates (bottom). Taken from Figure 1 &2 [1, 11] 
The largest available epidemiological study of OA prevalence is the 2010 Global Burden 
of disease study which systematically reviewed and compiled data on the prevalence 
of symptomatic, radiologically confirmed (K&L Grade 2-4) hip OA (HOA) and KOA. In 
this data compilation, Back OA was excluded on the basis it would be included in 
estimates of back and neck pain. Prevalence estimates were derived from 102 
published studies with most studies originating from Western Europe and North 
America (see Figure 1.1). Prevalence of KOA in 2010 was estimated at 3.8% globally, 
with a higher prevalence in females (mean 4.8%) than in males (mean 2.8%), with 
prevalence peaking at 50years (see Figure 1.2). HOA was less common than KOA, with 
a worldwide prevalence estimate of 0.85%, with, again, higher prevalence in females 
(mean 0.98%) than in males (mean 0.7%). Prevalence increased steadily with age (see 
Figure 1.2) with no  peaking [11]
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Figure 1.2: Prevalence (y-axis) of radiographic symptomatic KOA in males (top left) and females (bottom left) and radiological symptomatic HOA in 
males (top right) and females (bottom right) by age (x-axis) and country (individual’s lines).Taken from Figure 3 and 4 [11]
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Estimates of prevalence of OA will vary according to the definition of OA used 
(symptomatic or radiographic criteria), the joint affected and geographical location. In 
the large American cohort study, The Framingham Study, prevalence of radiological 
and symptomatic OA at several different sites (hand, hip and knee) was estimated. For 
HOA, age standardised prevalence of radiographic OA (defined as K&L grade >2) was 
19.6% which was almost 5 times higher than age-standardised prevalence for 
symptomatic OA (defined as radiographic OA plus hip pain) which was 4.2%. [12] 
Similarly, for KOA, prevalence of radiological KOA (K&L grade >2) at 15.7% was more 
than 50% higher than the prevalence of symptomatic KOA (pain experienced on most 
days >1month) estimated to be 9.5%. Prevalence increased with age and was generally 
higher in women than in men (see Table 1.3).[13] 
 
Table 1.3: The prevalence of radiographic and symptomatic KOA in the Framingham Cohort 
(n=1805). Adapted from Table 3 and table 5 [13] 
 
Age standardised prevalence of radiographic Hand OA (K&L grade >2) was 44.2% in 
women and 37.7% in men, which, again, were several times higher than the age 
standardised prevalence of symptomatic Hand OA (radiographic OA plus pain/stiffness) 
which was 14.4% and 6.9% in women and in men respectively [14]. Compared with 
data on OA prevalence, there are few reports on incidence rates of OA. However, an 
American cohort study using data from a large community health centre estimated 
incidence rates of 100, 88 and 240/100,000 person years for hand, hip and knee OA 
respectively [15]. 
1.2.2 UK 
According to estimates by Arthritis Research UK (ARUK), 8.75 million people in UK have 
sought treatment for OA which equates to a third of people aged >45years. In the UK, 
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4.11, 2.46, 1.77 and 1.56 million people were estimated to have OA of the knee, hip, 
foot/ankle and hand/wrist respectively [16]. According to data from ARUK, this 
equates to 10.92% and 18.25% of the total UK population having hip and knee OA 
respectively [17]. KOA is the most common form of OA in the UK, contributing to half 
of all consultations regarding OA. [16] 
Prevalence of OA differs by gender, BMI and physical activity level. Prevalence of KOA 
is higher in Females (19.7%, n=2,332,130) than in males (16.55%, n=1,775,721) in the 
UK. 
OA prevalence also increases with increasing age and BMI (see Table 1.4 and Table 1.5) 
[17]. 
 
Table 1.4: The association of age on UK prevalence rates (% of total UK population) of KOA 
and HOA. Adapted from [17] 
 
Table 1.5: The association of BMI on UK prevalence rates (% of total UK population) of KOA 
and HOA. Adapted from [17] 
1.2.3 Problems with Estimating OA prevalence and Incidence 
The Global Burden of Disease study 2010 pointed out many limitations to estimating 
OA prevalence and incidence.  
Firstly, as most of the data regarding OA prevalence is concentrated within North 
America and Western Europe, it is unclear if estimates based on this are representative 
of worldwide prevalence. The authors recommended that future research should focus 
on population studies in areas of missing data (see Figure 1.1), such as South America, 
Africa and parts of Asia, so that global estimates are more accurate and representative.  
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Secondly, estimates of prevalence and incidence can vary depending on the definition 
of OA used, with studies using estimates based on radiographic evidence being 
generally higher than estimates based on symptomatic OA definitions. This presents a 
problem with the comparability of studies which use different definitions of OA. [11] 
1.2.4 Disease Burden 
As the global population ages and prevalence of obesity increases, it is important to 
consider the burden of OA, as this is set to become a major problem in the future [11]. 
The WHO scientific group on Rheumatic disease estimated that 10% of the global 65+ 
population have clinical problems attributable to OA [18] and due to a global ageing 
population and increasing obesity rates this is expected to rise to 140% of current OA 
prevalence by 2025 [19]. 
The burden caused by OA can be viewed from different perspectives, including 
implications for quality of life for the individual sufferers and direct and indirect cost to 
society. 
1.2.4.1 Burden to the Individual 
KOA often results in pain and severe disability and affects everyday life because it 
limits ability to perform activities of daily living (ADLs) such as walking, climbing stairs 
and squatting.  These symptoms and related limitations often lead to more far 
reaching impacts on the patients’ lives including social interaction, mental functioning 
and sleep quality.  In consideration of this Health-Related Quality of Life (HRQoL) is 
often measured in studies of OA populations. HRQoL comprises 5 dimensions; physical, 
psychological, social and cognitive functioning and well-being [19]. Previous studies 
have consistently found lower HRQoL scores (indicating worse outcomes) in KOA 
populations compared to the general population which inversely correlates with pain 
and radiographic KOA severity [20, 21]. As knee pain is the strongest correlate 
regarding HRQoL in KOA patient, treatments which aim to improve quality of life in this 
clinical population need to be effective in reducing pain [19]. 
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1.2.4.2 Burden to Society 
The GBD 2010 study identified KOA as the 11th largest determinant of global disability 
(rising from 15th place in 1990) and estimated that it contributed to 2.2% (17.1 million) 
of the global years lived with disability [11]. 
In an analysis of DALYs (disability adjusted life years - a combination of years of life lost 
due to premature mortality and years lived with disability) for 291 diseases worldwide, 
MSK disorders accounted for 6.8% of total DALYs with 10% of this being due to OA. 
This equates to 249 DALYs per 100,000 people according to 2010 estimates. [22] 
Apart from the physical restrictions associated with OA, there are also social and 
mental impacts e.g. limitations on social interaction, mental functioning and quality of 
sleep [19]. Lower Health Related Quality of Life (HRQoL) has also been reported in 
those with KOA which inversely correlates with joint pain and disease severity [19]. 
a) Direct Costs 
Direct costs involve those directly related to the treatment of OA. Estimates of direct 
costs are variable depending on the geographical location and study population. Costs 
of treating people in the USA and Canada are approximately double those who do not 
have OA, at a cost of $3952/year in Canada and $5294-5704/year per person with OA 
in the USA [23].The direct costs of OA in Italy (as a result of hospitalisation, diagnosis 
and treatment) was estimated at €934/year, with 25% of that cost attributable to 
hospitalisation, despite the low numbers of patients hospitalised in the sample. 
Therapy was the smallest component of costs equivalent to €144/patient/year [24]. 
There is no published research data relating to direct costs of OA in the UK. However, a 
2008 costing report published by NICE found that, in 2005-2006, 167,000 and 1.4 
million OA patients were prescribed topical and ORAL NSAIDs respectively, at a cost of 
£8.5 million and £25 million respectively. In addition, £25 million was spent on 
arthroscopic debridement procedures, which are limited for use only in patients with 
mechanical problems due to their OA. It was estimated that £852 million was spent on 
hip and knee replacements in 2010, far outstripping the cost of other OA treatments 
[25]. 
b) Indirect Costs 
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Indirect costs refer to costs incurred not as a result of medical cost for OA, but due to 
loss in wages, productivity and increased costs such as childcare and home care 
needed as a result of OA. An analysis of costs related to OA concluded OA populations 
incurred several additional indirect costs compared to non-OA populations including; 3 
additional days of medical care per year, increased costs associated with home care, 
childcare and home remodelling and loss of jobs and earnings [23]. 
The indirect cost of OA in the UK is significant, with an estimated 32 and 30.6 million 
working days lost in 2002 and 2013 respectively due to musculoskeletal problems. 
Financial costs due to loss of work was also substantial, with £2.41 million paid in 
Disability Living Allowance (DLA) to those with arthritis, more than for heart disease, 
stroke and cancer combined. [25] 
A summary of the direct and indirect costs of OA in various countries was compiled by 
Chen 2012 [25], and is summarised in Table 1.6. 
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Table 1.6: Annual direct and indirect costs of OA (per patient and total population) in 7 
different countries. Taken from Figure 2 [25] 
1.3 Pathophysiology of KOA 
The pathogenesis of KOA is complex and current research is concentrating on the role 
of all joint tissues in the pathology of KOA. Broadly speaking OA can be considered an 
imbalance between the breakdown and repair of all the joint tissues, leading to a 
variety of pathological changes, including: 
 Hyaline cartilage loss 
 Subchondral bone remodelling 
 Capsular stretching 
 Quadriceps muscle weakness 
 Synovitis 
 Ligament Laxity 
 Development of bone marrow legions 
 Bone misalignment [26] 
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Figure 1.3: Model of OA of the biomechanical and inflammatory factors which cause 
structural damage in OA. Taken from Figure 1 [27]. 
Whilst many attempts have been made to compile a model of OA pathogenesis, these 
have been hampered by the complexity and changing ideas of what is involved in the 
pathogenesis of OA. However in a report by ARUK (2011), a model summarising the 
more recent evidence regarding OA pathogenesis was proposed (see Figure 1.3). This 
model highlights a shift from the ‘wear and tear’ hypothesis (which states that wear 
accumulated over a lifetime leads to the development of OA) to ‘tear, flare and repair’ 
where ‘tear’ represents some factor causing damage to the joint (e.g. overuse or 
obesity), ‘flare’ representing inflammatory processes which take place in OA, and 
‘repair’, the processes the joint undergoes to repair the damage. In the case of OA, this 
last ‘repair’ step may be suboptimal, leading to chronic damage or ‘tears’ which 
accumulate and result in OA. [28] 
It is thought OA is initiated when individual risk factors result in the changes in the 
joint which are illustrated in Figure 1.3. The exact risk factors (which I have explained 
in more detail in section 1.4) which drive the development of OA vary between 
individuals. 
According to the ‘wear, tear and repair’ theory, the process of KOA pathogenesis can 
be split into several main steps: 
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1. Biomechanical factors (‘Wear and Tear’): 
Biomechanical factors may contribute to Instability in the joint, which increases 
loading in the joint beyond its normal capacity. This can then lead to micro trauma or 
injury to the joints tissues. Such biomechanical factors may be the result of acute 
injury, ‘tear’, (such as ligament rupture or fracture of the bone’s articular surface) or 
more chronic in nature, ‘wear’, (e.g. mild developmental abnormalities, occupation 
related or repetitive activity, heavy loading on the joints, bone misalignment and 
obesity). The trauma or ‘tears’ which occur due to the above biomechanical factors are 
thought to contribute to the subsequent inflammatory effect in the joint seen in OA. 
[27] 
2. Joint Inflammation and Biochemical Mediators (‘Flare’): 
Historically, OA was considered a purely mechanical disease [29] but more recent 
studies have highlighted the important role of chronic inflammation in the 
pathogenesis and progression of OA [30-32]. It has been proposed that the 
inflammatory molecules produced as a response to biomechanical factors (and other 
potential systemic inflammatory drivers, e.g. metabolic syndrome, obesity and ageing) 
may tip the homeostasis of the joint tissues to net degradation.  
There are 2 main sites of inflammation in the OA joint: synovium and subchondral 
bone. Synovitis is now considered one of the hallmarks of KOA (discussed in more 
detail below) and bone marrow lesions in the subchondral bone are common. [27, 29, 
33]. Inflammatory cytokines and chemokines are thought to be produced by these 
tissues (mainly by the synovial cell and chondrocytes) locally, and can be measured in 
the synovial fluid of OA patients. Commonly these inflammatory molecules include; 
IL1, TNFα and MMPs (see the section 1.3.1 below for more detail about the 
inflammatory process in the joint tissues) and are thought to upregulate the 
production of enzymes e.g. aggrecanases and proteinases which degrade the cartilage. 
[33] 
 
 
 16 
3. Bone Response (‘Repair’): 
There are two main ways in which the bone responds to the above biomechanical and 
inflammatory insults; the formation of bone marrow oedema and cysts and the 
formation of osteophytes (see section 1.3.1 below for more detail about these bone 
responses). Both of these responses seem to be attempts to remodel and repair 
damaged bone tissue. In particular, bone marrow oedema correlates with joint pain in 
OA and with the progression of bone and cartilage lesions [27, 34]. 
1.3.1 The role of individual joint tissues in the pathogenesis of OA 
Considerable research has focused on identifying the involvement of the different joint 
tissues in the pathogenesis of OA. Whilst it is important to consider the process as a 
whole each tissue in the joint may respond differently to the OA development process, 
which eventually leads to disease.  
Below I have summarised the current evidence regarding the pathogenesis of OA in 
the various joint tissues. 
1.3.1.1 Cartilage 
Changes to the joint cartilage are the most characteristic pathological changes 
associated with OA. Cartilage is an avascular tissue composed of collagens, 
proteoglycans and chondrocytes, which maintain the extracellular matrix (ECM). 
During OA, the equilibrium between the breakdown and synthesis of the ECM by 
chondrocytes is disrupted, resulting in a net breakdown of cartilage tissue.  
Chondrocytes can respond to biomechanical influences (e.g. joint injury, instability and 
stress) and inflammatory molecules (e.g. cytokines and growth hormones), by 
prompting the release of degradative enzymes leading to the breakdown of the 
cartilage. I have summarised below two of the processes, inflammation and 
mechanical loading, which may lead to the expression of these degradative enzymes. 
MMPs (e.g.MMP-1, MMP-8, MMP-13, MMP-2, and MMP-9) and aggrecanases 
(ADAMTS-4, ADAMTS-5) are dysregulated in OA and degrade collagen and 
proteoglycans in the cartilage ECM. [35] 
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a) Inflammation 
Pro-inflammatory molecules, such as cytokines and chemokines, are produced by a 
number of joint cells in OA, including primarily, the synovial cells and chondrocytes. 
Chondrocytes then respond to these cytokines by producing proteinases and 
prostaglandins. These cytokines can promote the release of further pro-inflammatory 
cytokines, (e.g. IL-1 can induce the release of many pro-inflammatory cytokines) and so 
amplify the effect. Adipokines (pro-inflammatory cytokines released from white 
adipose tissue) have also been implicated in this process and may partly explain the 
link found between obesity and OA progression. This is discussed in more detail in 
section 1.4.2.1. 
b) Mechanical Loading 
Abnormal mechanical loading on the joint has been established as a risk factor for OA, 
particularly KOA. This process may be mediated though the chondrocytes which, in 
response to mechanical loading, increase expression of inflammatory molecules and 
proteases. This is a result of the activation of chondrocyte receptors, which usually 
activate in response to ECM components, but which are also activated by mechanical 
stimulation. [35, 36] 
1.3.1.2 Bone  
The role of the subchondral bone in the normal functioning of the joint is important, 
firstly in supporting the specific shape of the cartilage (important for smooth joint 
articulation) and for absorbing shock/stress applied to the joint. 
In OA, it is thought that repeated damage, or micro trauma, to the bone (brought 
about by biomechanical stresses) stimulates bone remodelling (where damaged bone 
is broken down by osteoclasts and replaced with new bone by osteoblasts). However, 
in OA, bone remodelling is increased and bone remodelling is high, resulting in 
abnormal growth and structural changes to the bone in response to damages [37]. It 
was originally thought that OA pathogenesis started with an increase in subchondral 
bone stiffness, which had subsequent impacts on the articular cartilage and a 
detrimental effect on the ability of the bone and cartilage to adapt to mechanical 
stresses [38]. However, it has been subsequently found that in early OA subchondral 
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bone density is decreased and existing bone hypomineralised, resulting in bone that is 
more easily deformed under mechanical pressure. The result of these bone changes is 
the increased loading on, and damage to, the cartilage. [34, 39] 
The abnormal bone growth, characteristic of OA subchondral bone, can take several 
forms and include: thickening of the subchondral plate, formation of osteophytes and 
formation of bone marrow lesions (BMLs) [37]. BMLs appear to be localized to areas of 
increased bone remodelling in the trabecular bone, which are sclerotic and 
hypomineralised, possibly the result of bone damage [40]. The presence and quantity 
of BMLs strongly correlate with knee pain, KOA progression and cartilage loss [41-43]. 
Osteophytes are bony outgrowths found at the edge of the joint. Osteocytes develop 
when periosteal cells (cells of the periosteum, a connective tissue which surrounds the 
bone) proliferate and differentiate into chondrocytes. These chondrocytes are then 
ossified and form the bony outgrowth which is the osteocyte. They are found in areas 
where joint loading occurs and are thought to contribute to the stability of the joint 
[34]. 
1.3.1.3 Synovium 
The presence of synovitis (inflammation of the synovial membrane which surrounds 
the joint) is now recognised as common and characteristic at all disease stages of OA, 
although to a lesser degree than that seen in RA. 
Several changes occur in the synovium during OA, including: 
- Thickening (hyperplasia) of the lining layer of the synovium 
- Increased vascularity 
- Infiltration of the synovium with inflammatory cells (mainly lymphocytes and 
monocytes) 
- Fibrosis of the synovium (seen in late stage OA) 
a) Synovial Changes in Early OA 
Studies in participant’s with early stage OA showed histological evidence of synovium 
lining proliferation, macrophage infiltration and increased vascularity [44]. Synovitis is 
fairly common and was present in 55% of participant’s with early OA [45]. 
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b) Synovial Changes in Late OA 
The main difference in the synovium of those with late stage OA is the type of 
inflammatory cell which infiltrates the synovium. Instead of macrophages, there are 
more lymphocytes, a characteristic which is more similar to RA [45]. 
Synovitis has an important role in cartilage degradation and in the pathophysiology of 
OA. The immune cell infiltrates and cytokines released by these immune and synovial 
fibroblast cells contribute to the destruction of the cartilage by stimulating the release 
of proteases which degrade the cartilage ECM (see Fig 1.4 below). The change in 
permeability of the normally semi-permeable synovial membrane during OA, also 
allows essential large molecules (lubrican and hyaluronic acid) to escape from the 
joint, resulting in a lack of joint lubrication. 
Synovitis is correlated with OA symptoms, predominantly pain and loss of function as 
well as rapid cartilage destruction [46, 47].  
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Figure 1.4: The sources and effect of pro-inflammatory cytokines in the pathogenesis of OA. 
Pro-inflammatory cytokines are secreted by inflammatory cells which have infiltrated the 
synovium and the synovial fibroblasts. Cytokines stimulate the release of proteinases which 
result in destruction of the cartilage. Taken from Figure 1 [48]. 
1.4 Risk Factors for OA 
Many potential risk factors for OA have been identified which may contribute to the 
development and progression of OA. These risk factors can be classified into systemic 
(those affecting the whole body) and local (those acting on the joint) factors. They can 
also be split into modifiable (factors which can be changed) and non-modifiable 
(factors which cannot be changed) risk factors (see Table 1.7)[2]. Classifying and 
identifying risk factors are important firstly for identifying the groups at high risk of OA, 
and secondly in the case of modifiable factors, as a basis for the development of 
interventions which may slow the progression of OA. Below I have summarised the 
main risk factors identified in the development and progression of OA. 
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Table 1.7: Risk factors for OA development and progression, classified by locality in the body 
(systemic or local) and ability to change (modifiable and non-modifiable) 
1.4.1 Non-Modifiable Risk Factors 
1.4.1.1 Age 
 
Figure 1.5: Estimated prevalence of those seeking treatment (estimated by number of GP 
consultations) for OA in the UK in 2015 by age and gender. Adapted from Figure 2 [49] 
OA is classically considered an ‘age related disease’ and has been consistently 
identified as a significant risk factor for the onset of KOA [50, 51]. The relationship 
between age and KOA is nonlinear, with a step increase in KOA incidence occurring 
from 50-75 years and then slower increases in incidence after this [51]. 
Systemic Factors Local Factors
Non-
Modifiable
Age                                                    
Gender                                           
Ethnicity                                        
Genetics
Modifiable
Obesity                                        
Nutrition                                             
Bone Density                                       
Smoking                                     
Hormonal Staus
Obesity                                      
Abnormal Joint loading                
Joint alignment                   
Occupational activities                
High impact/intensity sports    
Past joint injury/surgery               
Muscle (quadriceps) weakness
Summary of KOA risk factors
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Estimates by ARUK on people seeking treatment for KOA, affecting 33% >45 year olds 
and 49% women and 42% men >75years in the UK (see Figure 1.5).  
Although the incidence of OA increases with age, OA is not an inevitable consequence 
of age. On this basis, it has been hypothesised that ageing causes changes to the MSK 
system which increases susceptibility to development of OA when exposed to other 
OA risk factors [50]. In Table 1.8 below I have summarised some of the changes that 
occur in the MSK system with increasing age and indicated how these changes may 
affect the development of OA. 
Age-related changes to the MSK system Effect on the development of OA 
As cells age, they can adopt a ‘senescent 
secretory phenotype’ (characterised by the 
secretion of cytokines and Matrix 
Metalloproteinases [MMPs]). This phenotype 
is very similar to the changes seen in 
chondrocytes during OA (increased production 
of cytokines and MMPs). It is possible that 
induction of this senescent secretory 
phenotype in chondrocytes with age may 
increase likelihood of OA related changes 
Increased production of cytokines and 
MMPs by chondrocytes stimulates the 
release of proteinases by chondrocytes. 
This leads to degradation of collagen 
and aggrecans in cartilage (important in 
maintaining the structure of the 
cartilage). This may result in the 
characteristic cartilage degradation 
seen in OA. 
Older chondrocytes have a reduced response 
to growth factors (IGF-1, BMP-7, TGF-β), which 
normally stimulate the production of anabolic 
enzymes. A reduced response of chondrocytes 
to growth factors has also been observed in 
OA. 
Reduced production of anabolic 
enzymes results in decreased 
production of the ECM components of 
the cartilage. This potentially ‘tips the 
balance’ in the cartilage to net 
destruction of the cartilage tissue. 
Changes to the cartilage matrix proteins can 
occur over time with increased production of 
Advanced Glycation End-products (AGEs) 
occurring with increasing age. AGEs 
spontaneously form as a result of glycation of 
proteins. The turnover of proteins in the joint 
is very low (especially type 2 collagen which 
has a half-life of 100 years), providing 
opportunities for AGE accumulation 
specifically in cartilage. 
AGE formation in collagen causes 
‘cross-links’ to be formed which can 
change the biomechanical properties of 
the cartilage, making it more stiff and 
brittle and increasing the risk of 
injury/damaged to the cartilage under 
normal loading. 
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ROS (Reactive Oxygen species) production 
increases in ageing tissue, including in the 
cartilage. Because of the slow turnover of cells 
and matrix components in the cartilage, any 
ROS produced may accumulate, causing DNA 
damage in the chondrocytes which has several 
effects. Firstly, ROS may induce a senescent 
cell phenotype and therefore reduce cartilage 
ECM production. Secondly, cytokines released 
during OA, can induce ROS production in 
chondrocytes which can further induce the 
production of MMPs 
ROS may tip the balance of cartilage 
homeostasis to degradation by 2 
methods. Firstly decreasing anabolism 
of new ECM component by inducing a 
senescent phenotype in chondrocytes. 
Secondly by inducing the production of 
MMPs which actively cleave ECM 
components. 
Table 1.8: Summary of the changes in the MSK system with increasing age and their 
potential impact on the development of OA. [50, 52, 53] 
1.4.1.2 Gender 
The incidence and prevalence of OA are higher in women than in men from the age of 
50, particularly in the hand, foot and knee [2]. A 2010 meta-analysis of 8 studies has 
reported a pooled OR of 1.84 (95% CI 1.32–2.55) in favour of females having KOA. [54] 
The effect has been demonstrated to be independent of differences in body 
composition as a 10 year follow up study showing obesity (defined as a BMI >30kg/m2) 
was significantly associated with KOA incidence at 10 years (OR: 2.77, 95% CI: 1.35, 
5.71). According to this analysis there were no statistically significant interaction effect 
between gender and BMI, with the multivariate adjusted (adjusted for age, gender, 
work type and leisure time activities) association between obesity and KOA at 10 years 
demonstration a OR: 2.81 (95% CI: 1.32, 5.96). [55] 
It is unclear why this gender difference exists but it has been suggested that risk 
factors may differ between genders. The increase in OA incidence, particularly after 
the menopause in women, suggests hormonal status may be involved. However the 
mechanism through which female hormones such as oestrogen may affect OA 
incidence and progression is unclear and the available evidence is contradictory. [2] 
Cohort studies suggest that oestrogen may be protective in the development of OA 
[56-58], whereas other studies suggest exposure to oestrogen may lead to increased 
bone mass, which increases the risk of OA [59].   
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1.4.1.3 Ethnicity 
Prevalence of OA amongst different ethnicities differs, with comparisons between 
white and African American people the most extensively researched [2]. For example, 
the Johnson County Osteoarthritis Project (American population study (n=3018)) 
measured the prevalence of knee symptoms, radiographic and symptomatic KOA and 
found a non-significant trend for higher prevalence of knee symptoms, radiographic 
and symptomatic KOA and a significantly higher prevalence of severe (K&L grade 3-4) 
radiographic KOA in African Americans compared with Caucasians. [60] 
The reasons for the ethnic differences in OA are unclear and are likely multifactorial, 
involving lifestyle, socioeconomic and genetic factors [2]. 
1.4.1.4 Genetics 
There is strong evidence for genetic involvement in OA risk and heredity may explain 
65% risk in hand and hip OA, and 40% of the risk for KOA [61]. However the genetics of 
OA are complex and it is likely the result of polygenic inheritance rather than by 
inheritance of a single gene [62]. Many genome wide association studies (GWAS) [63-
66] and candidate gene studies have been conducted in KOA populations, however so 
far these studies have yielded inconsistent results, with only one OA candidate gene, 
growth differentiation factor 5 (GDF5), consistently reported as being associated with 
KOA [67-69].  
A 2014 meta-analysis reviewed the results of nine GWAS of >24,000 single nucleotide 
polymorphisms (SNPs) in 199 previously identified OA candidate genes in 5636 KOA 
patients and 4349 HOA patients. The results of the meta-analysis concluded that of the 
199 candidate genes tested, no genes were significantly associated with KOA and two 
genes, COL11A1 and VEGF (in men only), will significantly associated with HOA. [70] 
1.4.2 Modifiable Risk Factors 
1.4.2.1 Obesity 
Obesity is a significant risk factor for incidence and progression of KOA. How obesity 
mediates this greater risk can be attributed to its biomechanical and biochemical 
effects: 
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a) Biomechanical effects of obesity in KOA 
i) Overloading 
Overloading of the knee because of the increased weight in obesity may cause joint 
damage and instability, exacerbating progression of KOA. In support of this idea, it has 
been shown that for every kg increase in body weight, there is 2-3kg increase in the 
overall force across the knee [2]. This excessive mechanical force on joint tissues can 
lead to: 
 Changes in cartilage composition and structure leading to cartilage breakdown 
[2] 
 Bone marrow lesions [71] 
ii) Mechanoreceptor Activation 
Chondrocytes, osteoblasts and synoviocytes  possess mechanoreceptors, and it is 
hypothesised that increased load as a result of obesity can activate these 
mechanoreceptors, leading to a signalling cascade which induces the expression of 
cytokines, MMPs and prostaglandins, thus adding to the effects of inflammation seen 
in KOA and accelerating the breakdown of the cartilage [72] 
b) Biochemical effects of obesity in KOA 
Obesity is also a strong risk factor for OA in non-load bearing joints e.g. hand joints 
[73], suggesting that there is a systemic mechanism through which obesity mediates 
KOA. The following theories are proposed to explain how this may occur: 
i) Adipokines 
Adipokines (e.g. leptin, adiponectin and resistin), cytokines produced by adipose 
tissue, which are elevated in osteoarthritic joint tissues, have been proposed as 
candidates in mediating the systemic effects of obesity in OA pathogenesis [74]. The 
role played by adipokines in OA is not yet clear but it is thought they cause damage 
directly to joint tissue and indirectly through control of inflammatory pathways 
[75].Summarised below is current evidence on the adipokines thought to be key in OA: 
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ii) Leptin 
Leptin concentrations increase with increasing adiposity [76] and, in the obese, are 
higher not only in the blood but also in osteoarthritic cartilage and subchondral bone 
[74]. Leptin has many pro-inflammatory, catabolic effects in OA, e.g. 
 Inducing release of collagen from cartilage resulting in cartilage degradation 
 Up-regulating  MMP1, MMP-9 and MMP-13 expression in chondrocytes 
 Up-regulation of pro-inflammatory cytokines e.g. IL-1b  
 Increasing expression of aggrecanases ADAMT-4 and 5 [72, 74, 75] 
 
iii) Adiponectin 
The role of adiponectin in OA is contradictory. Adiponectin concentrations have been 
observed to be 100-fold higher in the synovial fluid of OA joints compared with 
corresponding concentrations in serum. Some evidence suggests that adiponectin may 
have a protective effect in OA by down- regulating MMP-13 and pro-inflammatory 
cytokine expression [75] and by increasing expression of the MMP inhibitor TIMP-2. 
However, some studies suggest a pro-inflammatory effect of adiponectin by 
stimulating vascular endothelial growth factor (VEGF) and MMP production [71]. 
iv) Resistin 
Resistin stimulates production of pro-inflammatory cytokines (e.g. TNFα, IL-1b, IL-
6)[74], which may be key in the pathogenesis of inflammation seen in OA [48]. In 
mouse cartilage extracts, resistin stimulated proteoglycan degradation and, in human 
explants, inhibited its synthesis, resulting in cartilage matrix breakdown [77]. 
c) Metabolic Factors 
Obesity may induce other systemic metabolic effects which affect OA pathogenesis 
such as disordered glucose and lipid metabolism, which result in increased pro-
inflammatory cytokine production. However few studies have focused on the effect of 
these metabolic factors in the obese with KOA [75]. 
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1.4.2.2 Nutrition 
In addition to nutrition’s importance as a determinant of obesity, the role of individual 
nutrients in influencing OA risk have been investigated. The results of these nutrient 
trials are conflicting and unclear after being reviewed systematically, as can be seen in 
Table 1.9 below. 
Nutrient Investigated Concluded effect on KOA 
Glucosamine Results of systematic reviews regarding the effect 
of glucosamine on KOA outcomes are variable but 
generally report small improvements in KOA 
outcomes in response to glucosamine 
supplementation. A 2010 systematic review of 10 
trials concluded no clinically significant reductions 
in KOA pain (measured by 10mm VAS) [78]. A 2015 
systematic review of 31 studies concluded 
significant improvements in WOMAC Pain and 
Functions scores SMD: −0.75 (95% CI: −1.18, 
−0.32), −4.78 (95% CI: −5.96, −3.59) with 
glucosamine supplementation [79]. 
However, NICE have concluded that clinicians do 
not offer the use of glucosamine for treatment of 
OA [10]. 
Chondroitin Results of systematic reviews of the effect of 
chondroitin on KOA generally show an effect of 
chondroitin on KOA pain. A 2007 systematic 
review of 22 trials of chondroitin in OA showed a 
large effect size of -0.75 (95% CI: -0.99, -0.50) of 
chondroitin vs placebo for pain outcomes 
(difference of 1.6/10cm pain scale). However 
there was a high level of heterogeneity between 
studies identified (I2 of 92%, p=0.001). Analysis of 
difference in change between chondroitin and 
placebo in JSN (mean difference: 0.23mm) 
revealed a small effect size of 0.18 SD units (0.23 
mm, 95% CI: 0.09, 0.37) in favour of chondroitin. 
[80] 
In a 2015 systematic review, it was concluded that 
chondroitin supplementation was associated with 
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significant reductions in pain (mean -
0.45cm/10cm) and JSN (standardised mean 
difference [chondroitin vs placebo] of 0.29, 95% CI 
0.04-0.50) compared with placebo treatment [81].  
However NICE have concluded in their 2014 report 
that chondroitin should not be recommended for 
treatment of OA [10]. 
MSM (Methylsulfonylmethane) Moderate amounts of evidence exist for the effect 
of MSM on KOA over 3 months [82]. Of the two 
RCTs published, one showed a significant decrease 
in pain index score (p=<0.001) with 1500mg/d 
MSM and the other reported a significant 
improvement in WOMAC pain and physical 
function compared to placebo with 3g/d of MSM 
[83, 84]. 
DMSO (dimethyl sulfoxide) Evidence for the efficacy of DMSO on KOA is 
unclear [82].  Of the four RCTs published all were 
short term (3-4 weeks) and used ‘suboptimal’ 
doses of DMSO. The results of these studies were 
contradictory, with one showing a significant 
difference in VAS pain between DMSO and 
placebo (p=0.015) and another showing no 
difference between DMSO and placebo in 
WOMAC Pain (p value NR) [85, 86]. 
Vitamin D Several observational studies have identified an 
inverse relationship between 25OHD 
concentrations and KOA outcomes [87-89], 
although evidence from supplementation studies 
are currently limited [90-92].  
A 2013 systematic review concluded [93] there 
was strong evidence for an negative association 
between 25(OH)D and cartilage loss and moderate 
evidence for a negative association between 
25(OH)D and radiographic KOA. However there 
was limited evidence for an association between 
25(OH)D and symptomatic KOA, with the authors 
identifying only two cross-sectional studies). 
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Unsaponifiables (ASUs): 
Avocado/Soybean lipids 
There is some evidence that supplementation with 
300mg ASUs/day over 3 months reduces NSAID 
intake (p=<0.01) [94, 95]. However a long-term 
study (2 years) of 300mg ASU/day showed no 
change in Joint Space Narrowing or KOA 
symptoms compared to placebo [96]. 
Table 1.9: A summary of the current evidence of the effect of individual nutrients on KOA 
outcomes. References provided within table. 
The authors highlighted that most of the studies regarding individual nutrients and 
KOA suffered from poor design and contradictory evidence. They also observed that 
many of the studies used unphysiological levels of the chosen nutrient in their trials, 
calling into question the relevance of such results and safety of using them in practice 
[97]. 
The role of Vitamin D in OA is currently under investigation in light of several cross-
sectional studies demonstrating correlations between serum 25(OH)D concentration 
(the accepted biomarker of vitamin D status) and progression of KOA, with those with 
low 25(OH)D status suffering from more severe disease [98]. However, further 
interventional studies are required to establish the direction of the relationship 
between KOA and vitamin D, and whether this could be a viable treatment option for 
sufferers.  
1.4.2.3 Occupation 
Occupations involving repetitive movement or weight bearing on specific joints 
increase the risk of OA in that joint; for example, occupations involving kneeling, 
bending or squatting along with load bearing increase risk of HOA and KOA. This is 
thought to be because forces in the knee increase in the squatting or bending position, 
and carrying a heavy load from this position further increases load on the joint, which 
may contribute to KOA risk. [2] 
In a French cross-sectional study [99] of 1394 patients diagnosed with hand, knee or 
hip OA, links with longest held occupation were investigated. This study had a higher 
than average (when compared with the French population) proportion of female 
cleaners (6x higher than expected) in the OA study sample. They also found those 
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working in construction, mechanics and the clothing sector had a high prevalence of 
hand OA (48%) and reported a high degree of subsequent extreme disability (42.8% 
compared with 25% in those with hand OA in different employment, p=0.04). The 
French researchers concluded that these occupations should be considered high risk 
populations for OA, and that the contribution of repetitive joint movement and heavy 
loading bearing are important contributors to the development of OA [99]. 
1.4.2.4 Joint injury and Surgery 
Risk of OA is significantly increased by the incidence of acute joint injuries, such as joint 
dislocation, ligament and meniscal tears and ruptures, which are thought to increase 
the instability of the joint, and which have been seen to precede the onset of OA [2]. 
The importance of earlier joint injury in the later development of OA was investigated 
in a prospective study with a 36 year follow up of 141 people who reported joint 
injuries to the hip, knee or both. This showed that injury to the joint substantially 
increased the risk of later development of OA in that joint (with a relative risk of 5.17 
and 3.5 for the development of KOA and HOA respectively) [100]. 
1.4.2.5 Muscle Weakness 
Quadriceps muscle weakness is commonly found in those with KOA, and can lead to 
pain and disability. However, it is unclear whether this weakness is a result of disuse 
due to the disease, or is a contributing factor in the development of the disease. A 
2010 cross-sectional study of quadriceps strength in women with no (K&L score <1), 
mild (K&L score 2) and moderate-severe KOA (K&L grade 3-4) found that the 
quadriceps of women with mild KOA was 18% weaker than those without KOA, and no 
significant difference in weakness with the moderate-severe KOA group. The authors 
inferred that quadriceps weakness is a feature of KOA which is present from the 
beginning of disease and that addressing this with early intervention with quadriceps 
strengthening exercises may be beneficial in preventing the onset of symptoms and in 
maintaining knee function [101]. This is supported by evidence from quadriceps 
strengthening exercise interventional studies, showing improvements in reported pain 
and function in those with KOA [102, 103]. 
 31 
1.5 Treatment of Osteoarthritis 
As there is no cure for OA; treatment of OA centres on the control of symptoms, 
primarily pain and function, and improvement of quality of life. The treatment 
received will vary between individuals depending on the risk factors presented in that 
individual, e.g. weight management options may be suggested for overweight and 
obese patients [104]. 
Treatments for OA can be split into three different groups; lifestyle (e.g. weight 
management, exercise and education), pharmacological (e.g. painkillers and intra-
articular injections) and surgical (e.g. arthroscopy and joint replacement).  
 
Figure 1.6: Summary of the treatments recommended by NICE Guidelines. All treatment 
starts with the central or ‘core’ treatments and progress outwards into pharmacological 
treatments (middle ring) and finally to the outer ring treatments, which generally more 
expensive and higher risk for the patient [105] 
 
The NICE guidance for treatment of OA patients in the UK is also split into core lifestyle 
treatments, progressing to pharmacological treatment and finally to more expensive 
and risky interventions for those who are unresponsive to the previous treatments 
(see Figure 1.6). 
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NICE recommend a holistic approach (see Figure 1.7) to treatment in OA by assessing 
the impact of the person’s condition on many different aspects of their life, including 
on function, quality of life, occupation, relationships, mood and leisure. Treatments 
are then offered based on the issues which are expressed [10].
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Figure 1.7: Holistic approach to assessing patients with OA for treatment as recommended by NICE. The holistic approach focuses on assessing the 
major areas of health and quality of life which may be effected by OA (as a core treatment in OA).Taken from [10]. 
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1.5.1 Core Treatments 
According to NICE Guidelines, all patients with OA will be offered at least these core 
treatments as part of their treatment plan. They are often prescribed in conjunction 
with other treatments e.g. painkillers or thermotherapy to achieve relief from 
symptoms. The importance of these treatments is stressed regularly and the 
Guidelines emphasise that they should not be offered just once at the beginning of 
treatment but reviewed regularly with the patient [10]. 
1.5.1.1 Patient Education and self-management 
This involves providing patients with verbal or written materials explaining what OA is 
and the options available for treatment. A strategy for self-management e.g. weight 
loss (where applicable) and exercise particularly and use of thermotherapy (application 
of hot or cold to the joint), should also be discussed [10]. 
1.5.1.2 Exercise 
Exercise is recommended to all OA patients, regardless of the joint affected, age or 
severity of disease. This includes two types of activity: aerobic and muscle 
strengthening activity. 
Muscle strengthening exercises are particularly useful in KOA, where quadriceps 
weakness is commonly seen and correlates with pain. Strengthening the muscles can 
increase the stability of the joints and improve pain [26]. A systematic review of PA 
interventions in KOA found an effect size (calculated as the difference in mean 
pain/disability score between intervention and control groups) change of 0.32 in 
interventions of home-based quadriceps muscle strengthening exercises for improving 
pain (95% CI 0.23, 0.42) and disability (95% CI 0.23, 0.41) [103]. 
Low impact aerobic exercises are also effective in reducing pain. Progressive, low 
impact exercise e.g. swimming is recommended to avoid pain. [26] In the same 
systematic review described above, aerobic walking exercises improved pain by an 
effect size of 0.52 (95% CI 0.34, 0.70) and disability by an effect size of 0.46 (95% CI 
0.25, 0.67) [103]. 
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The problem presented with recommending exercise interventions for OA is not their 
efficacy but how to deliver interventions in a way which will improve engagement with 
the patient. There is currently no consensus on how this can be achieved and this is a 
current topic of investigation [10]. 
1.5.1.3 Weight Loss 
Weight loss interventions in overweight and obese patients with KOA are 
recommended. Such interventions include: 
- Lifestyle interventions (improved diet, increased physical activity) 
- Pharmacological diet aids (e.g. orlistat) 
- Bariatric surgery (in those with BMI >35) [106] 
Because obesity is an important risk factor for the progression of OA (see section 
1.4.2.1), maintenance of a healthy weight is important in OA. A systematic review and 
meta-analysis of the effect of weight loss in obese patients with KOA showed a pooled 
effect size of 0.2 (95% CI 0 to 0.39) on knee pain and an effect size of 0.32 (95% CI 0.04 
to 0.42) on self-reported disability in favour of weight loss. The authors calculated that 
patients would need to lose 7.5% (0.6%/week) body weight to achieve a moderate 
clinical improvement in symptoms [107]. 
1.5.2 Secondary Treatments 
1.5.2.1 Topical and Oral Analgesics 
Paracetamol is offered as the first analgesic drug (along with topical NSAIDs) due to its 
safety and low cost. However, if pain relief by paracetamol is inadequate, treatment 
will proceed to NSAIDs[104, 108].  
NSAIDs can be prescribed in place of, or alongside, paracetamol use to combat joint 
pain and inflammation. It is recommended that NSAIDs are started at the lowest 
effective dose for symptom relief and co-prescribed with Proton Pump Inhibitor Drugs 
(PPIs), e.g. omeprazole, to mitigate gastrointestinal side effects. Gastrointestinal 
effects of the use of NSAIDs include gastric bleeding, and liver and renal toxicity [10, 
104]. 
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1.5.3 Tertiary Treatment 
1.5.3.1 Aids and Devices 
People with suspected biomechanical problems of joint instability should be offered 
bracing, joint supports and insoles according to NICE guidance [10]. The aim of the use 
of these devices is to alter and lessen loading on the joint. Additionally, aids such as 
walking sticks can be useful for patients who have difficulty with activities of daily 
living and can be used to reduce load on the joint while walking [26, 108]. 
1.5.3.2 Invasive and surgical treatments 
Invasive and surgical treatments are the last line of treatments to be considered for OA 
after conservative management methods have been exhausted [108]. The criteria for 
surgical intervention can vary, however NICE recommend referral for those with 
severe and persistent (after treatment with non-surgical options) symptoms which 
affect the patient’s quality of life [10]. 
Intra-articular injections of corticosteroid are recommended for relief of severe pain in 
OA. However, NICE does not recommend injections of Hyaluronic Acid due to 
inconsistent evidence and uncertainty (as a result of publication bias of reporting of 
positive results) on their efficacy [10]. They are however approved for use by the FDA 
in the USA [26]. 
Finally, there is joint replacement surgery, which is considered for patients with have 
symptoms which have a significant impact on their quality of life and who are 
unresponsive to all other treatment options. Joint replacement surgery involves the 
removal of the joint and replacement with a prosthetic joint, usually made of metal or 
ceramic. Joint replacement surgery is highly successful and can eliminate symptoms in 
those with end-stage OA. Due to the longevity of the prosthetic joint, patients with a 
life expectancy >20years after replacement may be considered for surgery at a later 
date or require revision surgery. Therefore, considerable discussion about the 
procedure (including risks and benefits of surgery and recovery and rehabilitation) will 
occur before referral for surgery [10, 26, 104]. 
As mentioned above, treatments for OA are often used in combination but there are 
no specific guidelines on how to use these treatments effectively in combination. NICE 
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have therefore highlighted the importance of research into the effect and benefits of 
different combinations of treatments to identify the most effective and cost effective 
treatment combinations for use in practice [10]. 
1.6 Vitamin D 
Vitamin D is a steroid hormone which is the ligand of the Vitamin D Receptor (VDR), a 
transcription factor which recognizes cognate vitamin D response elements (VDREs) in 
DNA and so regulates the expression of several hundred genes [109]. I will discuss in 
this section the sources, actions and factors influencing vitamin D.  
1.7 Vitamin D Metabolism 
1.7.1 Sources 
There are two different types of Vitamin D: D2 (Ergocalciferol) and D3 
(Cholecalciferol)[110]. D2 is derived from plant sources (from the UVB irradiation of 
ergosterol in plants, e.g. Fungi). D3 is derived from the UVB irradiation of the skin in 
animals and can be ingested from animal products (e.g. oily fish, eggs, meat) or 
synthesised from exposure of the skin to sunlight [111]. The majority of Vitamin D in 
humans comes from cutaneous synthesis, with dietary sources becoming more 
important as UVB exposure decreases [110]. 
The steps in Vitamin D metabolism from intake to production of the active Vitamin D 
metabolite (1, 25(OH)D) are described below. 
1.7.1.1 Cutaneous Synthesis 
The main source of Vitamin D is synthesis in the skin. The process of D3 production by 
cutaneous synthesis can be seen in Figure 1.8andis briefly as follows. Firstly UVB 
radiation (wavelength 280-315nm) penetrates the skin triggering the conversion of 7-
dehydrocholestrol (7-DHC) in the dermis (35%) and epidermis (65%) to pre-vitamin D. 
Pre-vitamin D is thermodynamically unstable and so is converted into Vitamin D (a 
more stable metabolite) via an uncatalysed thermal isomerization reaction  in the 
epidermal and dermal cells over the following 3 days [110, 112]. Finally Vitamin D3 is 
then translocated and diffuses into the dermal capillary bed for transportation to the 
general circulation. Little is known about the mechanisms of this process, although it is 
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thought that the movement of Vitamin D into the bloodstream may be prompted by its 
attraction to the DBP in the circulation [113]. 
Excessive exposure to UVB does not result in Vitamin D intoxication due to a variety of 
negative feedback mechanisms (pictured in Figure 1.8), including: 
 
Figure 1.8: Diagram summarising the metabolic pathway for the production of Vitamin D by 
endogenous synthesis. Adapted from Figure 4 [113]. 
1. Only 12-15% of 7-DHC in the skin is converted to pre-vitamin D (which reaches 
its peak concentration a few hours after exposure), limiting the amount of pre-
vitamin D produced[110, 112]. 
2. Prolonged UVB exposure triggers the conversion of pre-vitamin D into the 
biologically inactive metabolites e.g. lumisterol and tachysterol. The amounts 
of these Vitamin D photoisomers increase with time exposed to sunlight, e.g. 
after 1hr and 8hrs exposure, 30% and 60%, respectively 7-DHC is converted to 
lumisterol [113]. 
3. Once converted to Vitamin D, prolonged UVB exposure can also trigger a 
reversible isomerization conversion of Vitamin D in the skin to the 
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photoproducts suprasterol 1, suprasterol 2 and 5,6 pre-vitamin D3. This 
prevents the build-up of toxic concentrations of vitamin D and also means that 
when Vitamin D concentrations fall, these photoproducts can be converted 
back to Vitamin D for use in the body. [110, 112] 
1.7.1.2 Dietary Absorption 
Vitamin D obtained from diet becomes particularly important when UVB exposure is 
low and can contribute significantly to Vitamin D intake. As a fat soluble vitamin, 
vitamin D from food sources is absorbed in the small intestine with dietary fat. The 
latter is essential for effective vitamin D absorption, and a lack of dietary fat, or the 
presence of malabsorption disorders which inhibit fat absorption, can significantly 
reduce the body’s ability to absorb Vitamin D. In the enterocyte, Vitamin D along with 
lipids (e.g. cholesterol, triglycerides and lipoproteins) are packed together into 
chylomicrons which then travel via the lymph system into the general circulation. 
Chylomicrons are hydrolysed in tissues (e.g. adipose and skeletal muscle) which 
express lipoprotein lipase, releasing the vitamin D [110, 112]. 
1.7.2 Conversion to 250HD 
1.7.2.1 Vitamin D in the Circulation 
After vitamin D has been ingested or synthesized by the body, it is transported in the 
blood plasma, bound mostly by vitamin D binding protein (VDBP)[114]. VDBP carries 
most Vitamin D metabolites in the circulation, binding around 88% 25(OH) D with high 
affinity and 85% of 1,25(OH)D, with 0.4% metabolites ‘free’ or unbound and the 
remaining metabolites bound to other serum proteins such as albumin [115] (see 
Figure 1.8).  
Vitamin D does not remain in the plasma for long (half-life 4-6 hours) as it is either 
taken up by the adipose tissue for storage or transported to the liver for metabolism 
[109, 110, 116]. 
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Figure 1.9: Metabolism pathway and classical actions of Vitamin D in calcium homeostasis. . 
Vitamin D is absorbed and transported to the general circulation. Vitamin D is stored in 
adipose tissue or converted to 25(OH)D by 25-hydroxylase in the liver. 25(OH)D circulates in 
the bloodstream until low serum calcium concentrations are signalled by increased release 
of PTH stimulating the conversion of 25(OH)D to 1,25(OH)D in the Kidney. 1,25(OH)D 
stimulates calcium resorption from the intestine (by increasing the expression calcium 
transporters), kidney (by stimulating uptake of calcium from the distal renal tubule) and 
bone (By stimulating osteoblasts to produce RANKL, which enables the maturation of 
osteoclasts, which break down the bone matrix to release calcium). Serum calcium 
concentrations increase, PTH secretion decreases and 1,25(OH)D production by the kidney 
decreases. Taken from Figure 1 [117]. 
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1.7.2.2 Hepatic Metabolism of Vitamin D 
Vitamin D is metabolised by two major hydroxylation reactions, the first of which takes 
place in the liver where it is converted to 25(OH)D by 25-hydroxylases (see Figure 1.9). 
The 25(OH)D is transported back into the  bloodstream until required for conversion to 
1, 25(OH)D [110, 112] (see Figure 1.9). 
1.7.2.3 Conversion to 1,25(OH)D 
The tightly regulated process of the conversion of 25(OH)D to 1,25(OH)D occurs mostly 
in the renal proximal kidneys, although other tissues including bone, skin 
(keratinocytes), placenta, breast, colon, prostate, endothelial cells, pancreatic islets 
and parathyroid glands are able to carry out this reaction in small amounts for 
paracrine and autocrine purposes. I will describe 1,25(OH)D hydroxylation in the 
context of the kidneys and its role in calcium and phosphate homeostasis [110]. 
1.7.2.4 25(OH)D transport to the Kidneys 
When calcium or phosphate concentrations are low, the VDBP bound 25(OH)D from 
the general circulation is transported into the kidney by receptor mediated 
endocytosis, in the following process: 
1. VDBP bound 25(OH)D binds directly to Megalin in the renal proximal tubules. 
2. Cubilin isolates the 25(OH)D-Megalin complex on the renal cell surface. 
3. Megalin internalises the VDBP-25(OH)D and releases the complex within the 
cell.  
4. Megalin and Cubilin are recycled back to the cell surface [110]. 
1.7.3 25(OH)D conversion to 1,25(OH)D 
Once inside the cells of the proximal renal tubule of the kidney, the second 
hydroxylation reaction occurs, converting 25(OH)D (an inactive Vitamin D metabolite) 
into 1, 25(OH)D (the active Vitamin D metabolite) by 1a-hydroxylases, particularly 
CYP27B1 (a mitochondrial enzyme). 1, 25(OH)D then mediates many Vitamin D actions 
on e.g. renal, bone and intestinal cells [110]. This second hydroxylation is a tightly 
regulated process and when calcium and phosphate concentrations rise to the normal 
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range, 1,25(OH)D conversion ceases. The Vitamin D endocrine system and actions are 
described further Figure 1.9and in section 1.9.3. 
1.7.3.1 Breakdown and Excretion 
As the metabolism of Vitamin D is such a tightly regulated pathway, there are many 
stages of the pathway where Vitamin D metabolites may be inactivated, stored or 
broken down and excreted. These include: 
 When calcium levels are sufficient, instead of undergoing 1a-hydrosylation to 
1,25(OH)D, 25(OH)D is hydroxylated by 24-hydroxylases (CYP24). This results in 
an inactive water soluble molecule (mainly calcitriol acid). 
 1,25(OH)D can also modulate its own destruction by inducing the production of 
CYP24 in Vitamin D target tissues.  
 These inactive water soluble Vitamin D metabolites are then excreted via the 
bile in faeces, with very little excreted in urine [110, 112]. 
1.8 Biomarkers of Vitamin D status 
There are many Vitamin D metabolites in the body which could potentially be used as 
biomarkers of vitamin D status. However, plasma total 25(OH)D concentration is 
usually used for this purpose and is currently the best biomarker of Vitamin D status 
for the following reasons: 
 It combines dietary intake and cutaneously synthesised Vitamin D as both are 
converted into 25(OH)D. Therefore it reflects the total amount of Vitamin D 
taken into the body from all sources.  
 25(OH)D can be considered the storage metabolite for Vitamin D in the body 
since this is the major form in which it circulates in the bloodstream and is 
stored in adipose tissue. 25(OH)D is a widely used biomarker for Vitamin D 
status in multiple countries, and therefore allows studies to be comparable 
[110]. 
 Most other Vitamin D metabolites have very short half-lives and so are of 
limited practical use in assessing Vitamin D status. However, 25(OH)D has a 
longer half-life of 21-30 days. 
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 Since 1,25(OH)D concentration is  tightly regulated and is  determined mainly 
by calcium and phosphate concentrations (and not specifically vitamin D 
stores), it can be a poor measure of Vitamin D status [118]. 
However, there are several limitations in using 25(OH)D as a biomarker of Vitamin D 
status: 
 As 25(OH)D is a storage metabolite with no active function (unlike 1,25(OH)D, 
the ‘active’ Vitamin D metabolite, which can interact with the VDRE), it is 
therefore debatable whether 25(OH)D can be extrapolated in the case of 
Vitamin D effect. Therefore, studies linking 25(OH)D, rather than 1,25OHD 
status, to disease and clinical outcomes may be flawed. 
 The concentration of 25(OH)D in plasma can be affected by many difficult to 
control and quantify factors, such as UVB exposure, (reviewed in section 
1.10.5), which have the potential to introduce variation between individual 
study subjects during Vitamin D supplementation studies, potentially 
‘confounding’ any results. 
 There are no internationally agreed 25(OH)D concentration cut-off points for 
defining deficiency, insufficiency and sufficiency which means that results 
between countries may not be comparable [110]. 
 The concentration of 25(OH)D obtained from a blood sample can vary 
according to the type of assay used, the laboratory used and the quality 
assurance system employed. The ‘gold’ standard for 25OHD measurement, 
providing the most specific and sensitive results, is liquid chromatography 
tandem mass spectrometry (LC-MS/MS). However, due to the high equipment 
costs, LC-MS/MS is not widely used for clinical 25(OH)D measurements. 
Immunoassays are more often used for clinical diagnosis which can be more 
variable in their reliability and accuracy. Streamlining and standardisation of 
25(OH)D measurement methods however could improve the reliability of such 
assays for the measurement of 25(OH)D [119]. 
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1.9 Vitamin D Actions 
Vitamin D can act via both regulation of DNA transcription (genomic action) or through 
the activation of signalling pathways (non-genomic actions). Both are mediated by the 
interaction of 1, 25(OH)D with the VDR.  
The VDR is a steroid hormone receptor of the thyroid/Vitamin D/retinoic acid 
subfamily. VDR has 2 main binding domains: a C domain (DNA Binding domain) and an 
E domain (ligand binding domain – for which 1,25(OH)D has a high affinity) [110, 120]. 
The genomic and non-genomic actions of Vitamin D are outlined below. 
1.9.1 Genomic Actions 
 
Figure 1.10: Diagramatic representation of the proposed genomic mechanism of action for 
Vitamin D. Taken from Fig 4 [120] 
 1, 25(OH)D binds to the VDR of a target cell. 
 The ligand activated VDR then forms a heterodimer complex with retinoid X 
receptor in the cell nucleus. This step is essential for effective binding of the 
VDR to DNA. 
 The VDR-RXR complex then binds to VDRE (Vitamin D response elements). 
VDREs are sequences in DNA (usually 2 hexametric repeats of AGGTCA 
sequences separated by 3 nucleotides) that found in the promotor regions of 
genes that are regulated by Vitamin D. The VDR binds to the 3’end and RXR 
binds to the 5’end of the promotor region. 
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 A protein complex then forms on the VDRE with the attached VDR which acts 
to loosen the chromatin structure of the DNA. 
 A second protein complex then forms on the VDRE which initiated gene 
transcription or repression (see Figure 1.10)[120]. 
1.9.2 Non-Genomic Action 
The non-genomic  vitamin D-dependent responses within cells are thought to be 
carried out through interaction of the ligand activated VDR with cavolae that are small 
lipid raft pits involved in pathway signalling and endocytosis [121]) on the plasma 
membrane of target cells. 
The effects of ‘rapid response pathways’ can occur within 1-45mins compared with 
genomic responses which can take several hours [122]. 
VDR-cavolae may induce a signalling cascade resulting in the recruitment of the 
secondary messengers MAPK (mitogen-activated protein kinase) and cAMP (cyclic 
adenosine monophosphate) to affect calcium channels within the cell [110]. These 
pathways may also influence genomic actions of vitamin D by ‘cross talk’ (see Figure 
1.11) [122]. 
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Figure 1.11: Proposed mechanism of action for non-genomic vitamin D actions or ‘fast 
response pathways’. Firstly free 1,25(OH)D binds to VDRs located in the cavolae of cell 
membranes. This triggers a signalling transduction pathway, of which the secondary 
messengers stimulate the opening of calcium ion channels on the cell surface and rapid 
calcium uptake. These secondary messengers are also able to interact with the genomic 
actions of Vitamin D (gene expression). Taken from Figure 4 [122]. 
 
1.9.3 Physiological Actions 
1.9.3.1 Classical Actions 
The main action of Vitamin D is in ensuring homeostasis of calcium and phosphate 
concentrations in the body (see Figure 1.12). This is important for the mineralisation of 
the bone (ensuring a strong skeleton) and for avoiding hypocalcaemic tetany [120]. 
The main steps of this Vitamin D mediated homeostatic loop are summarized below: 
 It is important that serum calcium concentration is kept between 1-2.5nmol/L. 
 Decreases in circulating calcium concentration are sensed by calcium sensing 
cells (C-cells) in the parathyroid gland. 
 This induces the release of parathyroid hormone (PTH) into the general 
circulation [110]. 
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 PTH stimulates the kidney to convert 25(OH)D to 1,25(OH)D by increasing 1a-
hydroxylase activity. 1,25(OH)D has 3 main actions in increasing calcium 
levels:[120] 
1. Intestinal Calcium Absorption: 
a. 1,25(OH)D interacts with the VDR and initiates the expression of 
epithelial calcium channels and calbindin 9k (calcium binding 
proteins). 
b. The expression of these proteins leads to active uptake of calcium 
from the intestinal lumen (from dietary sources) into the general 
circulation[110]. 
c. Absorption is greatest in the duodenum and jejunum of the small 
intestine[112]. 
2. Kidney Calcium reabsorption: 
a. 1,25(OH)D and PTH stimulate reabsorption of calcium in the renal 
distal tubule. 
b. This ensures that calcium is retained and not excreted in the urine 
[112]. 
3. Bone resorption: 
a. 1,25(OH) D interacts with the VDR in osteoblasts and stimulates the 
expression of RANKL (NFκB ligand). 
b. RANKL induces the maturation and activation of osteoclasts. 
c. Osteoclasts resorb bone (osteoclastigenesis), releasing calcium 
stored within the bone matrix [110, 112]. 
 As a result of the above actions, serum calcium concentrations rise. This is 
sensed by the calcium sensing cells of the thyroid gland and PTH secretion 
reduces.  
 When serum calcium concentrations become too high, the C-cells of the 
thyroid gland secrete the protein calcitonin which blocks the bone resorption 
described above and therefore lowers serum calcium concentrations [110, 
112].  
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Figure 1.12: The stimulatory and suppressive effects of hormones (1,25(OH)D and PTH) on 
Calcium homeostasis. Low calcium concentrations are sensed by C-cells in the parathyroid 
gland (PTG) which responds by secreting parathyroid hormone (PTH). PTH stimulates the 
kidney to convert 25(OH)D to 1,25(OH)D which exerts its action on the bones, kidney and 
intestines to increase calcium resorption. Serum Calcium concentrations increase, which is 
sensed by the PTG and responds by decreasing PTH secretion (feedback mechanism).Taken 
from figure 1 [120]. 
1.9.3.2 Non-Classical Actions 
VDRs also occur in multiple cells unrelated to calcium and phosphorus homeostasis 
including, pancreatic, immune, epithelial, skin, colonic and placental cells [120]. 
Through these VDRs, 1, 25(OH)D regulates the expression of over 200 target genes, 
including genes involved in cell proliferation and differentiation, apoptosis and 
angiogenesis [117]. This suggests that Vitamin D may have roles in regulating the 
function of multiple cells and tissues, and inadequate vitamin D status may contribute 
to the aetiology of several diseases. Potential non-classical actions of vitamin D, 
summarised in Figure 1.13, include roles in immunity. 
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Figure 1.13: Diagram summarising the potential non-skeletal mechanisms of 1, 25(OH)D. 
Taken from Figure 2 [117]. 
a) Immunity  
Macrophages: When stimulated by infection (e.g. mycobacterium tuberculosis) or LPS 
(lipopolysaccharide), VDRs are expressed on macrophages and 25OHD from the 
general circulation is converted to 1,25(OH)D. Activation of the VDR leads to the 
expression of cathelicidin (peptide used to destroy infectious agents). When circulating 
concentrations of 25(OH)D are<50nmol/L, macrophages cannot initiate this innate 
immune reaction, leaving the individual more susceptible to the infection  [117]. 
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Lymphocytes: 1,25(OH)D produced by macrophages may act on locally activated T and 
B lymphocytes to regulate the expression and secretion of cytokines and 
immunoglobulins, therefore having an immunomodulatory effect [123]. 
1.10 Vitamin D Deficiency 
1.10.1 Defining Vitamin D Deficiency 
Historically, Vitamin D deficiency was diagnosed from the clinical presentation of 
rickets - a childhood condition caused by the impaired mineralisation and ossification 
of the bone, often resulting in skeletal deformities [124]. However, 250HD is now used 
as a biomarker of vitamin D status [125, 126]. 
Defining Vitamin D deficiency is difficult because there is currently a lack of consensus 
about what serum 25(OH)D concentrations define deficiency, insufficiency and 
sufficiency. Examples of the cut-offs for 25(OH)D concentration used by different 
authorities are summarised in Table 1.10 below.  
 
Table 1.10: The definitions of Vitamin D Deficiency, Insufficiency and Sufficiency based on 
serum 250HD concentrations (nmol/L). SACN= Scientific Advisory Committee on Nutrition, 
IOM = Institute of Medicine. [110, 112, 126]. 
Most definitions of Vitamin D status are based the concentrations at which 25(OH)D 
affect calcium, bone and muscle metabolism. Vitamin D deficiency is usually defined as 
the level of 25(OH)D below which skeletal disease (osteomalacia in adults and rickets 
in children) is most likely to occur [125]. This is defined by the Department of Health in 
the UK as the level at which 97.5% of the UK population would need to protect against 
osteomalacia and rickets.  
Vitamin D insufficiency and sufficiency cut offs can be more variable than estimates of 
deficiency, with cut off levels of insufficiency and sufficiency ranging from 25-75nmol 
25(OH)D and >50nmol-125nmol respectively [127]. 
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1.10.2 Prevalence of vitamin D inadequacy 
1.10.2.1 Vitamin D status Worldwide 
 
Figure 1.14: Map of global Vitamin D status (serum 25OHD [nmol/L]) in adults (18+yrs). 
Mean 25OHD Values calculated from winter measurements. Taken from Fig. 2 [128]. 
Low Vitamin D concentrations are of global concern. A systematic review of 200 
studies summarising the mean serum 25(OH)D in 46 countries concluded that Vitamin 
D inadequacy (defined as <50nmol/L 25(OH)D) was widespread across much of Asia 
and that the vast majority of countries were below the ‘optimum’ Vitamin D 
concentration of 75nmol/L 25(OH)D as depicted in Figure 1.14 [128]. 
1.10.2.2 Vitamin D status in the UK 
There have been concerns in recent years that Vitamin D deficiency is becoming more 
common in Western countries including the UK. From the 1960s in the UK and 
elsewhere in Europe, rickets has begun to emerge in the general population, and over 
the last 15 years there have been reports of cases of rickets across the UK [127]. For 
example, between 2002 and 2008, there were 160 cases of Vitamin D deficiency 
related rickets reported in a children's hospital in Scotland. 
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Figure 1.15: Graph depicting the serum 25(OH)D concentrations of 45 year olds from the UK 
by gender and season. (W/S= Winter/Spring, S/A=Summer/Autumn).Adapted from Table 2 
[129]. 
 
Figure 1.16: Graph depicting the % of the total study sample with 25(OH)D concentrations 
below 3 different vitamin D sufficiency cut offs (25nmol <25nmol/L, <40nmol/L and 
<75nmol/L), grouped by season. . Adapted from Table 2 [129]. 
In a cross-sectional study published by Hypponen (2007), 7437 white British 45 year 
olds completed dietary and lifestyle questionnaires on factors affecting 25(OH)D levels, 
and gave blood samples for 25(OH)D measurement. Average Winter/Spring serum 
25(OH)D concentrations were 41.1nmol/L and average Summer/Autumn serum 
25(OH)D levels were 60.3nmol/L. This suggested that, on average for half of the year, 
the British population is Vitamin D insufficient (<50nmol/L) (see Figure 1.15 and Figure 
1.16). The authors concluded that Vitamin D deficiency was not just a problem 
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restricted to 'at-risk' groups in the UK, but that it is a widespread problem amongst the 
general British population, which may have important implications for bone health 
[129]. 
 
Figure 1.17: Bar chart depicting the % NDNS sample with 25(OH)D<25nmol/L, grouped by 
age category. (Children: 4-10years, Adolescents: 11-18yrs, Adults: 19-64 and Older adults: 
>65yrs).Adapted from Table 6.3 [130]. 
 
Figure 1.18: Bar chart of mean serum 25(OH)D concentration of NDNS sample by age 
category.(Children: 4-10years, Adolescents: 11-18yrs, Adults: 19-64 and Older adults: 
 >65yrs).Adapted from Table 6.3 [130]. 
The National Dietary Nutritional Survey conducted by Public Health England and the 
Food Standards Agency, also measured 25(OH)D concentrations amongst UK 
participant’s in a rolling programme in 2007/2008 and 2011/2012. From serum 
25(OH)D measurements made throughout the year, average serum 25(OH)D 
concentrations were 43nmol/L in adults (19-64yrs) and 44.5nmol/L in older adults 
(65+yrs). Mean serum 25(OH)D concentrations and % <25nmol/L were lowest in 
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adolescents and older adults at 43nmol/L and 22%, and44.5nmol/L and 21% 
respectively (see Figure 1.18 and Figure 1.17). This information demonstrated that 
both adolescents and older adults are both ‘at-risk’ groups for Vitamin D deficiency in 
Britain [130] 
1.10.3 Seasonal Variation 
 
Figure 1.19:% of UK population with of 25(OH)D deficiency (<25nmol/L) by season. Winter 
(December-February), spring (March-May), summer (June-August) and fall (September – 
November). Taken from Figure 3 [129]. 
As can be seen in Figure 1.19, there are clear seasonal variations in Vitamin D 
deficiency in the UK due to the lack of available of appropriate UV light for cutaneous 
Vitamin D production in the UK between October and April [110]. As described in 
section 1.10.2.2 above, Hypponen assessed 25(OH)D levels in 7437 British adults and 
found mean 25(OH)D levels varied from 41.1 (95% CI: 40.4, 41.8) in December – May 
to 60.3 (95%CI 59.5, 61.0) in June-September, peaking in September and at their 
lowest point in January-April [129]. This data was also reflected in the NDNS 
2007/2008 and 2011/2012rolling programmes which showed a peak in 25(OH)D 
deficiency in the UK in January – March and lowest levels of 25(OH)D deficiency July-
September [130] ( see Figure 1.20). 
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Figure 1.20: Bar chart of the % of NDNS sample classed as Vitamin D deficient (<25nmol/L) 
from serum 25OHD measurement by month of sample collection and age group(Children: 4-
10yrs, Adolescents: 11-18yrs, Adults: 18-64yrs and Older adults: >65yrs) [130].Adapted from 
Table 6.3.1. NDNS [130]. 
1.10.4 Vitamin D deficiency: at-risk groups 
NICE is now emphasising the importance of ensuring that vitamin D adequacy in 
vulnerable groups is addressed in their recent guidelines ‘Vitamin D: Increasing 
supplement use in at risk groups’. This guideline focuses on increasing the awareness 
of the importance of vitamin D and access to vitamin D supplements in at risk groups. 
Supplementation of 100% RNI/day is recommended in this guidance: 340IU 
(8.5µg)/day for infants, 280IU (7µg)/day for children (<5yrs) and 400IU (10µg)/day for 
adults [131]. 
According to NICE Guidance, those considered ‘at risk’ groups for Vitamin D deficiency 
are:  
 Pregnant and Breastfeeding women 
 Infants and Children (<5 years) 
 Older Adults (>65 years) 
 People with low/no exposure to sunlight, e.g. those who cover their skin for 
cultural reasons or housebound individuals 
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 People with darker skin, e.g. individuals of African, African-Caribbean and South 
Asian descent[131]. 
In a 2014 review of Vitamin D status in Europe, Spiro et al. also identified additional at 
risk groups amongst the European population:  
 Migrant populations/Asylum seekers 
 Adolescents (particularly females)[127] 
Data from the NDNS (National Dietary Nutritional Survey) in England (2008-2012) also 
demonstrated that there was a high prevalence of Vitamin D deficiency amongst 
adolescents (11-18 yrs) and adults (19-64 yrs), with 40% and 39.3% of these groups, 
respectively, showing vitamin D deficiency (<25 nmol/L) during winter (Jan-
March)[130]. 
Data from earlier (2000-2001) NDNS reports demonstrate more differentiation 
between the adults groups and support the idea that younger adults are at higher risk 
of Vitamin D deficiency, compared with other adult groups (Figure 1.21) [132]. 
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Figure 1.21: % NDNS sample with serum 25(OH)D<25nmol/L in 4 adult age groups (19-64yrs) 
by gender. Adapted from Table 4.33 [132]. 
1.10.5 Summary of Factors affecting Vitamin D status 
Several environmental, dietary and individual factors influence each individual’s 
25(OH)D concentration (see Table 1.11), and negatively affect 25(OH)D production 
resulting in increased risk of 25(OH)D deficiency. Age and obesity are discussed in 
detail in sections 1.10.5.1 and 1.10.5.2. 
Factor affecting Vitamin D intake Explanation 
Environmental 
Factors 
UVB availability: 
Latitude, Season 
and Time of Day. 
UVB radiation between the wavelengths of 
280-315nm are required to trigger dermal 
synthesis of Vitamin D in humans. However, 
the amount of UVB reaching the earth’s 
surface depends heavily upon latitude, 
season, and time of day due to the variation 
in the angle the radiation takes through the 
earth’s atmosphere (specifically the ozone 
layer). The smaller the angle (e.g. at 
noon/summer/low latitudes), the more direct 
the path UVB radiation takes to the earth’s 
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surface and the more UVB reaches the 
surfaces [110]. 
The above means that in the UK, UVB 
exposure is effective for dermal Vitamin D 
production in the late spring, summer and 
early autumn (April-October) between 10:00-
15:00 [133]. 
Weather and 
pollution 
Cloud cover and pollution can filter and block 
sunlight of the required wavelength to make 
vitamin D, thereby reducing the amount of 
vitamin D that can be made by individuals 
[133]. Additionally, weather and pollution 
may influence individual’s choices on skin 
exposure and outdoor activities, which may 
further limit exposure to UVB [110]. 
Time spent 
outdoors 
As exposure to UVB radiation is essential to 
dermal Vitamin D production, individuals who 
are institutionalised or housebound are at 
high risk of vitamin D deficiency due to a lack 
of UVB exposure [133]. 
Clothing choices  Clothing can be effective in blocking sunlight 
exposure and therefore dermal synthesis of 
Vitamin D. Those who cover most of their 
body e.g. including face, head and arms may 
increase risk of Vitamin D deficiency [133].  
For example, a study of 100 young females 
from Istanbul measured serum 25(OH)D in 
those who adopted Muslim dress (covering 
whole body except face and hands) and those 
who did not. Mean serum 25(OH)D was 21.1 
(±6.7) and 29.7 (±3.1) and % vitamin D 
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deficiency (defined as <50nmol/l) was 55% 
and 20% respectively.  
Sunscreen use Sunscreens which block UVA and UVB 
wavelength radiation from penetrating the 
skin could limit the amount of Vitamin D 
produced by the skin. However, in a real 
world setting, due to variation in application, 
it is likely that Vitamin D production is 
possible even with sunscreen use [110, 112]. 
Dietary 
Factors 
Intake from 
Natural sources 
There are few naturally Vitamin D rich foods. 
The richest dietary sources of Vitamin D are 
Salmon (100-1000IU [2.5-25µg]/100g), Cod 
Liver oil (400-1000IU [10-25µg]/1tsp), 
Sardines (300IU [7.5µg]/100g), Mackerel 
(250IU [6.25µg]/100g), Tuna (230IU 
[6.25µg]/102g), Shitake Mushrooms (100-
1600IU [2.5-40 µg]/100g) and Egg Yolk (20IU 
[0.5µg]/yolk) [117]. 
Intake from dietary sources becomes 
particularly important when UVB exposure is 
low, and can contribute significantly to 
Vitamin D status along with supplementation 
and fortification [133]. E.g. Scandinavian 
countries receive limited UVB exposure, 
however, due to high oily fish consumption 
and food fortification policy, population 
25OHD concentrations are relatively high 
compared with the rest of Europe [127]. 
In the UK, Vitamin D intake from food sources 
(excluding supplements) is generally low, with 
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the average adult (18-64yrs) consuming 
3.6µg/day (27% daily RNI) [130]. 
Supplements Vitamin D supplement use and promotion 
vary between countries. In the UK, 
supplements are readily available and are 
recommended to specific 'at-risk' groups for 
Vitamin D deficiency, including; children 
<3years, pregnant/lactating women, adults 
>65years, ethnic minorities and those with 
restricted sunlight exposure [131]. 
Supplementation is also prescribed to those 
who are diagnosed as 25(OH)D deficient 
(<25nmol/L) (10,000IU [250µg]/day for 8-12 
weeks) [134]. 
Food Fortification Fortification of foods as a mechanism of 
increasing nutrient levels at a population level 
is particularly important in countries where 
intake of that nutrient may be low; however, 
Vitamin D fortification policies vary between 
countries. In Europe there is mandatory 
fortification of margarine (in 2013 in the UK 
this mandatory fortification was removed but 
fortification of many margarines continues on 
a voluntary basis [110]) and in the UK 
specifically mandatory fortification of infant 
formulae. There is also voluntary fortification 
of breakfast cereals and some milk products 
(e.g. yogurts). [127] 
Vitamin D fortified foods contribute 
significantly to the mean dietary vitamin D 
intake in the UK, with fat spreads, cereal 
products and milk products contributing 19%, 
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13% and 5% of the average adult (18-64) 
dietary vitamin D intake/day respectively 
[130]. 
However, there are disadvantages to 
fortification, e.g. fortification of a single food 
item means that non-consumers of that item 
will not increase their intake. Also, high 
consumers of that food item may be at 
increased risk of toxicity. This has led to 
suggestions that fortification of many 
different foods with low concentrations of 
Vitamin D may be a better option [127]. 
Individual 
factors 
Skin pigmentation Observational studies have shown that those 
with darker skin pigmentation have lower 
serum 25(OH)D concentrations. A meta-
analysis of studies assessing 25(OH)D 
concentrations in healthy free living 
populations found that Caucasians (n=96 
studies) had an average 25(OH)D 
concentration of 68.0 (±3.2) compared with 
47 (±4.0) nmol/l in non-Caucasians (n=55 
studies). This is a mean difference of 21.2 
(±5.1) (p=0.01) [135]. 
Reasons for this difference in 25(OH)D 
concentrations with skin pigmentation 
include differences in sun behaviours (e.g. sun 
avoidance or clothing coverage) and genetic 
differences.  
In addition, higher concentrations of melanin 
(the pigment giving skin its brown/black 
colour) in the skin may absorb more UVB, 
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leaving less UVB available to be absorbed by 
7-DHC (and subsequently be converted to 
Vitamin D). However, the results of studies 
examining the relationship between melanin, 
UVB exposure and Vitamin D production have 
been variable, and this issue requires further 
clarification [110]. 
Age As age increases, the capacity to synthesis D3 
from UVB exposure decreases (see 1.10.4.1 
for more details) [133]. 
Adiposity Obese individuals have lower serum 25(OH)D 
concentrations when compared with normal 
weight individuals (see section 1.10.5.2 for 
further discussion) [133]. 
Health status: 
Kidney and Liver 
Function 
Reduced liver function can limit conversion of 
pre-Vitamin D to 25(OH)D and lead to 
decreased 25(OH)D status and vitamin D 
deficiency.  
In addition, decreased conversion of 25(OH)D 
into 1,25(OH)D by the kidney can lead to 
decreased availability of active vitamin D and 
a build-up of 25(OH)D in circulation [110]. 
Table 1.11: Summary of factors which affect 25(OH)D concentrations. 
1.10.5.1 Ageing and Vitamin D deficiency 
 A combination of these factors including lower dietary intake, lower cutaneous 
synthesis of D3 and medication use affecting vitamin D metabolism, are likely factors 
contributing to increased risk of vitamin D deficiency in older people [136]. Reported 
factors which may contribute to increased risk of vitamin D deficiency in older people 
include: 
a) Low dietary vitamin D consumption 
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The results of the most recent rolling programme of the NDNS (2008/2009-2011-2012) 
showed that older adults (>65 years), had an average 25(OH)D concentration which 
was insufficient (<50nmol/L) for most of the year, with the exception of the summer 
months when the average 25(OH)D was 50.5nmol/L.  
Vitamin D intake from food sources (fortified and natural) and supplements was low, 
with a mean intake of 5.1 µg/day Vitamin D (51% RNI). However this is 1.5µg/day 
higher intake of Vitamin D than adults (18-64 years). [130] 
b) Adverse effects of institutionalisation 
Vitamin D status is significantly lower in the institutionalised older people, with mean 
values for men and women of 38.1nmol/L and 36.7nmol/L respectively compared with 
56.2nmol/L and 48.4nmol/L in free living men and women respectively aged >65years. 
Prevalence of deficiency (<25nmol/L) was also higher in institutionalised men and 
women (30.2% and 32.5% respectively) than free-living men and women (9.6% and 
15% respectively) >65years. [110] 
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c) Lower 7-dehydrocholestorol availability 
 
Figure 1.22 Graph demonstrating the effect of age in years (x-axis) on 7-dehydrocholestrol 
concentration (y-axis) in the dermis and epidermis of Caucasian adults (18-92 years). Taken 
from Figure 1 [137]. 
Amounts of  7-dehydrocholestrol in the epidermis decline steadily with increasing age 
(as depicted in Figure 1.22), probably due to the age associated steady decrease in 
epidermal mass seen >20years [137] which  may reduce the capacity for  Vitamin D 
from cutaneous synthesis. However the most recent SACN report on Vitamin D 
concluded that current evidence, was insufficient to conclude that 7-DHC was a 
limiting factor in Vitamin D production in older people [110]. 
d) Health status 
Poor health in older age, including conditions affecting the function of the liver and 
kidneys, may reduce conversion of Vitamin D to 25(OH)D and 1,25(OH)D (the 
metabolite of Vitamin D capable of exerting Vitamin D related actions). However, low 
circulating concentrations of 25(OH)D are usually a result of reduced Vitamin D intake 
(dietary and cutaneous), rather than impairments in Vitamin D metabolism [110]. 
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1.10.5.2 Obesity and Vitamin D deficiency 
A negative correlation between vitamin D status and body fat /BMI has been reported 
in many observational studies. For example, a recent systematic review of 23 
observational studies found that Vitamin D deficiency was 35% and 24% higher in 
obese and overweight respectively, than in normal weight comparators irrespective of 
age and study location [138]. 
The reasons for the relationship between vitamin D status and obesity are not clearly 
understood but may include: 
a) 25(OH)D sequestration in adipose tissue 
Adipose tissue is the main storage site for vitamin D, confirmed in Vitamin D radio 
labelling experiments[139]. In obese individuals, this may result in higher amounts of 
25(OH)D being 'sequestered' in adipose tissue and not released when required i.e. 
adipose tissue may act as a vitamin D ‘sink’, restricting entry to the circulation[110, 
112, 140]. 
This suggests that obese individuals have reduced Vitamin D bioavailability, and 
require a larger Vitamin D intake to achieve the same serum 25(OH)D concentration as 
a normal weight individual. In a supplementation study in which obese and normal 
weight individuals were given 700IU [17.5µg] Vitamin D per day, it was estimated that 
obese individuals need an additional 17% of Vitamin D for every additional 10kg above 
'normal weight' to achieve the same 25(OH)D status as the normal weight group[141]. 
In support of this Vitamin D sequestration/reduced bioavailability theory, weight loss 
studies have shown that body fat loss results in higher 25(OH)D concentrations[142]. 
b) Volumetric Dilution 
This theory challenges the sequestration theory by stating that the apparent difference 
in 25(OH)D concentrations in obese individuals, is simply due to dilution of 25(OH)D 
across the larger volume of body mass (see Figure 1.22). 
In a cross sectional study of 686adults, the differences in 25(OH)D attributed to obesity 
disappeared when serum 25(OH)D concentrations were adjusted for body 
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weight/body fat using linear and hyperbolic modelling. The author concluded that this 
rendered the theory of Vitamin D sequestration unnecessary, since when fat mass is 
taken into account appropriately, there is no difference in 25(OH)D concentration 
between obese and lean individuals. In light of this, the author also highlighted the 
importance of tailoring of Vitamin D intakes according to body size to achieve desirable 
25(OH)D status [143]. 
 
Figure 1.23:  25(OH)D is distribution throughout the body according volumetric dilution. 
Vitamin D is taken in by cutaneous synthesis or ingestion. This enters the circulation bound 
to DBP (Vitamin D binding protein) and also passively diffuses into the adipose tissue. It is 
then taken up into the liver for conversion to 25(OH)D. This means as body mass increases, 
25(OH)D dilutes over a larger area, leaving less 25(OH)D diluted in the serum.[143].Taken 
from Figure 2 [143]. 
c) Metabolism of Vitamin D in Adipose Tissue 
It has been proposed that lower Vitamin D concentrations in obese individuals are due 
to catabolism of Vitamin D in the adipose tissue via 24 hydroxylases which are 
expressed in adipose tissue[144].In a study in 37 obese and 20 lean participant’s 
plasma 25OHD concentrations in lean and obese people were 54nmol/L and 29nmol/L 
respectively (p=0.006), and correlated inversely with BMI (r=-0.38, p=0.017). 
Expression of CY2J2 (25-hydroxylase which metabolises Vitamin D to 25OHD) and 
CYP27B1 (1ᵅ hydroxylase which converts 25OHD to 1,25OHD) was decreased by 71% 
(p=0.0001), and 49% (p=0.05) in the subcutaneous adipose tissue of obese 
participant’s compared with lean participant’s. The authors concluded that adipose 
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tissue has an active role in the metabolism and catabolism of Vitamin D and that this 
becomes impaired in obesity [145]. 
1.11 Vitamin D and KOA 
I have summarised below the current observational and limited available 
interventional evidence regarding the relationship between KOA and Vitamin D.  
1.11.1 Observational Studies 
Several studies have assessed the relationship between serum 25(OH)D concentration 
and radiographic KOA severity, with mixed results.  
The Framingham Osteoarthritis Study, which measured radiographic KOA (K&L grade) 
in 715 at 2 time points 1993-4 and 2002-5, found only slight, non-significant worsening 
of OA (measured as proportion of participant’s with joint space loss) with low Vitamin 
D status (lowest tertile) (see Table 1.12). However, it is important to note that the 
majority of participant’s started without evidence of radiological KOA (87% K&L <grade 
2), with only 20.3% of these showing joint space narrowing at follow up. In addition, 
Vitamin D concentration was not measured at the time of radiograph, but was 
measured between the original visit and follow up visit (1996-2000), so it possible 
vitamin D status at this time was not representative of that when radiographs were 
taken [87]. 
 
Table 1.12: The proportion of knees showing joint space narrowing on follow up by serum 
25(OH)D tertile (High, Medium, low) in The Framingham Osteoarthritis Cohort Study. 
Adapted from Table 2 [87]) 
A 2013 systematic review of 13 observational studies and 2 RCTs concluded that there 
was moderate evidence (2 high quality cohort studies) for an association between 
25(OH)D concentration and radiological progression of KOA, and strong evidence (4 
high quality cohort studies) for an association between 25(OH)D concentration and 
cartilage loss (measured as changes in joint space narrowing or cartilage volume). This 
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review also highlighted the limited amount of research available to determine the 
relationship between 25(OH)D and OA in other joints (hand and hip) and symptomatic 
OA [93]. 
There are few observational studies addressing the relationships between serum 
25(OH)D status and symptoms of KOA. However, one longitudinal study of 769 older 
people (50-80yrs) with knee or hip pain, in which hip/knee radiographs and serum 
25(OH)D was measured at baseline, and after 2.6 and 5 years concluded that serum 
25(OH)D <25nmol/L predicted increases in self-reported knee pain (p=0.002) [89]. 
In summary, the observational evidence suggests that maintaining sufficient Vitamin D 
status may slow progression of KOA, but evidence regarding symptom relief is limited 
and requires further investigation. 
1.11.2 Interventional Studies 
The first large Vitamin D supplementation (2000IU [50µg]/day over 2 years) study in 
KOA participant’s assessing radiographic and symptomatic outcomes, showed a small 
non-significant improvement in self-reported knee pain (-2.31 points in vitamin D 
group vs -1.46 points in placebo group) (p=0.17). However, a sub-analysis of those with 
serum 25(OH)D<25nmol/L showed a larger (but still non-significant) difference 
between change in self-reported pain in the Vitamin D supplementation and placebo 
groups (-2.7points vs -1.0 points respectively). There was no significant change 
between Vitamin D and Placebo groups for any radiographic measurement, and the 
authors concluded that there was insufficient evidence that Vitamin D 
supplementation was beneficial in slowing the progression of KOA in those with serum 
25(OH)D <25nmol [92]. 
A very recent (2016) 3 year vitamin D supplementation study [146] in five UK hospitals 
of patients with radiographic KOA (K&L score 2-3), showed no significant difference in 
joint space narrowing (JSN) or self-reported of symptoms of KOA. However, it is 
important to note that participant’s with variable baseline 25OHD were recruited into 
the Vitamin D supplementation and placebo interventions. However, as we have seen 
from the McAlindon study above, those with lower baseline 25OHD show larger 
improvements in KOA outcomes with Vitamin D supplementation. Subgroup analysis of 
 69 
those with low 25(OH)D (classed as <50nmol/L in this study) showed no statistically 
significant interaction between baseline 25(OH)D and treatment effect for JSN 
(Treatment effect -0.06mm, 95% CI -0.20 to 0.32)[90]. 
1.11.3 Problems regarding current Vitamin D supplementation studies 
As highlighted above, there are flaws in the design of the few published studies. The 
primary problem is recruitment of study participant’s without regard to their baseline 
serum 25(OH)D concentration. One would predict that only those with “insufficient” 
vitamin D status would benefit from vitamin D supplementation so results could be 
“diluted” by lack of effect in study participants with adequate vitamin D status. This 
idea is supported by sub analyses in which those who are 25(OH)D deficient have 
yielded [92] larger improvements in KOA outcomes with supplementation than all 
25(OH)D levels combined [92]. 
Therefore, studies which examine the effect of vitamin D supplementation on KOA 
outcomes in 25(OH)D deficient populations are needed. However, this introduces 
problems in identifying (through screening) and recruiting such specific individuals 
(this issue is further discussed in Chapter 2)[147]. Pilot studies are therefore needed to 
identify the potential problems and solutions to recruiting suitable participants for a 
vitamin D supplementation study in KOA. 
1.12 Physical Activity and KOA 
Physical activity is defined as “any bodily movement produced by skeletal muscles that 
requires energy expenditure” (WHO, 2017 [148]). This can include any type of activity, 
taking place when working, playing, carrying out daily activities or as a recreational 
pursuit. Physical activity is not the same as exercise which is type of physical activity 
which structured and planned with the specific aim to improve fitness.  
Taking part in physical activity has a range of positive general health benefits including 
improving muscular and cardiorespiratory fitness, improve bone and function health, 
reducing risk of hypertension, coronary heart disease, stroke, diabetes and various 
cancers, reducing risk of falls and subsequent fractures and in regulating energy 
balance and controlling weight. [148] 
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However despite the massive benefits of physical activity on health, physical inactivity 
is prevalent. Physical inactivity (definitions of which vary according to different physical 
activity guidelines) is the fourth leading risk factor for global mortality, causing an 
estimated 3.2 million deaths globally. In 2010, approximately 23% adults over 18 years 
old (20% men and 27% women) were not active enough globally. [148] Addressing the 
current global problem of physical inactivity is essential for the prevention of non-
communicable disease (including osteoarthritis), so much so that the WHO has placed 
great focus on the matter in their 2010 "Global Recommendations on Physical Activity 
for Health" report. [149] 
1.12.1 Physical activity guidelines 
1.12.1.1 World Health organisation recommendations 
The WHO recommends all adults aged 18-64 years should do at least 150 minutes of 
moderate intensity (or 75 minutes of vigorous intensity) aerobic PA throughout the 
week, performed in bouts of 10 minutes. For additional health benefits it is 
recommended adults increase their PA to 300 minutes of moderate intensity (or 150 
minutes of vigorous intensity) PA throughout the week. Muscle strengthening exercise 
(involving major muscle groups) should also be done on 2 or more days a week. [150] 
For older adults (65 years and over), the WHO recommends the same level of activity 
as specified for adults aged 18-64 years (see above) with these additional 
recommendations: [151] 
 Older adults with poor mobility should perform PA to enhance balance and 
prevent falls on 3 or more days per week. 
 When older adults cannot do the recommended amounts of PA due to health 
conditions they should be as physically active as their abilities and health 
allows. 
1.12.1.2 UK Department of Health recommendations 
Recommendations on physical activity recommended by the UK Department of Health 
are very similar to the WHO recommendations. For adults aged 18-64 years, it is 
recommended that adults complete all activity recommended by WHO for that age 
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group (see section 1.12.1.1), with the addition of minimising the amount of time spent 
being sedentary for extended periods. [152] 
Recommendations for older adults (65 years or over) include all which is specified for 
older adults by WHO (see section 1.12.1.1) with the addition of minimising the amount 
of time spent being sedentary for extended periods. [153] 
1.12.2 Physical activity and the pathogenesis of KOA 
The exact role of physical activity in the pathogenesis of KOA is not currently 
completely understood. However there are several current theories as to what the role 
of physical activity may be in KOA, which will be described in this section. 
1.12.2.1 Physical activity, mechanical loading and KOA 
According to existing evidence, physical activity can have both beneficial and 
detrimental effects to the knee joint depending on the context.  
Under normal conditions, physical activity is beneficial to the knee cartilage as it acts 
as a mechanical stimuli to the cartilage (within a physiological range), which has 
several subsequent effects of the cartilage which are important for maintain cartilage 
homeostasis [154, 155]: 
 Increasing hydrostatic pressure, which enhances the profusion of the synovial 
fluid throughout the cartilage which provides nourishment for mature cartilage 
cells trapped within the cartilage matrix. This is important as the cartilage has 
no vasculature and therefore no other means of distributing nutrients. 
 Induces (via the action of mechanoreceptors) biosynthesis of components (e.g. 
type II collagen and aggrecans) of the ECM of the cartilage, thereby maintaining 
cartilage tissue integrity by preventing cartilage atrophy and ensuring the 
cartilage maintains deformation capacity 
 Induces chondrogenesis (production of new chondrocytes) by simulating the 
differentiation of undifferentiated stem cells.  
 Promotes the release of anti-inflammatory cytokines (e.g. IL-4) which 
subsequently reduce the expression of inflammatory cytokines (e.g. NFκB and 
TNFα) 
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Mechanical loading of the joint (in which physical plays a part) is regulated in the 
normal cartilage by the high water content within the cartilage which contributes to 
about 90% load support and shield the ECM from excessive stress or friction. However, 
changes to the careful balance of the structure of the cartilage (e.g. as a result of 
injury, repetitive loading or extreme torsional strain which can be induced by certain 
sporting, occupational or recreational activities) can result in excessive joint loading 
and induction of proinflammatory cytokine expression which cause subsequent 
damage to and degradation of the cartilage (a key event in the pathogenesis of OA), 
even under physiologically normal levels of loading to the joint.[2] And so in the 
context of other risk factors for the development of KOA (a comprehensive summary 
of which can be found in section 1.4) like previous injury or surgery to the joint and 
abnormal joint stability and range of motion, can produce and abnormal joint 
environment which may result in joint damage under normal physiological loading and 
activities such as physical activity. [2, 155] 
Immobility is also harmful for the joints, causing a loss of flexibility around the knee 
joint and surrounding tissues, which can lead to impaired or altered gait and unequal 
distribution of force across the joint, causing pain and dysfunction of the joint. [155] 
1.12.2.2 The impact of physical activity on other risk factors of KOA  
Physical activity is important for the modulation of other risk factors which contribute 
to the pathogenesis of KOA by promoting the growth and maintenance of the cartilage 
(via the mechanism outlined above), strengthening the muscles surround the joint and 
by regulation of obesity. I have briefly described the potential role physical activity on 
those risk factors below:  
a) Physical Activity and Obesity in KOA 
Physical activity, along with diet, is an essential component in maintaining energy 
balance. When energy input and output becomes unbalanced (due to increased energy 
intake, reduced energy expenditure, or commonly both) to produce an energy surplus, 
this results in fat accumulation and obesity. [156] As described in detail in section 
1.4.2.1, obesity is an important modifiable risk factor involved in the pathogenesis of 
KOA. It is therefore logical to assume that as physical activity has an important role in 
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the maintenance of energy balance and obesity has an important role in KOA 
pathogenesis, that physical activity may have a beneficial effect of KOA pathogenesis 
via the prevention or modification of obesity. Interventional studies have investigated 
the role of physical activity and diet for weight loss with the aim of improving KOA 
progression and symptoms. For example, a randomised, single blind clinical trial (the 
ADAPT Trial) of exercise and dietary interventions to reduce weight in community 
dwelling overweight and obese adults (> 60 years) found that an exercise plus dietary 
programme n=76) resulted in mean 5.2kg (95% CI 0.85, 9.55) weight loss and resulted 
in significant improvements in knee pain (p=<0.05), 6 minute walk distance (p=<0.05) 
and stair climb time (p=<0.05). The exercise only group within this study resulted in a 
mean 3.46kg (95%CI -0.77, 7.69) of weight loss and achieved significant improvement 
in 6 minute walk distance (p=<0.05). [157] 
b) Physical Activity and muscle in KOA 
Physical activity has an important role in strengthening the muscles which surround 
and support the joints which subsequently reduces risk of injury. [158] Impaired 
quadriceps strength have been linked to prevention of KOA in cross sectional studies, 
with increased quadriceps strength found to be protective against cartilage loss at the 
patellofemoral joint (OR: 0.4 [95% CI 0.2, 0.9] for highest versus lowest tertile of 
quadriceps strength).Quadriceps strength has also been associated with KOA 
symptoms in a cross sectional study of 300 KOA participants with knee pain (assessed 
by WOMAC questionnaire) vs 300 KOA participant without pain, which showed 
participants with pain had significantly (p=0.005) lower quadriceps strength than those 
without pain and that quadriceps strength was independently associated with pain 
(OR: 18.8 [95% CI: 4.8, 74.1).[159]Knee extensor strength has also been associated 
with decreased risk of developing symptomatic (but not radiographic) KOA in a 2010 
longitudinal study of 1617 older adults (aged 50-79 years), with women in the highest 
tertile of peak knee extensor strength (compared to the lowest tertile) having reduced 
incident symptomatic KOA with an OR of 0.5 (95% CI 0.3, 0.8). [160] 
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1.12.3 Physical activity and KOA: Observational Evidence 
1.12.3.1 Physical guidelines and KOA 
Low levels baseline levels of PA have been consistently reported in those with KOA in 
the literature. For example, a US study reported that 30% of KOA participant’s 
achieved recommended PA levels (30min/day moderate PA, 5days/week) compared 
with 45.4% reported by the general US population [161].A 2013 systematic review of 
21 studies of KOA patients included n=3266 participants with a weighted mean 
average age of 64 years, mean BMI 30kg/m2 and 63% had severe KOA (K&L grade III or 
IV). The weighted mean moderate-vigorous PA (MVPA) in bouts of >10 mins was 50 
minutes per week (95%CI 46, 55), weighted mean MVPA was 131 minutes per week 
(95% CI 125, 137) and weighted mean daily steps per day were 7753 (95% CI 7582, 
7924). Proportion of KOA participants meeting physical activity guidelines were also 
measured calculated and it was found there was high quality evidence that 13% 
participants met PA guidelines (defined as 150mins/week of MVPA in bouts of 
>10mins) and moderate quality evidence that 19% participant met the guidelines of 
10,000 steps per day. [162] This is low compared to the UK general population in which 
66% men and 54% women (>18 years old) met PA guidelines of >150min MVPA/week 
(according to 2012 data presented by BNF). [163] 
It has been hypothesised that pain avoidance contributes to the lower PA patterns 
observed in KOA sufferers, but this hypothesis has been disputed, with some studies 
demonstrating that pain does not have a significant relationship with the amount of PA 
performed in those with KOA [164, 165] 
1.12.3.2 Physical activity in preventing KOA  
Physical activity alone does not seem to increase risk of developing KOA. Current 
evidence shows either no associated effect of recreational physical activity on risk of 
KOA or decreased risk of KOA, e.g. a case control study of men and women (n=281) 
about to receive knee arthroplasty for primary KOA retrospectively assessed lifetime 
physical activity and found risk of arthroplasty decreased with increasing cumulative 
hours of recreational activity. OR (95%CI) in men with low and high (dichotomised by 
the mean) cumulative exercise hours for knee arthroplasty were 0.91 (95% CI 0.31, 
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2.63) and 0.35 (95% CI 0.12, 0.95) respectively. The OR for knee arthroplasty by 
cumulative exercise hours for women were less disparate than in men at OR (95%CI) 
0.56 (95% CI 0.3, 0.93) for low cumulative exercise hours and 0.56 (95% CI 0.32–0.98) 
for high cumulative exercise hours. [166]Studies of the Framingham cohort (n=1279) 
found that participation in self-reported recreational physical activity (walking, jogging 
and working up a sweat) was not associated with decreased or increased risk of OA 
(including in those classed as obese [defined as BMI >30kg/m2]).[167] Another study 
within the Framingham cohort (n=1415), which assessed self-reported hours per day in 
different intensities of physical activity ranging from sedentary to heavy activity) found 
no association with habitual physical activity and KOA after adjusting for age, BMI, 
knee injury, smoking and education. They also found no increased risk of KOA with 
increasing PA. [168] 
1.12.4 Physical activity and KOA: Interventional evidence 
1.12.4.1 Exercise and KOA 
Exercise is recommended as one of the first treatment options for KOA by NICE. [10] 
Many different types of exercise have been trialled in KOA populations but the 
consensus is that physical activity is beneficial for the joints tissues and improves 
symptoms and function in people with OA. [169] A Cochrane systematic review of RCTs 
of exercise interventions for knee osteoarthritis reported that exercise significantly 
reduced knee pain by 12/100 points (95% CI 10, 15)  and improved physical function by 
10/100 points (95% CI 8, 13) immediately after treatment. 12 studies also reported 
significant reductions in knee pain (6/100 points, 95% CI 3, 9) were sustained at 2-6 
months post treatment and 10 studies showed improvements in physical function 
(3/100 points, 95% CI 1, 5) were sustained at 2-6 months post treatment. [170] 
Many interventional studies have investigated the effects of certain types of exercise 
(e.g. aerobic, muscle strengthening, balance and coordination and water based 
exercises) on KOA outcomes. A systematic review and meta-analysis comparing the 
effect of aerobic walking exercises (4 studies) and quadriceps strengthening exercises 
(10 studies) in KOA populations concluded that both aerobic and strengthening 
exercises resulted in reduction of pain (weighted pooled effect size 0.52 (95% CI 0.34, 
0.70) and 0.32 (95% CI 0.23, 0.42) respectively) and reduced self-reported disability 
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(weighted pooled effect size 0.46 (95% CI 0.25, 0.67) and 0.32 (95% CI 0.23, 0.41)). As 
both types of exercise resulted in benefits in pain and disability outcomes, it was 
suggested by the authors of this paper that as both types of exercises produced 
benefits and adherence is the main predictor to response to exercise, in clinical 
practice patients should be offered a choice of the type of exercise intervention they 
would like to participate in. [103] The literature regarding exercise interventions to 
improve balance are more difficult to summarize due to the variation in their methods 
and interventions used. Once of the most common types of balance based exercise 
tested in KOA patients is Tai Chi. An RCT of n=56 participants randomised to a 12-week 
Tai Chi class or waiting list control group showed mean improvements in pain of 5.2 
points (95% CI, −0.8 to 11.1) (0-100 scale) and mean improvement in physical function 
of 9.7 (95% CI, 2.8–16.7) (0-100 scale). [171] Finally the effect of water based (or 
aquatic) exercise on knee osteoarthritis outcomes was assessed in a 2015 meta-
analysis of 6 RCTs of aquatic based exercise interventions. This meta-analysis 
concluded that there was no significant effect favouring aquatic exercise on physical 
function (SMD 0.31, 95% CI 0.01, 0.63), pain (SMD − 0.25, 95% CI 0.74, 0.24) or 
stiffness (SMD − 0.15, 95% CI 0.47, 0.17), when compared to land based exercise. 
When compared to no exercise, there was moderate evidence for a moderate effect of 
aquatic exercise of physical function (SMD − 0.55, 95% CI 0.94, 0.16) but not for pain or 
stiffness. [172] 
1.12.4.2 Physical activity and KOA 
Evidence regarding non-structured physical activity programmes for the treatment of 
knee osteoarthritis is sparser than for structured exercise programmes. It is important 
to establish if self-managed, lifestyle based physical activity interventions are effective 
in targeting and changing physical activity behaviours, as this is essential to modifying 
behaviour in the long term beyond the end of the intervention period. One home 
based, self-managed 12 week pedometer driven walking programme in older (>60 
years), community dwelling adults with symptomatic OA was reported. In this 
randomised trial, steps increased by 23% in the intervention group and decreased by 
15% in the control group but there was no significant difference in change of pain from 
baseline to 12 weeks between the intervention and control group  (F= 0.75, P = 0.40). 
[173] However more evidence of home based, self-managed PA programmes is needed 
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to establish their effectiveness in increasing PA, on KOA symptoms and on long term 
maintenance of activity.  
1.12.5 Physical Activity programmes and KOA: Gaps in the literature 
Despite the wealth of literature regarding the association between physical activity 
and KOA and many studies demonstrating that various type of physical activity 
interventions are beneficial for KOA symptoms (see section1.12.4), there are several 
gaps in the existing literature regarding the use of physical activity programmes in KOA 
populations which need to be addressed. These gaps are described below: 
Promotion of structured exercise is recommended in KOA [10] but not specifically 
increasing levels of wider types of physical activity. Therefore there is limited evidence 
about the effectiveness of interventions to promote PA in people with KOA, 
particularly in those with higher adiposity. 
Lifestyle based PA interventions in other populations of sedentary adults have been 
recommended as an alternative to more structured exercise programmes, to which 
there have been many identified barriers (e.g. lack of time and dislike of vigorous 
exercise). A study of 235 sedentary adults taking part in a two year lifestyle based PA 
or structured exercise programme concluded that both were equally effective in 
increasing PA and cardiorespiratory fitness [174]. PA interventions in older population 
groups can be effective up to 12 months (but beyond this was unclear) and that 
interventions which included goal setting activities were likely to be the most effective 
[175, 176]. Investigation of PA interventions in an older population of KOA sufferers is 
sparse and inconclusive, with no effect on symptoms reported. However, one study 
demonstrated that an individualised advice-based PA intervention raised PA levels and 
intention to exercise in sedentary, older OA sufferers [177]. 
Because PA helps to maintain energy balance and to reduce risk of weight gain, 
reduced PA can result in a vicious cycle of weight gain and decreased PA, which can 
exacerbate joint pain and disability in OA sufferers [178, 179]. This suggests that PA 
interventions could play a part in breaking this destructive cycle and, for this reason, 
investigations into effective PA interventions for use in obese KOA populations are 
needed. 
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This is particularly important given that exercise is recommended by NICE as a core 
treatment in OA [10] and that problems with exercise adherence and uptake amongst 
patients are acknowledged. 
1.12.5.1 Online Programmes for delivery of Physical Activity and Exercise 
Interventions. 
Home based self-management exercise programmes, such as walking programmes, are 
popular options for the delivery of interventions in those with KOA [173], and can offer 
benefits such as easier incorporation into patient lives and are inexpensive alternatives 
to structured, supervised programmes [173].They can be effective in improving 
symptoms and can be maintained for up to 1 year [180]. 
There are few examples of the use of online technology to improve PA in those with 
KOA. However, a 12 month online PA programme was tested in an older (50-80yrs) 
population with self-reported HOA or KOA. Subjective PA measures (with a subgroup 
of objective PA measures) and self-reported pain and quality of life measures were 
made at baseline, 3 and 12 months. The PA programme involved the completion of a 
baseline test, goal setting and time limited PA objectives (with prompting tests). 
Results demonstrated good adherence to the programme (46% completed 6/9 online 
modules) and increases in self-reported and objective (+24mins activity/day compared 
to control group) measures of PA. This demonstrates that online PA programme can 
engage participant’s and maintain PA improvements in the medium term [181]. 
When advising participant’s to improve their PA levels, in practice, there are limited 
options for those in primary care. Due to a lack of time during consultations, a lack of 
standardised activity advice and lack of facilities to which to refer patients, the 
development of home based, self-managed activity programmes are ideal, if not 
essential. With the growing influence of digital technologies and the pervasive 
availability of such technologies, web-based interventions provide the perfect 
opportunity to deliver low cost, accessible and flexible PA interventions [181]. 
However few studies have tested this approach to improving PA in older people, 
therefore issues such as presentation, accessibility and usage for an older population 
particularly have not been addressed. An exception is the Live Well programme, which 
developed and piloted an online intervention platform to deliver personalised lifestyle-
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related behaviours (including PA) intervention in older people [182, 183]. Therefore, I 
aim to develop and test in a pilot study the potential for using an online PA 
programme in older obese adults with KOA. 
1.13 Vitamin D and Physical Activity 
Many observational studies have observed a positive relationship between serum 
25(OH)D concentrations and increasing physical activity levels. [184-186]e.g. a 2010 
longitudinal study with a mean follow up of 2.6 ± 0.4 years found those with low 
25(OH)D (defined as <50nmol/L) at baseline had  significantly (p=<0.001) lower mean 
PA (8470.3 ± 3347.5 steps per day) compared to those with high 25(OH)D at baseline 
(9401.7 ± 3612.9 steps per day).  This study also found that change in PA was 
significantly positively correlated with change in 25(OH)D (r=0.19, p=<0.001). [187] 
Another study based on 2003-2006 NHANES data from n=6370 participants showed 
that for every 10 minute increase in moderate or vigorous activity per day, there was a 
corresponding increase in 25(OH)D of 0.8nmol/L (0.32ng/ml) and 0.45nmol/L 
(0.18ng/ml) respectively. [188] However, the nature and mechanisms underpinning 
this relationship are currently unknown.   
One theory regarding the relationship observed between 25(OH)D and physical activity 
is that increased physical activity levels reflect increased time spent outdoors and 
therefore increased amounts of sunlight exposure. Therefore the relationship 
observed between 25(OH)D and physical activity may be a result of the confounding 
effect of sunlight exposure (and the subsequent cutaneous synthesis of vitamin D). 
However, contrary to this hypothesis, cross sectional studies which have observed a 
positive relationship between 25(OH)D and physical activity which have also measured 
sunlight exposure (by dosimetry or self-report) have found this relationship remained 
even when taking into account sunlight exposure.[184, 187] This may indicate an that 
the relationship between 25(OH)D and PA is independent of sunlight exposure or may 
this may be a result of inherent errors with the sunlight exposure measurement, e.g. 
lack of proper compliance with the dosimetry measurement or as a result of covering 
the skin while outdoors (thereby preventing cutaneous vitamin D synthesis but still 
being recorded as being outdoors). [184] 
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An alternative theory regarding the relationship between 25(OH)D and PA is that 
people with lower 25(OH)D concentrations may be linked to lower muscle strength or 
usage which may then impact on ability to perform PA.  There is some evidence to 
support this theory in the literature, as there is some evidence to suggest that vitamin 
D is stored in the skeletal muscle and can be released during activity, e.g. a study of 
n=14 young healthy males who took part in indoor muscle building exercise for at least 
a year had significantly higher 25(OH)D concentrations vs age matched controls (mean 
57 ± 5 nmol/L vs. 40 ± 5 nmol/L, p=<0.05). [189] Conversely, there is also some 
evidence that 25(OH) may have direct effects on the muscle via the action of VDRs in 
the skeletal muscle which may encourage protein synthesis and muscle mass growth. 
[190] However a systematic review and meta-analysis of 17 RCTs showed no significant 
effect of vitamin D supplementation on proximal lower limb strength in patients with 
25(OH)D  <25nmol/L (SMD 0.1, 95%CI −0.01,0.22). [191] 
Based upon the currently literature, it is difficult to determine exactly what the nature 
of the relationship between 25(OH)D and PA, and therefore further studies, 
particularly investigating the role of PA alone (controlling for potential confounding 
factors) on the bioavailability and metabolism of vitamin D are needed. [185] 
Additionally as vitamin D and PA are both closely linked with many of the same risk 
factors of KOA (e.g. age, BMI, occupation) and have some reported evidence as 
(individual interventions) that they could be potentially used as treatments options in 
KOA, it is worth investigating vitamin D and PA have a potential synergistic relationship 
in the treatment of KOA. Part of the aim of this study would be to investigate if an 
investigation of these two interventions combined would be feasible.  
1.14 Scientific Justification for this study 
It is clear from information presented above that affordable and effective new 
treatments in KOA are needed. Current management options are limited and focus on 
the treatment of symptoms rather than slowing the progression of disease. 
Importance has been placed on the role of lifestyle interventions in OA, with NICE 
specifying them as core treatments for all with OA, but there are acknowledged 
problems with delivery, uptake and maintenance of these interventions (particularly 
exercise programmes)[10]. 
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We therefore, aimed to pilot two lifestyle interventions, for which there was potential 
evidence for a role in KOA pathogenesis, but where there was insufficient evidence 
from intervention studies to prove efficacy. These interventions were, Vitamin D 
supplementation and an online, self-managed physical activity programme. 
The current evidence behind and justification for choosing these particular 
interventions is described below in section 1.11.1. 
1.14.1.1 Choosing the Study Population 
To test the efficacy of interventions in KOA, we need to choose an appropriate ‘at risk’ 
population and, for the purposes of this project, that means those at risk of Vitamin D 
deficiency, with low PA and who have KOA. Increasing adiposity and age are important 
determinants of each of these factors. 
It was therefore decided that obese (BMI 30-40kg/m2) and older adults (50-70 years) 
would be chosen to pilot these interventions.  
Choosing an ‘at risk’ population was important because it increases the likelihood of 
identifying people with the correct profile for our study (low vitamin D, low physical 
activity levels and presence of KOA) thereby aiding in the identification and 
recruitment of people into the pilot study who are likely to benefit from such 
intervention.  
1.14.1.2 Piloting Interventions: Why it is important? 
The design of a large-scale study testing the effect of Vitamin D supplementation, and 
online lifestyle based PA programmes in a 2 by 2 RCT factorial design is a complex 
intervention addressing multiple interventions and outcome measures. Based on the 
MRC Guidelines for the development of Complex Interventions (displayed in Figure 
1.24: Diagram representing the key elements of the development and evaluation 
process for complex interventions as specified by the MRC. Adapted from Figure 1 
[193]), development of such complex interventions starts with the systematic 
development of interventions using best available evidence followed by pilot testing 
[192]. Piloting and feasibility testing is required to establish testing procedures, 
estimating recruitment and retention rates and in determining possible sample sizes.  
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Figure 1.24: Diagram representing the key elements of the development and evaluation 
process for complex interventions as specified by the MRC. Adapted from Figure 1 [193] 
In line with the MRC recommendations, we designed and conducted a pilot and 
feasibility study to test the feasibility and acceptability of the use of a web-based 
lifestyle PA and Vitamin D supplementation programme in at-risk KOA population with 
the aim of informing a more complex intervention. 
A pilot study can be defined as a ‘test of the methods and procedures to be used a 
larger scale…to test the feasibility of methods and procedures (pg. 1) [194]. 
A pilot feasibility study design is ideal to allow the exploration of issues surrounding 
the design, planning, recruitment and logistical management of studies. However, 
there can be variability in what is investigated and reported as part of pilot studies (see 
Table 1.13) [194]. 
Elements 
reported in pilot 
studies 
 
Explanation 
Calculating 
sample Sizes 
Pilot studies can provide initial data (means and SDs for study 
measurements/outcomes) on which to base sample size calculations.  
Testing study 
protocols 
Testing the study protocol using a ‘trial run’ allows problems or gaps to be 
identified. This ensures that when the full trial takes place all equipment, 
materials and training are in place.  
Testing study 
measures 
It is important to test study measures, especially if there will be several 
investigators taking measurements, to ensure consistency and 
appropriateness of the measurements. 
Recruitment 
strategies 
It is important to estimate recruitment rates in order to estimate the time 
needed for recruitment and to identify issues around recruitment, to 
ensure enough participants can be recruited into the fully-scale study. 
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Acceptability of 
Interventions 
Testing the acceptability of an intervention (particularly those which may 
be concerning, potentially harmful or difficult to administer) in your target 
population is essential to ensure good retention and adherence during 
trials. This allows optimisation of the intervention before use in a trial.  
Selection of 
primary outcome 
measures 
There are many factors which can influence the decision of what the best 
primary outcome measurement should be, including feasibility, 
acceptability, reliability and confounding factors.  
Resource 
assessment  
This allows estimates of the time and resources required to carry out a 
study and includes a realistic estimation of staff and resource 
requirements to be made. This is important to avoid wasting resources, 
whilst ensuring enough resources are available to carry out a high-quality 
study. 
Management and 
Logistical issues 
This allows for the optimisation of practical and logistical issues such as 
data management and storage and communication with the study 
team/participant. This ensures the smooth running of the full study in a 
timely manner. 
Scientific Integrity Assessing the research question using the pilot study can allow for the 
optimization of the aims and objectives to appropriately address the 
research question. 
Table 1.13: A summary of the variety of aims of pilot studies. Adapted from [194, 195]. 
It is advisable to pilot studies before conducting large trials for several reasons; to 
provide rationale for the study, test the feasibility of the procedures and 
measurements and identify any important logistical, methodological or study design 
issues to be addressed before running a full-scale trial. This can ultimately save money, 
prevent unnecessary burden on participants and ensures the usefulness of the 
research [194, 196]. 
The definition of what constitutes a feasibility study (distinctly from a pilot study) vary 
but broadly it can defined as a piece of research done before the main study which are 
used to estimate important parameters needed to design the main study, such as: 
[197] 
 SD of outcome measures 
 willingness of participants to be randomised 
 willingness of clinicians to recruit participants 
 numbers of eligible participants  
 characteristics of proposed outcome measures 
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 follow-up rates, response rates, adherence and compliance rates 
This information can be used to inform the design of the main study but is not used to 
evaluate outcomes or effect. A sample size calculation is not required in a feasibility 
study but adequate sample is needed to evaluate feasibility outcomes. [197] 
In this study we combined elements of the feasibility study (assessment the 
acceptability, recruitment, population eligibility, follow-up, response and recruitment 
rates, compliance to study measures and interventions) and pilot study (testing 
protocols, study measures and interventions and identifying issues in study design and 
management) to produce useful data to inform the design of an effective complex 
intervention. 
Using a pilot feasibility study design to trial these interventions is also a good 
opportunity to trial some of the recommendations made by authors on improving the 
design of the intervention, e.g. use of Vitamin D deficient KOA populations in the 
Vitamin D supplementation intervention. Using a pilot study design will allow us to test 
how feasible and acceptable this study design and interventions will be.  
1.15 PhD Aims and Objectives 
The aim of this PhD project was to explore relationships between Vitamin D status, 
habitual PA and KOA symptoms and to pilot an intervention study designed to deliver 
Vitamin D supplementation and an online PA intervention in older, obese people with 
symptomatic KOA. We aimed to do this by addressing the following objectives: 
1. To explore relationships between circulating concentrations of Vitamin D, 
objectively measured PA and KOA symptoms in older obese adults with 
symptomatic KOA using a cross-section study design.  
2. To design and implement a pilot intervention study to assess the 
acceptability and feasibility of an intervention providing Vitamin D 
supplementation and/or a web-based PA intervention in older obese adults 
with symptomatic KOA using a pilot intervention study design. 
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3. Using participant’s from the pilot intervention study, to assess the 
acceptability and feasibility of key aspects of the intervention study including 
procedures for recruitment, intervention modalities and outcomes measures, 
using a semi-structured qualitative interview design. 
1.16 Study Design Overview 
In order to test our aims and objectives, three studies were set up and conducted from 
September 2013-June 2016 as pictured in Figure 1.25. Each stage of the overall study 
design is explored in the remaining chapters of this thesis.  
Firstly, study participants were recruited by screening of patients from primary (North 
East site) and secondary (Liverpool site) care sources against the study eligibility 
criteria (April/September-December 2015). Potentially eligible participants were 
mailed study information packs and instructed to contact the study team if they were 
interested in taking part. Respondents were screened by telephone by the researcher 
and eligible participant’s invited to take part in the cross-sectional study. In Chapter 2, 
the methods and results of the recruitment from primary and secondary care are 
presented and compared.   
Cross-sectional study participant’s attended a 90minute cross-sectional study visit at 
North Tyneside General Hospital (NTGH) where anthropometric and knee function 
tests and questionnaires were completed and blood samples taken. Accelerometers 
were provided for wear 3-5 days post study visit which were returned by post to 
Newcastle University. Chapter 3 addresses the methods and results of the cross-
sectional study visits. The compliance and feasibility of the study measures is explored 
and the relationships between 25(OH)D, objective PA and self-reported KOA outcomes 
were analysed. 
Following completion of the cross-sectional study visit, all study participants were 
screened for eligibility for the 3-month pilot interventional study using the cross-
sectional study results. Eligible participants were invited to take part in the 3-month 
pilot intervention study, which included an initial study pack mail out (containing their 
study arm allocation, instructions and materials needed to complete their allocated 
intervention), and a midpoint (6 week) and end point (12 week) 90min study visit at 
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NTGH, which repeated the measures taken during the cross-sectional study visit. 
Chapter 4 will outline the intervention design and pilot intervention study methods. 
Study and intervention compliance, treatment effect and change in outcome measures 
are analysed. Finally, Vitamin D and online PA intervention study outcomes are 
compared. 
Directly after the 12week pilot intervention study visit, a 60-minute semi-structured 
qualitative interview study took place, exploring the participant’s views on the 
acceptability and feasibility of study recruitment, visits, measurements, materials and 
interventions. Qualitative data, in the form of interview transcripts, were analysed 
using the thematic framework method to identify qualitative ‘themes’. Chapter 5 
outlines the process of thematic framework analysis used and the resulting themes 
which were identified regarding the feasibility and acceptability of recruitment, study 
measures and materials and study interventions. Based on the themes identified, 
recommendations for the design and conduct of future studies were compiled. 
Finally, this thesis finishes with an overview and discussion of the results from the 
three research studies. The strengths and limitations of these studies are discussed 
and recommendations for future work based on the results of this PhD project are 
presented.  
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Figure 1.25: Overview of the design of the three studies comprising this PhD project. Study information was posted to potential participants and 
responders were screened by telephone against the study eligibility criteria. Eligible participants attended a 90-minute cross-sectional study visit 
at North Tyneside General Hospital where a range of study measurements were taken. At the end of the study visit, participants were provided 
with an accelerometer to wear for the following 3-5 days which was then returned to the study team by post. When all study measurement results 
were collected, they were collated into a participant feedback document which was posted to the participant. All cross-sectional study participants 
were screened for eligibility for the 3-month pilot intervention study. Eligible participants were assigned to study intervention arm (Vitamin D 
supplementation [2000IU [50µg]/d] and/or online PA programme) in an unrandomised design. Participants were mailed a study intervention 
starter pack followed up at 6 and 12-week study visits (repeating measurements from cross-sectional study). All pilot intervention participants 
were invited to take part in the #1hr semi-structure qualitative interview directly after the 12-week pilot intervention study visit. The qualitative 
interview focussed explored participants views on the acceptability and feasibility of the cross-sectional and pilot intervention studies.
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Chapter 2. Study Recruitment 
2.1 Introduction 
It has been observed that just over half of publically funded clinical trials recruit to 
their target within their study duration [198]. The consequence of inadequate study 
recruitment is either the investment of further resources by the funders or a reduction 
in statistical power, risking the misinterpretation of treatment effect. [198, 199]. Poor 
recruitment also delays study start and completion and restricts opportunities for 
participation [200]. As such, most funding bodies now require evidence of feasibility 
assessment or consideration of pilot study data before funding is allocated to a full 
scale clinical trial [199, 201]. Therefore the optimization of recruitment strategy, to 
ensure recruitment numbers are met, should be undertaken before full scale clinical 
trials are conducted as part of either an external (performed as a standalone study) or 
internal (performed as part of a clinical study) pilot study[199]. 
In consideration of this, as part of the pilot study reported in this thesis, two different 
clinical based recruitment strategies were compared in order to assess the most 
successful strategy to identify and recruit the target study population.  
2.2 Ethics and approvals 
2.2.1 REC application 
In accordance with Good Clinical Practice, NHS Research Ethics Committee (REC) 
approval was obtained before commencing the study by proportional review from 
London City and East Research Ethics Committee on 20/11/2014 ('Impact of Physical 
Activity and Vitamin D on osteoarthritic knee pain' - IRAS Project ID: 143184) (See 
Appendix A), using the online IRAS application portal. Permission for the cross-
sectional study, pilot intervention study and qualitative interview study were applied 
for and approved within a single IRAS application form. 
2.2.2 Study Permissions and Agreements 
All researcher specific permissions were completed prior to commencement of the 
study, including; 
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 Research Passport for the primary researcher [RB] to work within the Northumbria 
Healthcare NHS Foundation Trust (13/10/2016). 
 Honorary Contract was also obtained for the primary researcher [RB] for 
Northumbria Healthcare NHS Foundation Trust (18/12/2014) 
 Caldicott Approval for data storage and participant study visits was obtained on 
09/12/2014 (ID: C2952).   
General study agreements and contracts were also completed prior to commencement 
of the study including;  
 Application for NIHR CRN (Clinical Research Network) support including 
Research Nurse Support and Financial (recruitment costs) support was granted 
on 09/01/2015 (CRN Portfolio ID: Study 18199 – Impact of Physical Activity and 
Vitamin D on osteoarthritic knee pain). 
 Study Site approvals were obtained from R&D departments at North Tyneside 
General Hospital on 19/12/2014 (Northumbria Healthcare NHS Foundation 
Trust) and University Hospital Aintree on 29/11/2014(Aintree University 
Hospital NHS Foundation Trust)  
 A site agreement contract between Northumbria Healthcare NHS Foundation 
Trust and Aintree University Hospital NHS Foundation Trust was completed 
(see Appendix B). 
 Sample Transfer agreements between Northumbria Healthcare NHS 
Foundation Trust and Newcastle University were obtained. 
Finally, this study was registered with ClinicalTrials.gov on 13/11/2014 (Identifier: 
NCT02293889). The study protocol was uploaded and study status was updated as 
appropriate. 
2.3 North East Recruitment 
2.3.1 Methods 
In the North East, we planned a primary care recruitment strategy which involved 
recruiting GP surgeries to screen their patient lists against our eligibility criteria. All 
potential participants identified by the GP surgery were sent the study information and 
invited to take part in the study. This process (summarised in Figure 2.1) is in more 
detail below.  
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Figure 2.1: Summary flow diagram of the stages involved in the North East Primary Care 
recruitment strategy 
2.3.1.1 North East Commissioning service  
A 30 minute face to face meeting (16/09/2014) was arranged with the North East 
Commissioning Service to review the study design, study recruitment plan and 
requirements from the NECS. 
The proposed primary care recruitment strategy was agreed with NECS and NECS staff 
was assigned to recruit from each local Primary Care Trust (PCT): 
 Northumberland PCT 
 North Tyneside PCT 
 Newcastle Upon Tyne PCT  
A summary sheet of the study eligibility criteria, participant Information Sheet and 
Consent form was sent to the NECS recruitment staff in order to recruit GP surgeries. 
2.3.1.2 GP Practice Recruitment 
Due to time and resource constraints, not all GP Practices in our recruitment area were 
invited to participate in the study. Instead a selection of GP practices in the 
Northumberland, North Tyneside and Newcastle areas (shortlisted as surgeries with a 
known interest in or had previously participated in academic research) were 
approached by NECS with a summary of our study and study criteria (see Appendix C). 
GP practices who were interested in taking part in the study contacted NECS who 
confirmed with the study team [RB].  
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2.3.1.3 Patient Identification and Study Information Mail out 
Once GP practices were recruited, they screened their patient lists against our study 
criteria. Numbers of potential participants identified from this patient list screening 
was passed on to RB at Newcastle University, who prepared the correct number of 
prepaid study mail out packs (containing a letter of invitation (see Appendix D), 
participant information sheet (see Appendix E) and consent form (see Appendix F). 
These study mail out packs were delivered to the GP surgery who added a study 
invitation letter on the GP surgeries headed paper to the mail out pack. Potential 
participants’ addresses were added to the completed study mail out packs which were 
mailed by the GP surgery. GP surgeries were paid a £250 fee for time and labour.  
2.3.1.4 Patient Recruitment 
As detailed on the patient information sheet in the participant mail out pack, 
individuals who were interested in participating in the study contacted the study team 
at Newcastle University using the contact telephone number or email address 
provided. Potential participants gave their contact details and were further screened 
for eligibility by telephone using a telephone screening questionnaire (see Appendix 
G).Eligible participants were invited to a 90 min study visit at North Tyneside General 
Hospital (NTGH), ineligible participants were informed of the reason(s) for their 
ineligibility and thanked for their time.  
2.3.1.5 Recruitment records  
Logs of all individuals who contacted the study team were recorded including 
information on; date and time of contact, name, contact information, GP surgery, 
reason for call, eligibility for study and details of study visit arrangement (if applicable). 
Detailed logs of all recruited participants were kept in the form of a master 
recruitment log (containing names, study ID assigned, study recruitment date, home 
address, contact details, appointment details and GP practice). Individual participant 
contact sheets were also kept in the front of each participant case file detailing all 
contact with the study team (including date of contact, reason for contact and 
outcome of contact). 
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2.3.2 Results 
2.3.2.1 Recruitment of GP Surgeries 
 
Figure 2.2: Map of the North East (Northumberland area highlighted in green and North 
Tyneside and Newcastle area highlighted in red), with markers highlighting the location of 
GP Surgeries. Red markers indicate GP Surgeries not approached or recruited to the study 
and green markers indicate GP surgeries recruited to the study. 
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From the Northumberland, North Tyneside and Newcastle PICs, 8 GP surgeries were 
recruited to the study; 4 from Northumberland, 2 from North Tyneside and 2 from 
Newcastle PICs from March 2015-October 2015 (see Figure 2.4). A graphical 
representation of the location and spread of the GP surgeries in the geographical 
location and which of those took part in the study (highlighted by green markers) can 
be seen in Figure 2.2 and Figure 2.3. 
 
Figure 2.3: Map of Newcastle and North Tyneside area on which markers indicate the 
locations of GP Surgeries with those GP surgeries who took part in the study highlighted in 
green 
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Figure 2.4: Number of GP surgeries recruited in the North East throughout 2015 by month 
2.3.2.2 Reviewing GP Surgery Patient Lists (KOA Coding) 
The eight recruited GP surgeries then proceeded to screen their GP surgery patients 
against our study criteria. Screening at all GP surgeries was conducted electronically by 
identification of correct ‘codes’ (each surgery, as part of general practice, assigns codes 
to individual symptoms, signs and conditions which are recorded within every patients 
electronic medical record). Codes relating to each of our study criteria were searched 
for and patients which met all of these criteria were identified as potentially eligible 
for the study.  
An issue encountered using this electronic coding system was the variation in the 
coding terms used for KOA. The variation in the coding used to identify KOA between 
our 8 GP surgeries can be seen in Table 2.1 below. 
GP Surgery Geographical 
Location 
Codes used to search for KOA 
GP Practice 1 Northumberland Data not obtained 
GP Practice 2 Newcastle Upon Tyne  Data not obtained 
GP Practice 3 North Tyneside “Osteoarthritis of knee-X703L” 
“Osteoarthritis NOS, knee 
N05zL” 
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GP Practice 4 North Tyneside Data not obtained 
GP Practice 5 Northumberland “Knee osteoarthritis” 
“Osteoarthritis of knee” 
GP Practice 6 Newcastle Upon Tyne “Knee Osteoarthritis NOS – 
NO5z6-1” 
“Osteoarthritis NOS, of Knee – 
NO5zL” 
“Knee pain – 1M10” 
“Anterior Knee Pain – NO94W” 
“Painful Right Knee – 
EGTON279” 
“Anterior Knee Pain – 1M12” 
“Knee Joint Pain – NO946-1” 
GP Practice 7 Northumberland Data not obtained 
GP Practice 8 Northumberland Data not obtained 
Table 2.1: Variation in coding of KOA amongst recruited GP surgery electronic patient 
records. 
Anecdotally, the GP practices expressed that, particularly regarding searching for the 
ACR criteria we specified for defining symptomatic KOA, there was addition manual 
processing of the electronic records (reading through individual records to note if 
criteria had been recorded in the patients notes) to ensure this criteria was met in 
addition to be coded as having KOA by the individual surgery. 
2.3.2.3 Potential Participant Mail-out 
The numbers of eligible potential participants identified and mailed information can be 
seen in stratified by month and individual GP surgery in Figure 2.5 and Table 2.2.  
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Figure 2.5: Number of study invitation packs mailed by GP surgeries to potential participants 
throughout 2015. 
GP Surgery Number of packs 
mailed 
No of patients 
registered to GP 
practice 
% of practice 
patients eligible for 
our study 
GP Practice 1 375 14165 2.65% 
GP Practice 2 57 4429 1.29% 
GP Practice 3 43 6647 0.65% 
GP Practice 4 17 6063 0.28% 
GP Practice 5 121 9259 1.3% 
GP Practice 6 134 8576 1.56% 
GP Practice 7 22 4463 0.49% 
GP Practice 8 22 3627 0.6% 
Table 2.2: Number of eligible potential participants identified and mailed participant 
invitation packs by each GP surgery compared to the total number registered patients to 
that practice. 
2.3.2.4 Study Information Mail-out response and Cross-sectional Study Recruitment 
As part of the study information mailed to participants, they were instructed to 
contact the study team at Newcastle University by telephone or email. A total of 85 
people contacted the study team between March and December 2015 (see Figure 2.6), 
10.7% of the original 791 people who were mailed study information. 
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Figure 2.6: Number of respondents to the participant information pack which were screened 
by telephone (depicted in blue) and subsequently recruited into the cross-sectional study 
(depicted in red). 
45/85 of the people screened were deemed eligible to participate in the cross-
sectional study visit after completion of a telephone screening questionnaire, 5.7% of 
the original mail out population. The main reasons for exclusion during the telephone 
screening were those who inquired with questions but did not reply with interest in 
taking part in the study (n=12), those who had had knee replacement surgery (n= 10) 
and those who contacted to confirm they did not wish to take part (n=4) (see Figure 
2.7). 
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Figure 2.7: Flow diagram depicting the flow of participants from study information mail out, 
to participant response and recruitment into the cross-sectional study. 
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2.4 Liverpool Recruitment 
In Liverpool we planned a secondary care recruitment strategy involving identifying 
potential participants from referrals to three hospital clinics in University Hospital 
Aintree (UHA). This process is summarised in Figure 2.8 below: 
 
Figure 2.8: Summary flow diagram of the stages involved in the Liverpool Secondary Care 
recruitment strategy 
2.4.1 Methods 
2.4.1.1 UHA Clinic Recruitment 
Through on site negotiations with UHA R&D and hospital departments, we recruited 
three hospital clinics to recruit for this study and identified persons in charge of 
recruitment for each clinic: 
 Weight Management Clinic; 
 Physiotherapy Clinic; 
 Musculoskeletal Assessment Service (MCAS) 
The recruiters and staff in each clinic screened each referral to that clinic against the 
study eligibility criteria. Information about the study was disseminated during staff 
meetings and posters hung in clinics rooms (see Appendix H) to encourage staff 
screening.  
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2.4.1.2 Participant Identification and Study Information Hand out 
Information provided in participant referral letters to each clinic was screened for 
study eligibility by clinic staff. Patients identified as potentially eligible from this 
screening process would be informed about the study and given a study information 
pack (containing a study invitation letter, participant information sheet and consent 
form (see Appendix D-F) on their first visit to the outpatient clinic. 
2.4.1.3 Patient Recruitment 
Patient recruitment was carried out as in the North East (see pg. 91). Potential 
participants who were eligible for the study would be invited to a 90 min study visit at 
UHA and arrangements made with CRN research nurses at UHA to conduct the study 
visit.  
2.4.2 Results 
2.4.2.1 Recruitment of patients from secondary care 
Referrals to the above clinics were screened by clinical staff during the recruitment 
period (October- December 2015). No referrals were identified which met the study 
eligibility criteria during the study recruitment period and no study invitation packs 
were handed out.  Several reasons for a lack of success in recruiting patients from this 
location and environment were concluded from discussions with the recruitment staff 
at the Liverpool site, including;  
a) Recruitment workload vs resources 
Steps were taken during the study to engage staff within each participating 
department at UHA and encourage knowledge of and recruitment for the study. These 
steps included assigning a named clinician within each clinic tasked with managing and 
encouraging recruitment and dissemination to the wider clinical staff within each 
department by presentations regarding the study at departmental meetings and 
displayed posters (containing the study information and eligibility criteria) in all clinical 
spaces. However, despite this effort to disseminate knowledge regarding the research 
study, no recruitment was achieved. Feedback from clinicians involved reported that 
lack of time during their working day and a lack of eligible participants lead to non-
recruitment. Within this study, recruitment was a potentially timely process 
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considering that refers to each department were paper-based and had to be 
individually and manually searched for all of the study eligibility criteria. Due to this 
time intensive process, it was likely the staff within the department did not have time 
to dedicate to this task. 
b) Assessing study eligibility from referral records 
It was also highlighted by the UHA staff that information contained within the referral 
records the departments received for each patient was hugely variable, ranging from a 
single sentence to a full patient assessment and medical history. This meant that 
identifying the correct information to assess eligibility of a patient for this study based 
on the referral was often not possible, due to unavailable or incomplete data. This 
meant any patients could not be accurately assessed for eligibility into this study. 
2.4.2.2 Post hoc referral analysis 
To further investigate the issues encountered in recruitment from this site, an 
exemplar post hoc analysis (Feb-March 2016) was performed by RB of 3 months of 
historical referrals (November 2015-Feburary 2016) to the Physiotherapy, Weight 
Management and Musculoskeletal Assessment service clinics. This was done with the 
aim of identifying patterns in information contained within referrals and patient 
eligibility which may enlighten any issues which prevented recruitment from this study 
site.  
For each referral, the following information relating to demographics and our study 
eligibility criteria was extracted where available: age, gender, alcohol consumption, 
smoking status, date of referral, service/department referred from, primary reason for 
referral, history of KOA, BMI, and presence of any contradictory conditions.
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a) Baseline Statistics 
Basic characteristics of patients referred to each clinic were recorded and are 
summarised in Table 2.3 below. 
Baseline 
characteristics  
UHA Hospital Clinics  
Physiotherapy MCAS Weight 
Management 
All clinics  
Mean Age (range) 58.2 (31-81) 52.4 (16-98) NR 44.1 (16-98) 
Gender 
     Male 
     Female 
 
39% 
61% 
 
40% 
60% 
 
26% 
74% 
 
38% 
62% 
Ethnicity 
  White (British) 
     White (European) 
     Asian 
     Arab 
     Indian  
     Black  
     Other 
     Not Reported  
 
6% 
0.3% 
0.1% 
0% 
0.1% 
0% 
0% 
93% 
 
47% 
1.4% 
0.7% 
0.7% 
0.9% 
0.7% 
0.7% 
49% 
 
0% 
0% 
0% 
0% 
0% 
0% 
0% 
100% 
 
16% 
0.6% 
0.1% 
0.2% 
0.3% 
0.2% 
0.3% 
82.3% 
Alcohol Intake 
Non Drinker 
<14 Units/Week 
>14 Units/Week 
     Not Reported 
 
3.9% 
3.9% 
1.1% 
91.1% 
 
33.5% 
33.0% 
10.1% 
23.4% 
 
0% 
0% 
0% 
100% 
 
11.3% 
11.2% 
3.4% 
74.1% 
Smoking Status 
     Non Smoker 
     Previous Smoker 
     Current Smoker 
     Not Reported  
 
6% 
3% 
3% 
88% 
 
43% 
24% 
20% 
13% 
 
0% 
0% 
0% 
100% 
 
15.4% 
8.1% 
7.1% 
70% 
Table 2.3: Demographic characteristics of patients referred to UHA outpatient clinics 
between November 2015-Feburary 2016 
 
 103 
b) Reason for referral to clinics 
Analysis of the primary reason for referral to all clinics (represented in Figure 2.9) 
revealed the most common reason for referral was lower back pain (184 referrals) 
followed by shoulder pain (128 referrals). People were more likely to be referred for 
knee symptoms, e.g. knee pain (105 referrals) without a diagnosis of KOA than for 
confirmed KOA (74 referrals). 
 
Figure 2.9: Word cloud (produced in Nvivo) representing the primary reasons for referral to 
Physiotherapy, Weight Management and MCAS UHA clinics. The size of the word represents 
the frequency of occurrence, with large words occurring more frequently than smaller 
words. LBP=lower back pain, TKR=total knee replacement, THR=total hip replacement, 
KOA=Knee osteoarthritis, OA=osteoarthritis 
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c) Eligibility Analysis 
Next we analysed the content of the referrals against each of our main study eligibility 
criteria (outlined below) to determine how many participants would have been 
potentially eligible for the study, and to what degree each of these criteria was met 
among the referrals to the 3 UHA clinics. 
i) Age 
Age or DOB was consistently reported across all 3 clinics, with only 76 referrals (3.5% 
all referrals) not containing information on either. There was particularly high non-
reporting of age amongst the Weight Management Clinic (37.6% WM referrals) than 
the physiotherapy (0.6% of physiotherapy referrals). 
As can be seen in Figure 2.12, age was the study criteria most likely to be met by 
referrals when screened. When we look at the proportions of referrals deemed eligible 
and non-eligible by age criteria between the 3 clinics (see Figure 2.11and Figure 2.12) 
there were slightly higher numbers of non-eligible referrals, with 56.6% and 53.1% 
referrals determined ineligible from the Physiotherapy and MCAS clinics respectively 
and 42.8% and 46.9% referrals determined eligible from the Physiotherapy and MCAS 
clinics respectively.  
ii) Body Mass Index 
As can be seen in Figure 2.10, BMI was the criteria which had the highest levels of non-
reporting. Incidence of non-reporting was particularly high within the physiotherapy 
clinic at 95.6%and much lower within the weight management clinic at 14.9%. 
Of the referrals which reported information on BMI (see Figure 2.12), the MCAS clinic 
had the highest number of eligible referrals which met our BMI criteria at 75/573 
referrals (13.1%), followed by the Weight Management Clinic at 35/181 referrals 
(19.3%) and finally the Physiotherapy clinic at 23 eligible referrals (1.5%). 
iii) KOA Diagnosis 
The KOA criteria specified the referral must confirm a diagnosis of KOA for the 
individual to be considered eligible. Across all clinics, there were low numbers of 
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referrals containing information of a positive KOA diagnosis at 171/2201 referrals 
screened (see Figure 2.12). 
The pattern of KOA diagnosis non-reporting and ineligibility varied considerably 
between clinics. Non-reporting of KOA diagnosis status was high within the weight 
management and physiotherapy clinics with an incidence of 96% and 66.2% 
respectively. The MCAS clinic provided good reporting of KOA diagnosis status, 
however there was a large proportion of ineligible referrals (individuals without 
diagnosed KOA) compared to eligible referrals at 78.9% and 12.6% respectively. 
iv) Presence of Contraindicatory Conditions (CCs) 
The presence of conditions which would contraindicate our study interventions were 
recorded as these would lead to exclusion of potential participants. These included 
conditions affecting PA participation, e.g. angina and respiratory disease, and 
conditions which affecting Vitamin D supplementation, e.g. kidney and liver disease. As 
can be seen from Figure 2.11, there was low levels of referral exclusion based on the 
presence of contraindicatory disease at 7.2% of total referrals. However there were 
high levels of non-reporting with over half (56%) of all referrals not reporting on 
contraindicatory conditions at all. 
Age was significantly higher in those with confirmed CCs compared to those confirmed 
without CCs (t=16.2, p<0.001), with a mean age of 66yrs and 49 years respectively. 
There was also a higher proportion of females amongst those with CCs at 65.6% 
compared to those with no CCs (61.1%) or the whole sample (62%). There was also 
better reporting of alcohol intake amongst those with confirmed contraindicatory 
conditions with a non-reporting rate of 26% compared to 47.5% in those with no CCs. 
Zero alcohol intake reporting was also higher in the group with CCs compared to those 
without CCs, at 25.6% and 16.9% respectively. 
When the contraindicatory conditions recorded are broken down further (see Figure 
2.13), you can see the most common contraindicatory condition recorded was stage 3 
chronic kidney disease (28.75% of CCs) , followed by COPD (22.5% of CCs) and TKR 
(total knee replacement) (14.4% of CCs). 
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v) Diagnosis of Differential/Inflammatory Arthritis (IAs) 
The presence of alternate arthritic conditions, particularly inflammatory arthritis, was 
also excluded. As   with contraindicatory conditions, there was low number of referrals 
excluded based on presence of alternative/inflammatory arthritis diagnosis (4.4% of 
referrals) however there were high levels of non-reporting of such conditions with 
54.9% of referrals containing no information on potential alternative arthritic 
diagnosis. Non-reporting was particularly high in the Weight Management clinic at 
100% rate of non-reporting, followed by the Physiotherapy clinic at a rate of 67% non-
reporting. 
Age amongst those with IAs was significantly higher than those without IAs (t=3.9, 
p=<0.001) with mean ages of 57yrs and 51yrs respectively. The proportion of females 
was also higher in the groups with ICs that the group with no ICs, at 81.25% and 60.9% 
respectively. Non-reporting of alcohol use was substantially higher in the group with 
IAs at a prevalence of 74%, compared to those without IAs at a prevalence of 47.7%. 
When alternative/inflammatory arthritic conditions were analysed further (see Figure 
2.13), it can be seen the most common diagnosis was for Fibromyalgia (35.4% of IAs), 
followed by Rheumatoid Arthritis (24% of IAs) and Gout (8.3% of IAs). 
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Figure 2.10: Graph depicting the number of referrals not reporting eligibility criteria, 
stratified by hospital clinic; MCAS: Musculoskeletal Assessment Service, WM: Weight 
Management and Physio: Physiotherapy 
 
 
Figure 2.11: Number of referrals deemed ineligible by eligibility criteria, stratified by hospital 
clinic; MCAS: Musculoskeletal Assessment Service, WM: Weight Management and Physio: 
Physiotherapy 
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Figure 2.12: Number of referrals deemed eligible by eligibility criteria, stratified by hospital 
clinic; MCAS: Musculoskeletal Assessment Service, WM: Weight Management and Physio: 
Physiotherapy 
 
Figure 2.13: Graph depicting the frequency of different contraindicatory conditions recorded 
from referrals which would result in exclusion from the study. COPD: Chronic Obstructive 
Pulmonary Disease, TKR: Total Knee Replacement, THR: Total Hip Replacement 
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Figure 2.14: Graph depicting the frequency of different alternative/Inflammatory arthritic 
conditions recorded from referrals which would result in exclusion from the study. 
 
vi) Combining Eligibility Criteria 
To determine how many referrals would be considered eligible once criteria were 
combined, we analysed all the results from each hospital clinic, the outcome of this 
can be seen in the Venn diagrams in Figure 2.15, Figure 2.16, Figure 2.17 and Figure 
2.18. The Venn diagrams display the number of eligible referrals on combination of the 
study eligibility criteria. 
When all criteria were combined to give a final number of potential eligible patients, 
only 8/2203 were considered eligible, all originating from referrals to MCAS. Of these 
eight potentially eligible patients, there were five males and three females. 75% were 
non-smokers and 50% were non-drinkers. Mean age was 52 years and mean BMI was 
30.1.  
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Figure 2.15: Numbers of eligible referrals from all UHA hospital clinics based on 
combinations of study eligibility criteria, with each circle representing a single study 
eligibility criteria. 
 
Figure 2.16: Numbers of eligible referrals (from UHA Physiotherapy hospital clinic) based on 
combinations of study eligibility criteria, with each circle representing a single study 
eligibility criteria. 
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Figure 2.17: Numbers of eligible referrals (from Weight Management clinic) based on 
combinations of study eligibility criteria, with each circle representing a single study 
eligibility criteria. 
 
Figure 2.18: Numbers of eligible referrals (from Musculoskeletal Assessment Service clinic) 
based on combinations of study eligibility criteria, with each circle representing a single 
study eligibility criteria. 
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2.5 Discussion 
In this chapter, I have reviewed the two recruitment strategies tested as part of this 
pilot feasibility study with the aim of finding the most effective strategy for identifying 
an obese, older KOA population for research study participation. A primary care 
recruitment strategy was conducted in the North East by recruiting GP surgeries across 
Northumberland, North Tyneside and Newcastle upon Tyne, to screen their practice 
patient lists against our study eligibility criteria, and mail out study information to 
identified potential participants. A secondary care recruitment strategy was conducted 
in Liverpool by recruiting 3 hospital clinics, Physiotherapy, Weight Management and 
Musculoskeletal Assessment Service, within University Hospital Aintree (UHA) to 
screen referrals sent to each clinic during our winter recruitment periods (January-
April 2015/October-December 2015). 
2.5.1 Primary Care Strategy 
Our primary care recruitment strategy in the North East was successful in recruiting 
8/153 GP surgeries with a combined practice patient number of 57,229. From these 
surgeries 791 patients were identified as meeting the study criteria (1.38% of total 
registered to these practices). If we compare this to the reported data from ARUK 
[202]of those with KOA in the North East (using the closest available filters to our study 
eligibility criteria; Aged 45-74 and Obese BMI), there are 18,225 people who meet our 
study eligibility criteria in the whole North East (excluding screening for concurrent 
alternative arthritis diagnosis and contraindicatory conditions), meaning study 
information was mailed to approximately 4.3% of the available eligible participants in 
the North East.  
Recruiting participants from primary care introduces specific problems, which have 
been summarised in a paper by Bower et al. in 2009 [203]. They identified 4 specific 
stages in the recruitment of patients from primary care to research studies 
(summarised in Figure 2.19); recruitment of the primary care site, process of 
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recruitment/screening at the primary care site, patient agreement to take part in 
research and participant retention after recruitment.  
 
Figure 2.19: Flow diagram summarising the stages of recruitment from primary care and the 
factors affecting recruitment at each stage. Taken from Figure 1 [203]. 
As part of this article, a number of factors affecting recruitment from primary care 
resources were discussed, many of which we encountered during this study, for 
example the need for development of an infrastructure to allow primary care 
involvement in research. This was an initiative addressed by the NIHR CRN, which was 
established to provide support and raise awareness of clinical research involvement 
among primary care practice [203]. As part of this study, we obtained CRN support 
provided by NECS (the North East Commissioning Service). NECS supported our study 
by advertising, liaising and recruiting GP surgeries to partake in our study and provided 
financial incentives for participation, both previously identified factors (see Figure 
2.19) important in the recruitment of primary care sites to research.  
An advantage of using of GP surgeries as recruitment sites was access to the use of 
electronic health records for patient eligibility screening. The use of electronic records 
is a significantly less time consuming and more efficient process than manual hand 
searching of records, as condition and symptoms are usually recorded as codes which 
can be electronically searched and identified. Additionally, this meant we could also 
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screen an entire practice relatively quickly, with a turnover time of a few weeks. 
However, the coding of symptoms and conditions was variable between GP practices 
and therefore led to variation in their use for searching for those with KOA (as can be 
seen above in Table 2.1). This variation in coding between practices could potentially 
lead to under or over reporting of these criteria in patients, leading to a loss of eligible 
participants or potential inclusion of ineligible participants. 
After recruiting GP surgeries and screening potential eligible participants, it was the 
choice of the participant on receiving our study information pack, whether to 
participant in this study (‘opt-in’ strategy). It has been suggested in the literature that 
‘opt in’ strategies results in lower response rates and a more biased sample (due to 
participant self-selection) than an ‘opt out’ strategy. However the ‘opt out’ strategy 
poses many ethical issues, particularly regarding the presumption that individuals 
would find it acceptable to be contacted repeatedly about a study without specifically 
expressing willingness to take part[204].As described in Figure 2.19, this willingness to 
participate in research can depend on a number of different factors and addressing 
these factors may improve recruitment. For example, a well-established practical 
strategy to improve recruitment includes conducting telephone reminders after the 
original study information is sent, which has been shown to increase recruitment by up 
to 3 times compared to no reminder [205]. Therefore any future studies following on 
from this pilot study using the primary care recruitment strategy, may consider using 
reminders as a simple way of increasing recruitment. 
2.5.2 Secondary Care Recruitment 
As discussed in 2.4.2, our Secondary Care recruitment strategy was unsuccessful in 
identifying and recruiting any eligible participants during our recruitment period. In an 
effort to understand why this strategy was unsuccessful, an exemplar post hoc analysis 
was conducted of referrals sent to our recruited hospital clinics in the 3 months 
following the close of study recruitment (December 2015-March 2016). Using this post 
hoc analysis of and through discussion with the recruitment team at UHA, we 
identified pertinent explanations for the failure of this recruitment strategy: the 
balance between recruitment workload and available resources and quality and 
eligibility of referrals to our selected clinics.  
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Feedback from clinicians involved reported that lack of time and eligible participants 
lead to non-recruitment. It has been previously reported that lack of allocated or 
specific time for study recruitment and the demands of working in a busy outpatient 
environment are well known barriers for clinicians to adherence of recruitment tasks 
in research. [200] Another potential contributing factor to this was the manual nature 
of searching the paper based referrals to each clinic, which was a time consuming and 
inefficient process. Improvements can be made by allocating specific staff, e.g. 
research nurses, to this particular task, however, this often depends on the amount of 
resource available to the study team [200]. 
After our post hoc analysis (section 2.4.2.2) of referrals sent to the three UHA clinics 
over 3 months, we identified several potential issues. Firstly, as highlighted by the 
recruitment team, the quantity and quality of information contained within the 
referrals to these clinics was hugely variable. This meant that identifying information 
regarding our study eligibility criteria was often not possible. Additionally, as identified 
in our exemplar post hoc analysis, many eligibility criteria had high levels of non-
reporting on referral documents, particularly regarding BMI status (excluding the 
Weight Management clinic which consistently provided this information as part of 
their referrals). There were also high levels of exclusion based on lack of specific KOA 
diagnosis and reporting of KOA symptoms, although ‘knee pain’ was commonly 
reported on referrals, but without a KOA diagnosis (see section 2.4.2.2). This lack of 
clarity regarding study eligibility criteria within referrals could potentially have led to 
exclusion of eligible participants.   
2.6 Conclusions 
Overall, the primary care strategy was successful in identifying and recruiting 
appropriate participants to our study. As this approach included screening medical 
records for specific KOA diagnosis according to ACR criteria, I believe this is a more 
relevant and targeted approach than could be achieved by advertisement to the 
general public, which would potentially lead to greater numbers of non-eligible 
volunteers, requiring further effort in manually screening people who met our study 
criteria. The primary care strategy also provided several advantages over the 
secondary care strategy we reviewed, including: 
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 Adequate information, via access to electronic patient medical notes, on which 
to assess study eligibility. 
 Availability of adequate resources, e.g. staff with allocated time to recruit for 
our research study, to allow recruitment 
 More efficient screening process, via electronic searching of patient medical 
notes, allowing screening of large numbers of individuals in GP surgeries 
compared to secondary care clinics. 
In conclusion we have demonstrated the use of a primary care recruitment strategy is 
feasible for identifying and recruiting an older, obese population with KOA for 
involvement in a research study investigating the effect of Vitamin D and PA on KOA. 
However, further improvements to our primary care strategy can still be made by 
making use of reminders (postal or telephone) during study recruitment, to boost 
study participation. 
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Chapter 3. Cross-Sectional Study 
3.1 Introduction 
Chapter 2 described how people with symptomatic KOA aged 50-70yrs and with a BMI 
30-40kg/m2were recruited from primary and secondary healthcare sources into a 
cross-sectional study. Chapter 3 includes an overview of the design of this cross-
sectional study which aimed to assess KOA symptoms, Vitamin D status and PA in an 
older aged (50-70yrs), obese (BMI 30-40kg/m2) people with symptomatic KOA. This 
chapter also includes details of compliance with the study measurements to assess the 
feasibility of their use in this study population. Because the relationships between 
Vitamin D status and KOA symptoms were relatively unexplored at the beginning of 
this PhD project [93], data from this cross-sectional study were used to look for 
potential relationships between serum 25(0H)D concentration and outcomes relating 
to KOA symptoms. In addition, whilst the benefits of increasing PA through structured 
activities (such as exercise) on KOA symptoms are well-described[103], evidence on 
the extent to which light activity patterns and unstructured daily activity may relate to 
KOA symptoms is sparse. In the present chapter, this evidence gap was addressed by 
investigating potential relationships between PA intensity (assessed objectively using 
an accelerometer) and outcomes relating to KOA symptoms. 
3.2 Methods 
3.2.1 Ethics and Consent 
REC approval was obtained before commencement of the cross-sectional study as part 
of an IRAS combined ethical approval form (see Appendix A). Written informed 
consent was obtained from each participant at the beginning of the cross-sectional 
study visit.  
3.2.2 Study Design 
Once recruited into the study, participants were invited to participate in a 90 minute 
cross-sectional study visit which was designed to obtain quantitative information on 
Vitamin D status, PA and physical capability and subjective assessment of KOA 
symptoms as detailed in the SOP (see appendix I).These visits were time-tabled to 
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occur during the ‘winter period’ (April 2015 and October-December 2015) when 
cutaneous synthesis of vitamin D was zero. This cross-sectional study provided 
information about the feasibility of, and experience in, conducting study visits for the 
measurement of anthropometrics, Vitamin D, PA and KOA symptoms in older obese 
adults with symptomatic KOA. In addition, data from this study visit were used to 
assess eligibility of participants for inclusion in the pilot intervention study (described 
in Chapter 4). 
The protocol for the cross-sectional study is illustrated in Figure 3.1and described in 
more detail in section 3.2.6.
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Figure 3.1: Overview of the cross-sectional study procedure. Study information was posted to potential participants and responders were screened 
by telephone against the study eligibility criteria. Eligible participants were invited to participate in the cross-sectional study visit and an 
appointment time was arranged. Participants then attended a 90 minute cross-sectional study visit at North Tyneside General Hospital where a 
range of study measurements were taken. At the end of the study visit, participants were provided with an accelerometer to wear for the 
following 3-5 days which was then returned to the study team by post. When all study measurement results were collected they were collated into 
a participant feedback document which was posted to the participant. *= mail outs, ≠=data collection. 
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3.2.3 Study Participants 
3.2.3.1 Participant Sampling and Recruitment 
A targeted convenience sample of individuals meeting the study eligibility criteria (see 
section 3.2.3.2) was recruited to the study in the North East and Liverpool areas.  
We opted for an older adult population as the incidence of KOA increases substantially 
with increasing age. In addition, older adults with a BMI 30-40kg/m2 because an adults 
classified as obese are more likely to have low Vitamin D and PA levels. Finally we 
selected people with symptomatic KOA in order to assess KOA symptoms throughout 
the duration of the study.  
As described in Chapter 2, participants were recruited from Primary Care Sites (GP 
surgeries) in the North East of England. With the assistance of NECS, GP surgeries in 
the Northumberland, North Tyneside and Newcastle upon Tyne areas were recruited 
to the study. Recruited GP surgeries then screened their patient lists against the study 
eligibility criteria and potentially eligible participants were mailed a study pack 
(including a study invitation letter, a patient information sheet and consent form) 
which included contact information for the study team at Newcastle University. 
Individuals were instructed to contact the study team if they were interested in 
participating. Eligibility was confirmed by telephone in respondents and those who 
were eligible were invited to take part in the cross-sectional study visit at North 
Tyneside General Hospital. 
For more information regarding recruitment methods, please see section 2.2. 
3.2.3.2 Study Eligibility Criteria 
a) Study Inclusion Criteria  
1. Obese: BMI 30-40kg/m2 as defined by WHO criteria [206] 
2. Older adults: 50 – 70 years 
3. OA of the knee according to ACR Guidelines on symptomatic KOA criteria (using 
history and physical examination: 
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 Pain in the knee 
AND 3 OF THE FOLLOWING: 
 Over 50 years of age 
 Less than 30 minutes of morning stiffness 
 Crepitus on active motion 
 Bony tenderness 
 Bony enlargement 
 No palpable warmth of synovium[4] 
4. Good understanding of written and spoken English (as no translation services were 
available to support this study). 
b) Study Exclusion Criteria 
1. Any other type of arthritic condition, e.g: 
 RA 
 Fibromyalgia 
 Ankylosing Spondylitis 
 Gout 
 Lupus 
 Paget’s Disease 
 Polymyalgia rheumatic (PMR) 
 Psoriatic arthritis 
 Scleroderma 
 Sjogrens Syndrome 
2. Currently taking part in a different  PA or exercise intervention study 
3. Taking Vitamin D, cod liver oil or Calcium capsules/supplements 
(topical/oral/intravenous, prescribed/non-prescribed) above 10µg/day of 
vitamin D and/or 500µg/day of calcium. 
4. Taking part in another intervention study/trial (depending on researcher’s 
discretion) 
5. Chronic alcohol abuse (> 21 (women) and 28 (men) SI units/week 
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3.2.4 Study Materials and Measures 
3.2.4.1 Study Measurement Selection 
Table 3.1 presents the targeted outcome measurement and the measurement tool 
selected and summarises the rationale for tool choice. 
Outcome Measurement 
Tool Selected 
Rationale for tool choice 
Weight, BMI, 
Body Fat% and 
Body Fat Mass 
Tanita 
Bioimpedance 
Scales 
These scales provided an easy, non-intrusive and 
portable device for measuring body weight and 
for estimating body fat content by bioelectrical 
impedance. Compared with body imaging 
(MRI/CT) and Dual X-ray absorptiometry (DXA), 
bioelectrical impedance is inexpensive and safe 
and requires no specially trained staff. Compared 
with densitometry (underwater weighing), the 
gold standard of body composition measurement, 
it is quick and simple [207, 208] 
Waist 
Circumference 
Tape Measure A standardised protocol was selected for waist 
measurement according to the WHO 
recommendation. Waist circumference was 
measured with a flexible tape measure, midway 
between the lowest rib margin and the iliac crest. 
Due to potential variability in measurement (even 
within the same subject depending on stance, 
respiration and stomach contents), I measured in 
triplicate and calculated the mean measurement. 
[208] 
Height Stadiometer This is a cheap, accessible and reliable method of 
measuring height and was used in the calculation 
of BMI. 
Knee Function Timed Up and 
Go 
Timed up and Go is a test of functional mobility 
and has been widely utilised in older study 
populations. Monitoring changes in TUG can 
detect changes in mobility, especially important 
in those with potentially mobility limiting disease 
such as OA[209]. TUG has been previously used in 
KOA populations as a measure of physical 
function [210]. Additionally it is easy to set up and 
requires no specialist equipment.  
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Knee Symptoms Visual 
Analogue Scale 
(VAS), WOMAC 
Questionnaire 
WOMAC is a widely used, validated questionnaire 
for use in people with OA, which assesses pain, 
stiffness and physical function.  
The VAS provides a subjective measurement, on a 
scale of 0-10, of the participant’s perception of 
their pain level. 
Vitamin D 25(OH)D 
concentration 
in venous 
Blood and 
Dried Blood 
Spot (DBS) 
25(OH)D concentration in serum samples is the 
most widely used and accepted measurement of 
Vitamin D status, due to its long half-life [110]. 
In addition, DBS is emerging as a novel method of 
collecting blood samples for multiple analyses 
including 25(OH)D [211]. As part of this study we 
decided to test the acceptability of using the DBS 
method for collecting blood for measuring 
25(OH)D by comparison with the traditional 
serum sample method.   
Physical Activity Accelerometer: 
Actigraph 
GTM1/GT3X 
Accelerometry provides an objective way of 
measuring PA, which is more accurate than a 
pedometer and which can measure a range of PA 
outcomes (including PA intensity, frequency and 
duration). Compared with self-reported PA e.g. 
via questionnaires, it is more reliable and not 
subject to recall bias. Accelerometers are non-
invasive and easy to use and practical for use in a 
lifestyle setting for monitoring PA over several 
days [212] 
Quality of Life SF-36 
Questionnaire 
SF-36 is a validated and widely used 
questionnaire for measuring physical and mental 
quality of life. This is important as it adds context 
to participant problems (e.g. any emotional 
problems which may be contributing to their 
symptoms) and can be used as a method of 
assessing participants personal perception of 
change/response to a treatment [213]. 
Table 3.1: Outcomes measured in both the cross-sectional (this chapter) and pilot feasibility 
(Chapter 4) studies, the tool selected for measuring each outcome and the rationale for 
choice of this tool. 
3.2.4.2 Cross-Sectional Study Measurements 
During the 90 minute cross-sectional study visit, the quantitative measurements 
summarised in Table 3.2 were made according to the protocols set out in the study 
SOP (see Appendix I) 
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Outcome Equipment Procedure Approximate 
Time Taken to 
complete 
ACR 
Symptomatic 
KOA Criteria  
None Participants were asked to expose their 
bare knee. The researcher then 
physically examined the knee for signs 
of KOA. The method for knee 
examination has been previously 
published[214]. 
5 mins 
Height Stadiometer Participants were asked to stand with 
their back towards Stadiometer ruler 
and the marker was brought down to 
the top of the head. Height was 
measured from the marker. Height was 
measured 3 times. 
5 minutes 
Weight (kg), 
BMI, Body 
Fat%, Fat 
Mass (kg) 
 
Tanita 
Bioimpedance 
Scales 
Participants were asked to stand 
barefoot on Bioimpedance scales and 
age, body type, gender and height were 
imputed. Results for anthropometric 
measures are printed and recorded in 
the data collection sheet. 
5minutes 
Waist Size 
(cm) 
 
Flexible 
measuring tape 
(marked in 
centimetres) 
Waist size was measured using a 
measuring tape halfway between the 
bottom rib and hip bone. 
5 minutes 
Physical 
Function  
Marker cone, 
measuring tape, 
stopwatch 
Participant begins seated and on 'go' 
the participant rises unaided and walks 
2 meters in forward and back, then sits 
down unaided. This process is timed 
and repeated 2 more times. 
10 minutes 
Knee Pain, 
Stiffness and 
Function 
 
WOMAC 
Questionnaire, 
pen 
Each question on the questionnaire 
was read out by the researcher and the 
answers provided by the participant 
were recorded. 
10 minutes 
Quality of Life 
 
SF-36 
Questionnaire, 
pen 
The questionnaire was completed by 
the participant with the researcher 
available for assistance if required. 
10 minutes 
Knee pain 
 
VAS 
Questionnaire, 
pen 
Each question on the questionnaire 
was read out by the researcher and the 
answers provided by the participant 
were recorded. 
5 minutes 
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Table 3.2: Measurement methods, equipment and duration of the quantitative 
measurements taken during the cross-sectional study visit 
 
In addition to the equipment specified above for the measurements taken during the 
cross-sectional study visit each individual participant’s file was updated so that it 
contained: 
Serum 
Vitamin D, 
Serum 
Calcium and 
Haematocrit  
1x Plain, 2x 
Serum Gel and 1x 
EDTA Vacutainer 
Tubes, Butterfly 
needle, 
vacutainer tube 
holder, antiseptic 
wipe, disposable 
tourniquet, 
gauze, plaster, 
Pathology 
sample bag 
The participants arm is assessed and 
prepared before blood is taken from 
the median cubital or cephalic vein, 
using a vacutainer blood collection 
system, by RB. If there were problems 
with blood collection, a research nurse 
was called.  
10 minutes 
Serum 
Vitamin D 
 
DBS (Dried Blood 
Spot) Kit: 
containing DBS 
card, Foil 
packaging, high 
flow lancet, 
plaster, 
antibacterial 
wipes and sterile 
gauze. 
The participants washed their hands 
thoroughly. The researcher disinfected 
finger before blood is obtained by 
fingerprick. Blood drops are placed on a 
filter paper and dried at room 
temperature. 
5 minutes 
Physical 
Activity  
Pre-set Actigraph 
monitor 
(GTM1/GT3X), 
elastic 
waistband, Self-
addressed, 
prepaid 
envelope, 
accelerometer 
instructions and 
accelerometer 
log 
The accelerometer was presented to 
the participant and instructions on use 
were given. A self- addressed, prepaid 
envelope was provided for return of 
the device. 
3-5 days 
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 2 copies of consent form (see Appendix F): one copy for participant and one 
copy for research team. 
 Data collection form (see Appendix J): including details on painkiller use, 
smoking and drinking status, health status, medication status, ACR criteria, 
anthropometrics, time up and go measurements, checklist for questionnaire 
completion, checklist for blood collection and processing and checklist for 
accelerometer provision. 
 Sample Tracking Form (see Appendix K): containing instructions on sample 
processing and checklist for sample collection and processing. 
The above documentation was filled out during the cross-sectional study visit and 
completed questions and blood sample results were also stored in the participant file 
on their completion and return. 
3.2.5 Study Setting 
All study visits took place within North Tyneside General Hospital within clinical rooms 
within the Jubilee Day Hospital. All appropriate staff, equipment and logistical 
provisions were prepared at each study site before the study visits commenced, as 
follows:  
3.2.5.1 Site staff 
One CRN nurse, Ms Kirstie Walker, was allocated to assist RB with study visits between 
September-November 2015.A team of recruiters at NECS conducted recruitment in the 
North East and Liverpool study sites. 
3.2.5.2 Equipment and Services 
-80 freezer space for sample storage was arranged at NTGH pathology labs. Site 
Initiation Visits, involving presentation of the study aims and methods and a practical 
study visit run through, was completed at both sites. Site files containing ethical 
documents, study protocol, study manuals and freezer logs were created. 
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3.2.6 Procedures 
3.2.6.1 Study Visit Invitation 
Study Visits were arranged by telephone based on the participant availability and 
hospital clinic room availability. Once an appropriate time was determined, a study 
visit appointment letter stating the time and location of the participant’s appointment 
and a map of NTGH was mailed to the participant’s address. Transport arrangements 
were discussed prior to the appointment with taxis offered by the study team if 
transport was unavailable. If the participant travelled by car, parking charges and 
mileage were reimbursed, and if participants travelled by bus, cost of bus tickets were 
reimbursed. 
3.2.6.2 Study Visit set up 
Before each study visit, a clinical room within the Jubilee Day Hospital, NTGH was 
booked for the appropriate time. The study team arrived at the booked room 15 mins 
before the appointment time to prepare and set up all the required equipment for the 
study visit. This involved preparation of blood collection equipment, set up of Tanita 
Bioimpedance scales and Stadiometer, set up of the timed up and go test and 
organisation of the participant’s documentation.  At the appointment start time, the 
participant was called from the Jubilee Day Hospital waiting room. 
3.2.6.3 The Study Visit 
The study visit, conducted by the author of this thesis (RB) began with a discussion 
about the study (i.e. study aims and objectives and what taking part would involve), 
and if the participant was happy to take part, written consent was taken. Study 
measurements (summarised in Table 3.2) were then taken in accordance with the 
study SOP (see Appendix I). At the end of the study visit, the participant was thanked 
for their participation and informed that they would receive mailed feedback on their 
measurements in due course. 
3.2.6.4 Data and Sample Storage 
Blood samples were centrifuged at 3000rpm for 10mins to separate serum for the 
measurement of vitamin D and calcium concentrations and spare serum for future 
analyses (labelled Storage). The serum was transferred to a sample tube labelled with 
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the participant ID, date, sample type (vitamin D, Calcium or Storage) and Study Visit 
(CS- cross sectional) and stored in sample storage boxes in a -80C freezer at NTGH R&D 
department. Sample storage sheets detailing the sample and location within the box 
were updated as samples were added to the freezer. Frozen samples for Vitamin D and 
Calcium assay were transferred to Newcastle and NTGH pathology labs in batches (by 
storage box) for analysis. Spare storage sample boxes were kept at -80C at NTGH until 
study close, when all samples were transferred to Newcastle University (Biomedical 
Research Building, Campus for Ageing and Vitality). 
All hard copies of participant data were kept in individual participant files labelled with 
the participant ID and were transferred by RB to Newcastle University after the study 
visit was completed. All participant files were kept in a locked filing cabinet, within a 
locked room in a Newcastle University staff and student accessible building 
(Biomedical Research Building, Campus for Ageing and Vitality). Data was also imputed 
to SPSS (electronic statistical package) and saved as a database. All information 
contained within the electronic database was identifiable only by participant code and 
was password protected and encrypted. 
3.2.6.5 Participant Feedback 
On conclusion of the cross-sectional study, each cross-sectional study participant was 
mailed a letter thanking them for their participation in the study and an individual 
feedback sheet which provided data collected during their study visit. This included:  
 Weight (kilograms, stone and pounds) 
 BMI 
 Waist measurement (centimetres and inches) 
 Knee pain (scale of 0-20) 
 Knee stiffness (scale of 0-8) 
 Blood Vitamin D (25(OH)D) concentrations (nmol/L – deficient, insufficient and 
sufficient) 
 Blood Calcium concentrations (mmol/L – normal, low and high) 
 Time spent in physical activity Intensities (% time in sedentary, light and 
moderate activity) 
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They were also informed that they would receive a telephone call in due course to 
inform them of their eligibility for the pilot intervention study (described in Chapter 4). 
3.2.7 Data Processing and Analysis 
Study data was processed before being entered into an electronic database, as follows: 
3.2.7.1 Means of repeated measurements 
For measurements taken in triplicate during the study visit (Height, Waist 
Circumference and Timed Up and Go) a mean and standard deviation was produced, 
which was entered into the electronic database. 
3.2.7.2 WOMAC LK3.1 Questionnaire Scoring 
Responses to the WOMAC Questionnaire were calculated for each participant 
according to the scoring instructions outlined by the questionnaire developer, Nicholas 
Bellamy, in the WOMAC Osteoarthritis Index User Guide XI [215]. The participant 
response for each question was calculated (None=0, Mild=1, Moderate=2, Severe=3 
and Extreme=4). These question scores were then totalled by section, resulting in 
WOMAC Pain score (0-20), WOMAC Stiffness Score (0-8) and a WOMAC physical 
function score (0-68). The results of all the questionnaire sections were also totalled to 
provide a WOMAC Total score (0-96).  
3.2.7.3 SF-36 Questionnaire Scoring 
Responses to the SF-36 Questionnaires for each participant were scored using the 
Quality Metric Health Outcomes Scoring Software 4.5. Responses to each question 
were imputed into the software. After all responses were recorded, the software 
calculated a range of outcomes (shown in Table 3.3), each on a scale of 0-100, MCS 
and PCS were the primary SF-36 Scores used during statistical analysis in the present 
study. 
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SF-36 Outcome Low scores High Scores 
Physical 
Functioning (PF) 
Indicate imitation in 
performing physical activities 
Indicate no/little limitation in 
physical activities 
Role Physical (RP) Indicate problems with work 
or other activities due to 
physical health 
Indicate no/little work/activity 
limitation due to physical health 
Bodily pain (BP): Indicate high pain levels which 
interfere with daily activities 
Indicate no pain with no related 
effect on activities  
General Health 
(GH): 
Indicate poor general health 
which is likely to decline. 
Indicates good general health 
Vitality (VT): Indicate tiredness Indicates high energy levels 
Social Functioning 
(SF): 
Indicate low involvement in 
social activities due to physical 
or emotional problems 
Indicates normal involvement in 
social activities without any 
interference from physical or 
emotional problems 
Role Emotional 
(RE): 
Indicate problems with work 
or activities due to emotional 
problems. 
Indicates no work/activity 
limitation related to emotional 
problems. 
Physical 
Component Score 
(PCS): 
Indicate limitations in PF and 
participation in work and 
activities due to physical 
health 
Indicate no physical limitations 
or disability, high energy levels 
and good general health. 
Mental 
Component Score 
(MCS): 
Indicate psychological distress, 
social and work/activity 
problems due to emotional 
problems and poor general 
health. 
Indicated no psychological 
distress of limitations and good 
general health. 
Table 3.3: A summary of the interpretation of different Quality Metric Health Outcomes 
from SF-36 questionnaire data [216] 
3.2.7.4 Actigraph Data downloading and processing: 
On return of the accelerometer device to RB, data was downloaded from the 
Accelerometry device to the Newcastle University computer system using the Actilife 5 
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software. The accelerometer was connected to the computer using a USB cable and 
opened using the Actigraph 5 software. Raw data files were saved under each 
participant IDs in individual participant computer files. Using the Actigraph software, 
the following outcomes (see Table 3.4) were calculated and downloaded into the 
participant’s computer file, and then inputted into an SPSS database. 
PA Outcome  Details 
Wear Time Analysis Includes calculation of times of wear and 
non-wear of the accelerometer device. 
Energy Expenditure Includes calculation of energy expenditure 
in kilo-calories (kcals) in total and from 
physical activity. 
Activity Cut Points The proportion of time spent in different 
activity cut points (a table of the default cut 
points used can be seen in Appendix L) 
Activity Bouts Separates activity cut points into bouts of 
>10mins. All data collected in bouts of 
<10mins will be discounted (in line with UK 
government guidance that activity should 
be performed in bouts of >10mins [217]). 
Number of bouts, total time spent in bouts 
and average time in each bout is calculated. 
METs Metabolic Equivalents are calculated (1 
MET - 1kcal/kg body mass/hour) as an 
average over time of wear. 
Table 3.4: PA Outcomes calculated using Actilife 5 software[218] 
3.2.7.5 Data Management and Analysis 
All participant data were kept in hard copy and electronic database format. Electronic 
databases were created and used to conduct statistical analysis. All statistical analyses 
were performed using IBM SPSS Statistics Version 23. Descriptive data analysis, 
including means and standard deviations, were calculated for all outcome measures. 
Data was also grouped according to established criteria (e.g. PA classifications or 
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vitamin D status) which are described in detail within the results, and means and 
standard deviations calculated for outcome measures within those groupings. 
3.3 Results 
3.3.1 Study Measure Compliance 
As part of the assessment of feasibility during this pilot study, I investigated 
compliance with the study measurements made during the cross-sectional study. The 
same measurements were used in the pilot intervention study which is described in 
Chapter 4.  
3.3.2 Study Visit Measurements 
Compliance with measurements made in the cross sectional study visit are 
summarised in Table 3.5. Compliance with anthropometric measurements was high 
with only 1/45 participants missing waist measurement. Compliance in completing 
questionnaires was also high with 100% compliance for questionnaires completed with 
the researcher (VAS and WOMAC) and 44/45 completing the questionnaire that was 
completed independently (SF-36). Compliance with conventional collection of venous 
blood (44/45) was higher than for the dried blood spot samples (40/45). The single 
example of non-compliance with venous blood samples was due to difficulty in taking 
blood from the participant. Non-compliance with DBS samples was due to investigator 
error (4/45) and refused consent (1/45).  
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Study Measurements Compliance 
Anthropometric 
Measures 
Height 100% 
Bioimpedance Measurements (Weight, BMI, 
Body Fat%, Body Fat Mass)  
100% 
Waist Circumference 98% 
Knee Function 
Measures 
Timed Up and Go 100% 
Questionnaires VAS 100% 
WOMAC 100% 
SF-36 97.8% 
Blood Samples Venous Sample 97.8% 
Dried Blood Spot Sample 88.9% 
Table 3.5: Compliance with measurements made during the cross sectional study visit 
 
3.3.3 Accelerometry 
3.3.3.1 Use of Activity Monitor and Data Retrieval 
Of the accelerometers distributed during the cross-sectional study, all devices were 
returned by participants. Accelerometry data could not be retrieved from 1 monitor 
due to a technical fault with the device and step count data was missing for 10 more 
participants due to errors when setting up the accelerometry devices. 
3.3.3.2 Wear Time Analysis  
The mean length of time that participants wore the accelerometer per day is 
summarised in Table 3.6. It is generally accepted that 10hours/day of monitor wear is 
the minimum acceptable monitoring period when measuring activity using 
accelerometry[219] so I used this cut off point as the standard for valid accelerometry 
data within this study. 
Only 3/44 (7%) of participants had a mean of <10hours/day of accelerometry 
monitoring. Table 3.6summarisestotal % wear and non-wear time for all 44 
participants, for the 41 participants deemed to have valid data (mean > 10 hours/day 
monitoring)  and the 3 participants without valid (mean < 10 hours/day monitoring) 
data. There was no observable differences in age or BMI between excluded (3) and 
included (41) cases. 
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 All Participants 
(n=44) 
Mean (SD) 
Participants with 
valid data (N=41) 
Mean (SD) 
Participants with 
invalid data (n=3) 
Mean (SD) 
Mean Age 
(years) 
61 (±5.5) 61 (±5.6) 63 (± 3.5) 
Mean BMI 
(kg/m2) 
34 (±4.6) 34 (±4.0) 36 (±11.1) 
Mean Daily 
Wear Time 
(mins) 
779 (±133.0) 798 (±101.0) 514 (±252) 
Total Wear time 
(% of total 
monitoring time) 
59 (±8.5) 60 (±7.8) 47 (±9.7) 
Total Non-Wear 
Time (% of total 
monitoring time) 
40(±9.1) 40 (±7.8) 41 (±23.3) 
Table 3.6: Mean (SD) wear time of accelerometers over the activity monitoring period in all 
participants, participants with valid data (defined as participants with mean >10 hours/day 
of activity data) and participants with invalid data (defined as participants with mean <10 
hours/day of activity data) 
As can be seen in Table 3.6, participants with invalid accelerometry data wore the 
accelerometer for a mean 284 minutes less than participants with valid accelerometry 
data. Participants with valid data spent 60% of their time wearing the accelerometer 
compared to 47% in participants with invalid data. This disparity in wear time is 
reflective in the validity of the participant’s data. 
3.3.4 Participant Characteristics 
A summary of the participant characteristics is provided in Table 3.7. Of the 45 
participants in the cross-sectional study, there was 22 females (49%) and 23 males 
(51%). All participants were Caucasian and the majority were current non-smokers 
(89%). Mean participant age and BMI was around the middle of our age (50-70 years) 
and BMI (30-40 kg/m2) eligibility criteria at 61 years and 34.3 kg/m2 respectively. The 
majority of participants reported Bilateral KOA (69%) followed by Left KOA (22%) and 
Right KOA (9%).On knee examination, I identified which ACR criteria were met by each 
participant, the results of which are summarised in Table 3.8.Overall, 31% and 33% of 
participants reported previous injury or previous surgery to the affected knee joint 
respectively with no significant relationship between reported previous injury and 
surgery. 28% of our sample were currently employed with 72% retired or on sickness 
leave. 
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Table 3.7: Characteristics of participants in the cross-sectional study by gender. *Indicates 
missing data 
 
 
Participant characteristics All Participants (n=45) 
Mean (SD) 
Females (n=22) 
Mean (SD) 
Males (n=23) 
Mean (SD) 
Age (years) 61.2 (±5.31) 59.9 (±4.84) 62.3 (±5.57) 
Height (cms) 169.9 (± 8.91) 163.8 (±6.33) 175.4 (±7.19) 
Weight (kgs) 106.2 (±23.15) 104.0 (±26.93) 108.3 (±19.33) 
BMI (kg/m2) 34.5 (±4.65) 34.5 (±4.32) 34.6 (±5.04) 
Body Fat (%) 40.6 (±7.93) 46.1 (±4.35) 35.5 (±7.08) 
Body Fat Mass (kg) 40.6 (±11.70) 43.1 (±9.84) 38.3 (±13.04) 
Waist Circumference (cms) 112.8 (±12.12) 108.6 (±11.50) 116.8 (±11.57) 
Timed Up and Go (secs) 9.5 (±2.19) 9.8 (±2.49) 9.3 (±1.89) 
VAS Daily Score (0-10) 4.3 (±1.84) 4.0 (±1.74) 4.6 (±1.94) 
WOMAC Pain 8.4 (±3.44) 8.1 (±3.74) 8.5 (±3.20) 
WOMAC Stiffness 4.4 (±1.95) 4.3 (±2.02) 4.5 (±1.91) 
WOMAC Activities of Daily Living  27.9 (±10.78) 28.0 (±12.05) 27.8 (±9.72) 
WOMAC Total 40.6 (±15.25) 40.3 (±17.00) 40.8 (±13.86) 
SF-36 MCS (Mental Capacity 
Score) (0-100) 
48.6 (±11.5) 44.9 (±10.81) 52.5 (±11.26) 
SF-36 PCS (Physical Capacity 
Score) (0-100 
38.6 (±9.5) 40.9 (±8.76) 36.6 (±10.01) 
Serum 25(OH)D (nmol/L)* 43.6 (±23.4) 42.4 (±20.50) 43.6 (±24.12) 
Serum Calcium (mmol/L) 2.2 (± 0.28) 3.0 (±0.29) 2.2 (±0.28) 
% 25(OH)D Deficient 
(<25nmol/L)* 
27 (12/45) 27 (6/22) 26 (6/23) 
% 25(OH)D Insufficient (26-
50nmol/L)* 
36 (16/45) 32 (7/22) 39 (9/23) 
% 25(OH)D Sufficient 
(<51nmol/L)* 
36 (16/45)  36 (8/22) 35 (8/23) 
% time in sedentary activity 63 (±10.6) 61.9 (±10.39) 66.5 (±10.36) 
% time in light activity 33 (±9.4) 34.2 (±8.75) 29.6 (±10.03) 
% time in moderate activity 44 (±3.1) 3.9 (±3.22) 3.9 (±3.34) 
Average daily time in sedentary 
activity (mins) 
1276 (±2693.8) 1535 (±3096.3) 1029 (±2296.6) 
Average daily time in light activity 
(mins) 
263 (±87.6) 289 (±81.6) 239 (±88.3) 
Average daily time in moderate 
activity (mins) 
31 (±26.0) 33 (±29.1) 30 (±23.3) 
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When comparing the anthropometrics of male and female participants, differences in 
height and body fat % can be observed, with females being on average 11.6cms 
shorter and 10.6% (equating to  4.8kg of fat mass) higher body fat % than the males. 
However the females did have a smaller waist circumference at a mean 8.6cm less 
than the males. 
When comparing self-reported knee osteoarthritis symptoms, there are no notable 
differences observed between genders apart from in the SF-36 scoring.  Females 
reported having worse mental health outcomes, with a mean SF-36 MCS 7.6 points 
lower than the males (on a scale of 0 to 100, with 0 representing worse mental 
wellbeing and 100 representing best mental wellbeing). Conversely males reported 
slightly worse physical health outcomes with a mean SF-36 PCS   4.3 points lower than 
the females (on a scale of 0 to 100, with 0 representing worse physical wellbeing 
outcomes and 100 representing best physical wellbeing). 
There was little difference in vitamin D concentration (nmol/L) and vitamin D status 
between genders.  However there were slight differences in physical activity recorded 
between the genders.  Males spent 4.6% more time in sedentary activity and 4.6% less 
time in light activity than females, while levels of moderate activity between men and 
women didn’t differ.
 137 
 
ACR Criteria % participants with criteria 
Pain in Knee during last 3 months  96% 
>50years old  100% 
<30mins knee stiffness in morning 71% 
Crepitus on active motion 91% 
Bony tenderness 69% 
Bony enlargement 69% 
No palpable warmth of the synovium 58% 
Table 3.8: Proportion (%) of cross-sectional study participants meeting each ACR 
symptomatic KOA criteria as determined by physical knee examination 
Painkiller use in participants of the study was common. Of all participants, 67% (n=), 
62% (n=28), 4% (n=2) and 22% (n=10) reported taking paracetamol, NSAIDs, opioid 
painkillers (e.g. codeine and tramadol) and other painkillers (e.g. amitriptyline and 
gabapentin) respectively. Interestingly those participants who reported taking NSAIDs 
also reported higher levels of WOMAC Pain compared to those who did not take 
NSAIDs (mean WOMAC pain score 9.1 ± 3.1 vs 6.9 ±3.5 respectively).  
In addition to KOA, the study participants reported multiple concurrent health 
conditions the most common of which were hypertension (40%, n=18), cardiovascular 
disease e.g. angina, arrhythmias (29%, n=23), type 2 diabetes (20%, n=9%) and 
depression (20%, n=9).  
Information was also collected on incidence of previous knee injury or previous knee 
surgery. Of our study participants, 35% (n=16) reported previous knee injury and 65% 
(n=29) did not report any previous knee injury. Regarding previous knee surgery (not 
knee replacement surgery), 38% (n=17) reported having previous knee surgery while 
62% (n=28) did not report any previous knee surgery. 
When PA status was assessed against the government PA guidelines [217], 18 
participants (41%) were classed as ‘inactive’ (<30mins moderate activity/week), 4 
participants (9%) were classed as ‘low activity’ (30-59mins moderate activity/week), 10 
participants (23%) classed as ‘some activity’ (60-149mins moderate activity/week) and 
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12 participants (27%) classed as ‘met activity guidelines’ (>150 mins moderate 
activity/week) 
3.3.5 Physical Activity and KOA symptoms 
As part of the aim of this cross sectional study was to investigate the relationship 
between PA and KOA symptoms, I have performed a descriptive analysis of the PA and 
KOA symptom data from the cross sectional study participants. 
For this analysis participants were classified into groups according to the NHS England 
PA classification groups (see Table 3.9). [217] 
PA Level Classification Study Sample Size 
n= (%of total 
sample) 
Inactive <30mins moderate activity per week 18 (41) 
Low 30-59mins moderate activity per week 4 (9) 
Some 60-149mins moderate activity per week 10 (23) 
Met Guidelines >150mins moderate activity per week 12 (27) 
Table 3.9: Table demonstrating the classification for activity levels by amount of moderate 
intensity activity completed per week according to UK government guidelines 
As can be seen in Table 3.10, time to complete the timed up and go test was a mean 
2.0 and 1.9 seconds longer in the inactive participants compared to participants 
achieving low PA or those which met PA guidelines respectively. Interestingly when 
observing self-reported pain (WOMAC Pain score, 0-20 scale), those who reported the 
lowest mean levels of pain were those who achieved low PA levels and those with the 
highest mean levels of pain were those participants who met PA guidelines (with a 
difference in mean WOMAC pain score of 3.0 points between these groups). This 
pattern was also the same for WOMAC stiffness (with a mean difference of 3.0 points 
on a scale of 0-8) and for WOMAC activities of daily living (with a mean difference of 
11.8 on a scale of 0-68). 
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Measures of KOA 
symptoms 
Physical Activity Level Classification 
Inactive 
(n=17) 
Mean (SD) 
Low 
(n=4) 
Mean (SD) 
Some 
(n=11) 
Mean (SD) 
Met Guidelines 
(n=9) 
Mean (SD) 
Timed Up and Go (secs) 10.4 (±2.45) 8.4 (±0.67) 9.4 (±1.91) 8.5 (±1.71) 
VAS Daily Score (0-10) 4.0 (±2.24) 3.8 (±1.26) 4.5 (±1.90) 4.3 (±1.67) 
WOMAC Pain (0-20) 8.2 (±2.98) 6.3 (±0.96) 7.7 (±4.30) 9.3 (±3.60) 
WOMAC Stiffness (0-8) 3.8 (±2.28) 2.5 (±1.73) 4.5 (±2.22) 5.2 (±1.19) 
WOMAC Activities of 
Daily Living (ADL) (0-
68) 
27.6 
(±10.30) 
17.5 (±7.33) 27.7 (±12.05) 29.3 (±11.16) 
WOMAC Total (0-92) 39.6 
(±14.71) 
26.3 (±9.22) 39.9 (±17.95) 43.8 (±14.95) 
Table 3.10: Mean and SD of measurements of self-reported KOA symptoms by PA Guideline 
grouping 
3.3.6 Vitamin D Status and KOA Symptoms 
As part of the aim of this cross sectional study was to investigate the relationship 
between Vitamin and KOA symptoms, I have performed a descriptive analysis of the 
Vitamin D and KOA symptom data from the cross sectional study participants. 
Vitamin D was organised according to vitamin D status: deficient (25(OH)D <25nmol/L), 
insufficient (25(OH)D 25-50nmol/L) and sufficient (25(OH)D >50nmol/L). A descriptive 
analysis of measurements of KOA symptoms by vitamin D status is presented in Table 
3.11. 
 
There is little observable difference in time taken to complete time up and go between 
vitamin D status’s, with vitamin D sufficient participants 1.3 seconds faster than the 
vitamin D deficient group. Regarding self-reported pain, stiffness and activities of daily 
living, the vitamin D insufficient group had lowest reported severity of symptoms 
compared to the vitamin D deficient group who reported the highest severity of 
symptoms. 
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Measures of KOA 
symptoms 
Vitamin D status 
Deficient 
(n=12)  
Insufficient 
(n=16) 
Sufficient 
(n=16) 
Timed Up and Go (secs) 10.2 (±2.55) 9.4 (±2.38) 8.9 (±1.41) 
VAS Daily Score (0-10) 4.4 (±2.23) 4.2 (±1.65) 4.4 (±1.67) 
WOMAC Pain (0-20) 9.1 (±3.80) 8.0 (±2.99) 8.3 (±3.53) 
WOMAC Stiffness (0-8) 4.8 (±1.99) 4.1 (±2.31) 4.2 (±1.60) 
WOMAC Activities of 
Daily Living (ADL) (0-
68) 
31.6 (±9.50) 26.3 (±10.59) 26.2 (±11.46) 
WOMAC Total (0-92) 45.5 (±14.71) 38.4 (±14.81) 38.6 (±15.67) 
Table 3.11: Mean and SD of measurements of self-reported KOA symptoms by vitamin D 
status 
3.3.7 Vitamin D and Physical Activity status 
As part of the aim of this cross sectional study was to investigate the relationship 
between Vitamin and physical activity, I have performed a descriptive analysis of the 
Vitamin D and physical activity data from the cross sectional study participants. For 
this analysis, participants were classified according to NHS England PA classifications 
(as in section 3.3.5) and vitamin D was measured as serum levels of 25(OH)D in nmol/L. 
The participants with the highest serum 25(OH)D concentrations were in the low PA 
group, while the group with the lowest 25(OH)D concentrations were those in the 
some PA group (with a total mean difference of 19nmol/L between these groups). 
Those participants who met PA guidelines had a mean 25(OH)D 4nmol/L higher than 
the inactive PA group. 
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Physical Activity Level Classification 
Inactive 
(n=17) 
Mean (SD) 
Low 
(n=4) 
Mean (SD) 
Some 
(n=11) 
Mean (SD) 
Met 
Guidelines 
(n=9) 
Mean (SD) 
Vitamin D (25(OH)D) 
concentration 
(nmol/L) 
42 (±23.3) 58 (±35.7) 39 (±21.2) 46 (±22.4) 
Table 3.12: Mean (SD) serum 25(OH)D concentrations (nmol/L) of participants according to 
PA classification 
3.4 Discussion 
This cross-sectional study was designed to serve two objectives: i) to ascertain the 
feasibility of measuring Vitamin D, PA and KOA symptoms in older obese adults with 
symptomatic KOA ii) to explore the relationships between vitamin D, physical activity 
and KOA symptoms in our study population and iii) to identify potential participants 
for the pilot intervention study which is described in Chapter 4.  
In Chapter 2 the feasibility of recruitment for this cross-sectional study was 
investigated. This investigation revealed a number of issues affecting recruitment, 
particularly recruitment from secondary care sources (see section 2.4 for more 
details). The present chapter focuses on the acceptability, and feasibility, of conducting 
the relevant measures. The results of this feasibility analysis are discussed below 
according to study resources, management and scientific data [194]. 
3.4.1 Study Resources 
3.4.1.1 Study Measure Compliance 
As can be seen in section 3.3.1, compliance with study measurements was high, with 
only one individual unable to give blood by venous collection, five people who did not 
give a DBS sample (one did not give consent and for four there was a lack of DBS kits 
available when needed). PA data was missing for one participant due to accelerometer 
malfunction and three participants were excluded from PA analysis due to low 
compliance with wear time (<10hrs/day). This high level of study measurement 
compliance demonstrated that overall these measurements seemed to be acceptable 
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to the participants. This issue is explored further in the qualitative interview study 
which is reported in Chapter 5. 
3.4.1.2 Study Equipment 
a) Cost and availability 
The cost and availability of equipment, such as accelerometry devices, will inevitably 
affect the measurements that can be made as part of a study. In the present study, this 
cost was avoided by borrowing devices from various research departments within 
Newcastle University.   
b) Equipment retention  
One of our measurements involved the hand out of equipment (accelerometry 
devices) to participants to use after the study visit. With this comes the risk of 
equipment loss or damage. We aimed to reduce the risk of monitor loss or damage by 
following best practice recommendations [219] including demonstration of how to use 
the device correctly, provision of written instructions on device use and use of wear 
logs. All activity monitors in this study were returned using the postal method, which is 
better than the estimated 5% that are usually lost/missing when using the mail out 
method of returning the activity monitors [219]. 
3.4.2 Study Management 
3.4.2.1 Study Timescale 
Due to a protracted ethical approval process, this study which was designed to start in 
October 2014 was delayed until April 2015. I had intended to begin recruitment in 
October 2014 so that participants could be recruited during the winter to reduce the 
confounding effect of Vitamin D synthesis through sunlight exposure since dermal 
Vitamin D synthesis is not possible in the UK during the winter months (October to 
April) [110]. The delay in obtaining ethics committee approval reduced the time frame 
in which I could perform this study and reduced the sample size that I was able to 
achieve. Lack of time has often been reported as a major barrier to recruitment, 
especially in a clinical environment where additional support may be limited [220]. NB 
Although assistance from a research nurse had been offered originally, shortly before 
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the main period of recruitment was due to start, this offer was withdrawn because of 
the unavailability of staff. 
3.4.3 Scientific Data 
3.4.3.1 Participant characteristics 
My participants met my eligibility criteria by being classified as obese (mean BMI: 34.3 
±4.8), reporting mild-moderate knee pain (mean 8.4 ±3.4on a 0-20 scale) and Knee 
stiffness (4.4 ±1.9 on 0-8 scale) and were aged with the specified age range of 50-
70years (mean 61.2 ± 5.3).I had almost equal numbers of men (n=23) and women 
(n=22) in the study. This observation shows that the recruitment strategy was 
successful in attracting both genders to volunteer for this study. Note, however, that 
KOA is diagnosed more often in women than in men [221].  
Vitamin D status was assessed by quantifying serum 25(OH)D (nmol/L) concentration  
This revealed that 27%, 36% and 36% participants were classed as Vitamin D deficient 
(<25nmol/L), Vitamin D insufficient (26-50nmol/L) and Vitamin D Sufficient 
(>51nmol/L) respectively[110]. The results of a large UK cohort study of >45 year olds 
by Hypponen[129] showed vitamin D deficiency (25 (OH)D <25nmol/L) prevalence 
during Winter/Spring in the UK obese population and residents of Northern England 
were 13.5%, 17.5% respectively and vitamin D insufficiency (25(OH)D <40nmol/L) 
prevalence in these groups were 43.3% and 46.6% respectively. If we compare the 
prevalence of vitamin D deficiency (25(OH)D <25nmol/L) in this study (27%) with the 
cohort study by Hypponen [129] (17.5%), there is comparatively higher vitamin D 
levels of vitamin D deficiency within our study cohort.  
Analysis of PA data collected in this cross-sectional study when compared against the 
UK guidelines [217] revealed that 40%, 9%, 36% and 21% of participants were classed 
as having inactive, low, some and met guidelines levels of physical activity (see Table 
3.9for details). These results differ from the UK PA statistics compiled by the British 
Heart Foundation [163](based on data from the Health Survey for England [HSE]) 
which recorded 26%, 5%, 14% and 55% of men and 27%, 6%, 12% and 55% of women 
aged 55-64 years old were classed as having inactive, low, some and met guidelines 
levels of activity. These results suggest this cross-sectional study cohort had 
comparatively higher levels of inactivity and lower proportions of individuals meeting 
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PA guidelines compared to the general UK population surveyed as part of HSE. This 
difference in recorded PA levels may be due to the prevalence of KOA in this cross-
sectional study population which can be supported by evidence from a 2013 
systematic review [162] also showed populations with KOA achieved lower levels of PA 
compared to the general population, with 13% of people with KOA achieving the PA 
guidelines of >150 minutes of moderate activity per week (in bouts of >10mins). 
Several non-disease related factors (e.g. sex, age and BMI) and disease related factors 
(e.g. pain, dysfunction and OA severity) may be responsible for the differences in 
physical activity levels found in those with, and without, KOA [222-224]. 
3.4.3.2 The relationship between PA, vitamin D status and KOA symptoms 
The results of our descriptive analysis of self-reported KOA symptoms by PA 
classifications (defined based on guideline produced by NHS England [217]) showed 
that those participants classed as ‘inactive’ took a mean 1.9 seconds longer to 
complete the Timed Up and Go (TUG) test than the participants who ‘met activity’ 
guidelines. This may imply that as moderate physical activity (on which these PA 
guidelines are based upon) increases, physical function (represented by decreased 
time taken to complete TUG) improves or vice versa. This relationship between 
physical activity and physical functioning has been observed in other cross-sectional 
studies, e.g. 2013 cross-sectional study of 160 older and overweight and obese 
individuals with KOA [225], who found a significant correlation between physical 
functioning (measured using the Short Physical Performance Battery) and time 
(minutes) in Moderate/Vigorous intensity physical activity (r=0.315, p=<0.001). Further 
evidence from intervention studies with the aim of increasing PA in older individuals 
with KOA [226, 227]also show improvements in physical function with increased PA, 
suggesting PA may be the causal factor in this relationship. 
Interestingly during this descriptive analysis of PA groups and KOA symptoms it was 
also observed that the worst reported severity of KOA symptoms were seen in those 
who ‘met PA’ guidelines while those with ‘low’ activity levels had the lowest reported 
severity of KOA symptoms. This is contrary to most evidence which suggests that 
exercise programmes which increase physical activity result in improvements in pain 
and disability outcomes. [103] There are several potential explanations to account for 
 145 
this observation. Firstly, as the distribution of participants between the different PA 
classification groups is highly variable (n=4 in the ‘low’ activity group vs n=9 in the ‘met 
guidelines’ group) and the sample size was too small to conduct statistic comparisons, 
it may be this observation is not due to a true effect but has occurred by chance. The 
only way to test this assumption would therefore be to collect a larger sample and 
conduct a statistical analysis. Secondly, as highlighted by the Centers for Disease 
Control and Prevention (CDC) recommendations on exercising safely with arthritis, it is 
important that people with arthritis who are generally inactive increase their PA 
slowly, giving the body time to adjust to the new level of activity and also to choose 
activities which are ‘joint friendly’ and therefore provide low risk of injury to the joints. 
[228] This information was provided as part of our PA intervention, however if 
participants did overexert or injure themselves this is likely to provide a source of pain. 
However, as we did not formally record this information, it is not possible to provide 
data to support this theory from this study.  
The results of our descriptive analysis of self-reported KOA symptoms by vitamin D 
status showed little observable difference between the vitamin D groups in KOA 
symptoms. This reflects recent evidence collated by a 2013 systematic review by Cao 
et al [93] which showed limited evidence for an association between symptomatic KOA 
and 25(OH)D levels. One 2011 cross sectional study showed a significant association 
between Vitamin D deficiency and KOA symptoms in those <60 years old (OR: 2.26, 
95%CI: 1.15-4.4, P=0.018) but not in those >60 years old (OR: 1.01, 95%CI: 0.48-5.9, 
P=0.96) [229], suggesting it may be an age specific relationship. However due to the 
narrow age range of our participants (50-70 years) and low numbers of participants it 
would not be possible to compare the effect of age as a potential factor in the 
relationship between vitamin D and KOA symptoms in this study.  
Finally, in our descriptive analysis of the relationship between 25(OH)D concentrations 
and PA classification groups, it was observed that those with the lowest serum 
25(OH)D concentrations were those in the ‘some’ activity group and those with the 
highest serum 25(OH)D concentrations were found in participants achieving ‘low’ PA 
levels. This is at odds with much of the existing research literature which consistently 
demonstrate a positive relationship between serum 25(OH)D concentrations and PA 
levels, e.g. a US study based on NHANES data showed that for every 10 minute 
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increase in moderate intensity activity per day there was an associated serum 25(OH)D 
increase of 0.8nmol/L [230]. Proposed explanations for the relationship between 
serum 25(OH)D and PA seen in the existing research literature include; i) that those 
with higher 25(OH)D concentrations are more physically able and are therefore more 
active, ii) those who are more active may increase their 25(OH)D concentrations 
through increased sunlight exposure, or iii) an external factor may affect both 25(OH)D 
and physical activity levels [231].I speculate this difference in what was observed 
within our cohort and the existing literature is due to the disparity in sample sizes 
between PA classification groups and that a larger, more equally distributed sample 
would be required to explore this relationship adequately. 
3.5 Summary 
This cross-sectional study has shown that it is feasible to assess Vitamin D, PA and KOA 
symptoms in older obese adults with symptomatic KOA with high adherence to all 
aspects of the study protocol. 
Analysis of this cross-sectional data highlighted interesting areas of future 
investigation, which have informed the following recommendations: 
 KOA populations, including this cross-sectional cohort, have low activity levels 
compared to the general UK population. Increasing PA, particularly moderate 
intensity activity, may be beneficial KOA cohorts in order to improve health 
outcomes [162].   
 Moderate intensity activity may be associated with physical function. 
Promoting increased moderate intensity activity may also be important in 
improving knee function in those with KOA [225]. 
 In this sample 25(OH)D concentrations were lowest in those achieving ‘some’ 
activity and those with the highest 25(OH)D concentrations achieved ‘low’ 
activity, contrary to the majority of the existing literature. A cross-sectional 
study with a larger sample size which takes into account potential confounding 
factors is required to statistically explore the relationship between 25(OH)D 
and PA in this study population.  
 There was no trend observed regarding a relationship between 25(OH)D 
concentrations and PA classification (which has been observed in the current 
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literature) in this study, however this may be due to small sample size and 
unequal distribution of sample size between PA classification groups. In light of 
previous studies which have observed a relationship between 25(OH)D and PA 
which has been [230], and evidence of association between 25(OH)D and KOA 
[93, 103] and PA and KOA [103], further (as yet not conducted) studies 
investigating the potential cumulative effect and relationship between vitamin 
D, PA and KOA are needed to investigate this further. Ideally a factorial RCT 
intervention administering Vitamin D and PA would be conducted to 
investigate the effect of Vitamin D and PA on KOA cumulatively and separately. 
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Chapter 4. Pilot Intervention Study 
4.1 Introduction 
In this chapter, I describe my pilot intervention study which was designed to assess the 
feasibility of delivering a vitamin D supplementation and web-based PA intervention to 
obese older adults with KOA. At the start of this PhD, there were few intervention 
studies which investigated the impact of Vitamin D supplementation on KOA 
symptoms [147]. In addition, despite evidence supporting a positive relationship 
between increasing PA levels and KOA symptom relief [103]and recommendations 
from NICE that PA should be a first line treatment option for those with OA [10], there 
is little evidence available regarding the effect of home-based web delivered PA 
programmes [181]. No study to date has conducted a randomised controlled trial 
assessing the use of both Vitamin D supplementation and web-based PA programmes 
with the aim of KOA symptom relief. The purpose of this pilot interventional study was 
to assess the feasibility and acceptability of conducting such a RCT. 
4.2 Methods 
4.2.1 Ethics and Consent 
REC approval was obtained before commencement of the cross-sectional study as part 
of an IRAS combined ethical approval form (see Appendix A). Written consent was 
obtained from each pilot interventional study participant at the beginning of the cross-
sectional study visit and verbal consent was obtained before commencement of the 
pilot interventional study. 
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4.2.2 Study Design 
4.2.2.1 Study Design 
 
Figure 4.1: Original design of the pilot intervention study. *=screening, ≈=randomisation 
The pilot intervention study was designed to assess the acceptability and feasibility of 
two intervention modalities, Vitamin D supplementation and a web-based PA 
intervention, over three months. To avoid confounding through cutaneous synthesis of 
vitamin D the intervention was intended to occur in the winter months (January-March 
2015 and January-March 2016). The2x2 factorial design of the study allowed the 
intervention modalities to be assessed independently and also permitted investigation 
of any potential interaction. The specific design and content of these interventions is 
described in section 4.2.2.2-4. 
a) Amendments to Study Design  
The pilot intervention study design was originally a 2x2 factorial randomised controlled 
trial design with four study arms (see Figure 4.1). Participants who met the eligibility 
criteria (see section 4.2.3.2.) were randomly (through random number sequence 
allocation) allocated to one of these study arms. 
However due to low numbers of participants meeting the eligibility criteria for both 
intervention modalities (required for the fully randomised study design), the study 
design was changed to an unrandomised design (see Figure 4.2) with those eligible 
only for the Vitamin D intervention assigned to the Vitamin D intervention, those 
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eligible for the web-based PA intervention assigned to the web-based PA intervention 
and participants eligible for both interventions assigned to both. This decision was 
made so there would be adequate numbers within each intervention group to assess 
the feasibility and acceptability of the intervention. For more details about the study 
allocation procedures see section 4.2.6.1. 
 
Figure 4.2: Diagramatic representation of the study flow of the amended pilot intervention 
study design.*=screening 
b) Intervention Design  
The design of the two study intervention modalities (Vitamin D supplementation and 
web-based PA intervention) for this pilot intervention study were developed with 
collaborators at Newcastle University (Dr Thomas Hill and Professor John Mathers) and 
based on the current academic literature. I have described the rationale, development 
process and final intervention content for each intervention below. 
4.2.2.2 Vitamin D Intervention 
When designing the Vitamin D intervention, several issues had to be addressed. Below 
I have described the evidence base, development process and final intervention 
content for the Vitamin D supplementation intervention:  
a) Vitamin D supplementation Intervention: Evidence Base 
Before designing the Vitamin D intervention, I reviewed the existing literature on 
studies implementing Vitamin D interventions in a KOA population. From this review, I 
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identified several design issue which were important in informing the design of my 
study:  
 Participant baseline serum 25(OH)D concentrations: Any response to 
supplemental vitamin D is likely to depend on the vitamin D status of the 
participants at baseline. In the only published RCT of Vitamin D 
supplementation in KOA patients available at the time of intervention design 
[92], the authors reported a small non-significant improvement in WOMAC Pain 
Score among those supplemented with Vitamin D who had low baseline 
25(OH)D concentrations (<37.44nmol/L).   
 Vitamin D administration and delivery: Vitamin D supplementation is available 
as a subcutaneous depot injection or for oral ingestion in the form of capsules, 
tablets, powders or sprays.[110] Most Vitamin D supplementation 
interventions for older populations in clinical studies have used oral 
supplementation methods [92],[232],[233]. Vitamin D supplements are also 
available as Vitamin D2 or Vitamin D3, with evidence that D3 is significantly 
more effective in raising serum 25(OH)D concentrations than D2 [234, 235]. 
 Vitamin D dosage: The amount of Vitamin D given daily in Vitamin D 
supplementation studies is highly variable. The dosage used in McAlindon’s RCT 
of [92] Vitamin D and KOA was 2000IU (50 µg) Vitamin D/day. A dose of 1000-
2000IU (25-50µg) daily (10,000IU or 250µg monthly) is also recommended 
clinically for Vitamin D deficient and insufficient individuals over 3 months to 
raise 25(OH)D concentrations to sufficiency (>50nmol/L) [134]. 
 Vitamin D supplementation confounders: The main contributor to 25(OH)D 
concentrations is sunlight exposure, followed by dietary ingestion (consumed 
as supplements or food) [110]. 
 Vitamin D supplementation safety: There is no official ‘cut off point’ for Vitamin 
D toxicity specified and estimates of the serum Vitamin D concentrations 
indicative of toxicity in the literature are variable [236-238]. However, it is 
generally recognised that Vitamin D toxicity is rare and occurs at high Vitamin D 
doses, consistently reported as above 375-500nmol/L [239]. Additionally the 
side effects from Vitamin D toxicity are not thought to be a direct result of 
Vitamin D itself, but a result of its effect on calcium metabolism. Vitamin D 
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toxicity may lead to hypercalcemia which produce the side effects experienced 
during toxicity [240, 241]. 
b) Vitamin D Intervention: Interventional Development 
Based on the literature reviewed above, I developed my own Vitamin D intervention. 
The rationale and development process for this is reviewed below: 
 Participant baseline serum 25(OH)D concentrations: Based on the evidence 
suggesting that those with low baseline 25(OH)D concentrations may benefit 
through improvement in KOA symptoms after Vitamin D supplementation [92], 
I decided to also recruit Vitamin D insufficient (26-50nmol/L 25(OH)D) 
individuals. Vitamin D deficient (<25nmol/L 25(OH)D) individuals were excluded 
on ethical grounds (I had originally intended that some participants would be 
Controls and so not receive vitamin D – see Fig 4.1) and so, with the 
participant’s permission, they could be referred directly to their GP for follow 
up[134]. 
 Vitamin D administration and delivery: As Vitamin D3 is more effective than D2 
in raising vitamin D status and as this form of the vitamin is more readily 
available as a supplement, I chose to use a Vitamin D3 preparation. Due to 
logistical issues and availability of trained staff to administer injections, we 
rejected delivering Vitamin D by depot injection. The use of powders and spray 
mechanisms for supplementation were rejected due to product availability and 
cost issues. This left the study team with a choice of capsules or tablet 
supplement. Commercially available products were reviewed according to 
product composition and cost and Boots Pharmaceuticals Vitamin D 25µg 
tablets were selected for use in the study. 
 Vitamin D dosage: I decided to administer the clinically recommended dose of 
2000IU (50µg)/day of Vitamin D deficient individuals over 3 months with the 
aim of raising serum 25(OH)D concentrations of Vitamin D insufficient 
participants to Vitamin D sufficiency (>50nmol/L). 
 Vitamin D supplementation confounders: As cutaneous synthesis is the largest 
contributor to 25(OH)D, sunlight exposure presented as a potential confounder 
to our Vitamin D supplementation intervention by providing an unregulated 
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Vitamin D source during the study. In addition, dietary supplements e.g. multi-
vitamin tablets are a potential source of vitamin D. I therefore took several 
steps to attempt to reduce the amount of cutaneous Vitamin D production 
during the study and confounding from dietary sources: 
o No consumption of any other Vitamin D containing supplements. 
o No sunbed use by participants during the pilot intervention study. 
o No holidays to areas where exposure to significant sunlight exposure is 
anticipated which is likely to cause cutaneous 25(OH)D production. 
o Conduct of pilot interventional study during the UK ‘winter’ months, 
October-April, when cutaneous 25(OH)D production is not possible 
[110]. 
 Vitamin D supplementation safety: Participant safety with regards to Vitamin D 
supplementation was fully considered and  the following procedures were in 
place: 
o Serum concentrations of 25(OH)D were monitored at each study time 
point (6 week and 12 week) to ensure they had not surpassed current 
safe upper limits>100ng/ml (220nmol/L) [241]. 
o Serum calcium concentrations were monitored to ensure observed 
concentrations remained within the normal physiological range. 
o Individuals allocated to the Vitamin D supplement only group were 
asked to limit non-essential Vitamin D supplementation. 
o Participants were monitored (by observation/reporting of any 
symptoms of hypercalcemia/Vitamin D toxicity and monitoring of serum 
25OHD and Calcium during the study) to identify any 
hypercalcaemic/Vitamin D toxicity symptoms. 
o Participants with health conditions/taking medications that could 
exacerbate the effect of Vitamin D or make Vitamin D supplementation 
dangerous were excluded (see section 4.2.3.2.) 
c) Vitamin D Intervention: Final Intervention Content 
In summary, the study intervention involved participants taking 2000IU (50µg) (in the 
form of 2x1000IU [25µg] tablets/day) D3 per day. These tablets were provided to 
participants in 6 week batches (refilled with more D3 tablets at the week 6 study visit) 
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in pill boxes, which included a separate box for each day of the 6 weeks. Each separate 
days box was filled with 2x 1000IU (25µg) tablets (see Figure 4.3).  Participants were 
instructed to leave any missed tablets in their original position in the pill box to allow 
compliance to be measured at each study visit. At the start of the study intervention, 
the participants were provided with their pill box and a Vitamin D Intervention manual 
(see Appendix M) containing instructions on following the intervention. 
 
 
Figure 4.3: (Top) Picture of pill case give to participants as part of the Vitamin D intervention, 
containing 3 weeks supply of Vitamin D supplements. (Bottom) Picture of the contents of 
each individual’s day’s pill box. 
 
4.2.2.3 Online PA Intervention 
The online PA intervention, ‘POW’ (People with Osteoarthritis Walking programme) 
aimed to increase PA, walking in particular, among older obese adults with KOA 
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through goal orientated lifestyle changes. POW was adapted from the ‘moving more’ 
module of the LEAP (Living, Eating, Activity and Planning in Retirement) intervention 
that formed part of the ‘Livewell’ project, developed at Newcastle University [182]. 
LEAP is a web-based intervention accessible by PC, tablet and smartphone and the 
‘moving more’ module supports participants to be more physically active. Each 
participant is given a pedometer at the start of the intervention and encouraged to 
record their daily step counts and set step count goals. They are also provided with 
access to information on how to be more PA in different ways, with links to PA 
information in the local community, and provided with a diary feature which allows 
them to schedule and record any PA they have undertaken [183]. The POW 
intervention involved adapting the LEAP ‘moving more’ module in the following ways: 
 An introduction page was added that provided information on exercising safely 
with KOA (see Figure 4.4) (adapted from ARUK ‘Knee Pain and Exercise’ 
Information Sheet[242]. 
 Content on KOA and general goals to be achieved through being more active 
were added (see Figure 4.5) 
 Content on KOA specific barriers and solutions to performing additional 
physical activity (identified through review of the literature [243-255]) were 
added (see Figure 4.6). 
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Figure 4.4: Screenshot of the Online POW PA programme introduction page outlining the 
purpose and use of the website and advice on exercising safely in KOA. 
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Figure 4.5: Screenshot of the Online POW PA programme goal setting page where users can 
set goals they would like to achieve by becoming more active. 
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Figure 4.6: Screenshot of the Online POW PA programme barriers and solutions page where 
participants can select a barrier they might anticipate in completing an activity, and POW! 
offers a number of possible solution to that barrier from which the participant may choose. 
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This KOA specific PA intervention was renamed ‘POW’ (People with Osteoarthritis 
Walking programme), as the main activity promoted was walking supported by the use 
of pedometers that were provided. In collaboration with Hippo 
(www.hippomarketing.eu), the web-based intervention was designed. Hippo hosted 
the website, carried out website maintenance and amendments and provided reports 
on website use (i.e. using Google analytics, PiWik and raw CSV data files).  
a) PA Intervention 
Promotion of the use of the online PA programme (POW) was the main focus of the PA 
intervention. Instructions on pedometer use and a PA specific intervention manual 
(including instructions of website use – see Appendix N) were developed and provided 
to participants at the start of the intervention. Paper activity sheets were also provided 
to participants to allow them to record step data if they were unable to go online. 
4.2.2.4 Standard Care 
This study arm was designed as a comparison group for the Vitamin D and PA groups 
and involved administering a daily placebo identical to the Vitamin D supplement 
provided to those in the Vitamin D supplementation arm. These details were outlined 
as part of Standard Care Instruction manual (see Appendix O) which was mailed to 
participants at the start of the pilot intervention study.  
a) Changes to Design  
Due to logistical issues (regarding length of time required and cost to produce a 
placebo supplement), the production of a placebo and identical Vitamin D supplement 
was not possible during the study timeframe. Therefore this group was changed to a 
standard care group, which would receive neither the Vitamin D supplementation nor 
web based PA intervention, but were instructed to continue their usual care practices 
regarding their KOA. Standard Care participants were instructed not to deliberately 
alter their Vitamin D (through use of supplements, sunbeds or sunny holidays) or PA 
(through structured exercise programmes or deliberate exercise increase) patterns 
during the duration of the study.  
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4.2.3 Study Participants 
4.2.3.1 Participant Sampling and Recruitment. 
A targeted sampling method was used to recruit into the pilot intervention study. 
Participants who took part in the cross-sectional study were screened against the pilot 
intervention study eligibility criteria. Those who met the eligibility criteria for the 
Vitamin D supplementation intervention were entered into the Vitamin D 
supplementation intervention and those who met the eligibility criteria for the Online 
PA intervention were entered into the Online PA intervention. 
4.2.3.2 Study Eligibility Criteria 
The eligibility criteria for the pilot interventional study are detailed below with * 
indicating those criteria which related specifically to the Vitamin D intervention and ≠ 
indicating those criteria which related specifically to the online PA intervention.  
a) Inclusion Criteria 
The same inclusion criteria as used in the cross-sectional study (see Chapter 3) were 
adopted with the addition of: 
1. Low objectively measured concentrations of Vitamin D, defined as:* 
Insufficient (25-50nmol/L), and excluding those considered vitamin D deficient (<25 
nmol/L).  
2. Low PA recorded from accelerometers defined as: ≠ 
<60min/week of moderate PA, <30min/week vigorous PA (2*credit of moderate 
activity) defined as being ‘inactive’ and ‘low’ in activity by UK government guidelines. 
Activities only counted if they occurred in >10mins bouts[217]. Activity was defined as 
moderate if it made the participant ‘breathe faster, feel warmer or sweat’ and 
increased heart rate. Activities identified as moderate included: brisk walking, cycling, 
gardening, housework, DIY, climbing stairs and carrying heavy loads. 
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b) Exclusion Criteria 
The same exclusion criteria used in the cross-sectional study were adopted with the 
addition of: 
1. Health conditions which can interfere with Vitamin D supplement absorption: * 
 Malabsorption syndromes: e.g. cystic fibrosis, celiac disease, Whipple’s 
disease, Crohn’s Disease, bypass surgery, short bowel syndrome,  
 Diagnosed restrictive eating disorder 
 Hypercalcaemia (albumin-adjusted plasma calcium > 2.60 mmol/l) 
 Hypocalcaemia (albumin-adjusted plasma calcium < 2.15 mmol/l) 
 Renal Stage 4-5 Chronic Kidney Disease: GFR < 30 ml/min/1.73m2 
 Primary hyperparathyroidism 
2. Health conditions that can affect normal baseline concentration of vitamin D:* 
 Current pregnancy, delivery of child/breast feeding 1 year prior to recruitment 
 Holiday with significant sunlight exposure (specified by list of sunny 
destinations) in the last 3 months and plans for holidays to sunny/skiing 
destinations for the duration of the study. 
 Current Anticonvulsant drug therapy  
 Current Glucocorticoid use 
 Current HIV/treatment with Antiretroviral drugs  
 Current anti-oestrogen (aromatase inhibitors, oestrogen receptor inhibitors 
and selective oestrogen receptor moderators) such as used to treat breast 
cancers  
 Those currently taking cytostatic/anti-tumour drugs 
 Granulomatous disorders: sarcoidosis, TB, Lymphomas 
 
3. Current health conditions which may be made worse by vitamin D consumption* 
 Chronic Renal Disease: stage 4 and 5 (see above)  
 Liver disease 
 Histoplasmosis 
 hyperparathyroidism  
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 Hypocalcaemia or hypercalcemia (as defined above) 
 Lymphoma  
 Current/recent (in the last 6 months) 
supplementation(topical/oral/intravenous, prescribed and non-prescribed) 
with: Phosphorous, >10µg/day Vitamin D and >500mg/day Calcium 
4.2.4 Study Materials and Measures 
4.2.4.1 Study Measures  
All study measurements made during the cross-sectional study visit (see section 
3.2.4.2) were repeated at the 6 week and 12 week pilot interventional study visits. 
Study Intervention compliance was also measured at each study visit. 
4.2.4.2 Study Materials 
All pilot intervention study materials were developed and compiled prior to 
commencement of the pilot intervention study. These included all materials for the 
Vitamin D, Online PA and standard care interventions as specified in Appendix P. 
4.2.5 Study Setting 
All study visits took place within North Tyneside General Hospital in clinical rooms 
within the Jubilee Day Hospital. All appropriate staff, equipment and logistical 
provisions were prepared as described in section 3.2. 
4.2.6 Procedure 
Standard Care participants attended a 6 week and 12 week intervention visit, where 
cross-sectional study visit measures were repeated and intervention compliance 
assessed.  
4.2.6.1 Study Arm Allocation 
In accordance with the original study protocol, all cross-sectional study participants 
were screened against the pilot intervention study criteria and randomised (using an 
online random number allocator) to one of four study arms (Vitamin D, PA, Vitamin D 
& PA or standard care). 
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a) Study Arm Allocation Amendment 1 
The above randomised allocation yielded only 4 eligible participants from the pool of 
45 cross-sectional study participants. Due to these small numbers, an amendment was 
submitted to the research ethics committee to revise pilot intervention study criteria. 
This allowed inclusion of participants with low activity levels (<60mins moderate 
activity/week) as well as sedentary activity levels (<30mins moderate activity/week) to 
increase the study numbers. This change yielded an additional 2 eligible participants 
for the pilot intervention study, who were subsequently randomised (using an online 
random number allocator) to a study arm.  
b) Study Arm Allocation Amendment 2 
It was concluded that 6 participants were insufficient to test our pilot interventional 
study aims of testing acceptability and feasibility of the study interventions, therefore 
the decision was made by the study team to abandon the randomisation procedure to 
increase participant numbers in the pilot intervention study, allowing us to test our 
study aims. Therefore, participants who were eligible for the Vitamin D intervention 
according to the pilot intervention study Vitamin D eligibility criteria were entered into 
the Vitamin D study and participants who were eligible for the online PA activity 
intervention according to the pilot intervention study PA criteria were entered into the 
Online PA intervention (see Figure 4.7). By opting for an unrandomised study design, 
increased participant numbers were obtained to facilitate an assessment of 
acceptability and feasibility of study procedures and Vitamin D and PA interventions. 
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Figure 4.7: Diagram representing allocation procedures used during the pilot intervention 
study.On the left is the original planned randomised allocation procedure for pilot 
interventional study, where participants are randomly allocated to 1 of 4 study arms. On the 
right is the unrandomised allocation procedure where participants are allocated to the study 
arm which they meet the study criteria for (Online PA or vitamin D). 
4.2.6.2 Pilot Intervention Initiation 
Following completion of eligibility screening, eligible participants were contacted by 
telephone to inform them of their eligibility. Once verbal reconsent was obtained from 
participants, they were allocated to the appropriate intervention arm using the 
allocation procedures detailed in section 4.2.6.1. Once study arms were allocated to 
each participant, the appropriate study intervention starter pack and study materials 
were mailed out to the participant’s home address. 
Participants were informed by telephone when their starter pack was mailed and were 
instructed to read the intervention instructions and familiarize themselves with the 
study materials on the starter packs arrival, but not to start the intervention. 
Participants were also instructed to complete and return (by self-address, prepaid 
envelope) the study starter pack receipt and consent slip to the research team as soon 
as they received the study starter pack.  
On receipt of the consent slip, each participant was contacted to review the 
intervention instructions and to answer any participant questions. Once the participant 
understood the intervention and felt they were able to complete it, an intervention 
start date was set (see Figure 4.8below) for summary of study initiation process.
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Figure 4.8: Process of recruiting cross-sectional study participants into the pilot intervention study and the initiation of the pilot interventional 
study. 
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4.2.6.4 Six week Follow-Up Visit  
Participants were invited to attend a follow up visit at approximately 6 weeks from the 
start of the pilot intervention study.  An appointment was made according to 
participant and clinical room availability and an appointment letter and hospital map 
was mailed to each participant. The study visit began with a short review of the 
participant’s intervention progress and collection of details regarding intervention 
compliance. The study visit then proceeded in the same way as the cross-sectional 
study visit except the consenting process. All data and samples were stored as 
specified in sections 3.2.7 and, and data was processed and analysed as outlined in 
section 3.2.7. 
4.2.6.5 Twelve week Follow-Up Visit (study close) 
Participants were invited to attend a follow up visit at approximately 12 weeks after 
the start of the pilot intervention study.  An appointment was booked as described 
above and the participant was reminded the qualitative interview would take place 
directly after this appointment. An appointment letter and hospital map was mailed to 
the participant. The study visit was conducted as described for the six week follow up 
visit above.  
4.2.6.6 Participant Feedback  
On conclusion of the pilot interventional study, each pilot intervention study 
participant was mailed individual feedback based on the data collected over their 3 
study visits, including information on:  
 Weight (kilograms, stone and pounds) 
 BMI 
 Waist measurement (centimetres and inches) 
 Knee pain (0-20) 
 Knee stiffness (0-8) 
 Blood Vitamin D levels (nmol/L – deficient, insufficient and sufficient) 
 Blood Calcium levels (mmol/L – normal, low and high) 
 Steps  
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Participant feedback additionally contained a letter thanking participants for their 
participation in the pilot interventional study. A feedback evening on 17/11/2016 was 
also arranged where mean data for weight, BMI, waist circumference, TUG, serum 
25(OH)D concentrations and Physical Activity levels (sedentary, light and moderate 
intensities) by intervention group (Vitamin D supplementation and web based PA 
interventions) as a PowerPoint presentation.  
4.2.7 Data Processing and Analysis 
4.2.7.1 Data Processing 
All study data, labelled by participant code and study visit, were entered into 
electronic databases for analysis. All repeated measurements, WOMAC and SF-36 
Questionnaire data and accelerometry data were scored and processed as described in 
section 3.2.7. 
4.2.7.2 POW Website Usage Data Extraction 
Data on the usage of the POW Website was collected using csv. files (provided by 
hippo) or data imputed into step graphs by users. Data on frequency, time and 
duration of POW website use for each PA intervention participant was collected using 
the PiWik Website Analysis website.  
4.2.7.3 Data Analysis 
a) Primary Outcomes 
 Recruitment rates (numbers/% recruited from general population and from 
potential participants identified) 
 Dropout rates (at each study time point) 
 Compliance to study measurements at each time point 
 Compliance to Vitamin D intervention (pill counts) 
 Compliance to PA intervention (frequency of use/time spent on online system, 
data input to online system and comparison of compliers to non-compliers. 
b) Secondary Outcomes 
 Anthropometric Measurements 
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 KOA Symptoms 
 Physical Activity 
 Vitamin D 
All statistical analyses were performed using IBM SPSS Statistics Version 23. Baseline 
data for pilot intervention study participants are the data collected for the cross-
sectional study. Change in variables were calculated by subtracting the data point from 
Week 12 of the intervention from the data point for baseline (measurement taken for 
the cross-sectional study). Descriptive statistics summarising primary and secondary 
outcomes at each study visit and change in outcomes over study visits for each 
intervention group are reported using mean and median values with variance reported 
as standard deviation or 95% confidence intervals.  
4.3 Results 
17 eligible people from the cross-sectional study were recruited into the pilot 
intervention study between December 2015-April 2016. Nine participants were 
assigned to the Vitamin D supplementation intervention and nine participants were 
assigned to the Online PA intervention (due to the change in study arm allocation 
during the study from randomised to unrandomised, n=3 participants took part in both 
the physical activity and vitamin D intervention study concurrently, resulting in 17 
participants with 9 participant allocated to each intervention group).  
4.3.1 Primary Outcomes 
4.3.1.1 Study Retention 
As displayed in Figure 4.9below, retention throughout the 3 month pilot intervention 
was 100%. Mean follow up time (days) from pilot intervention start to the week 6 
study visit was 46.7 days (±5.0) and mean follow up time (days) from week 6 study visit 
to week 12 study visit was 49.3 days (±7.8). 
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Figure 4.9: Summary of recruitment and retention throughout the pilot intervention study 
4.3.1.2 Measurement Compliance 
 
Study Measurements 
Compliance (N=17) 
Baseline Week 6 Week 12 
Anthropometric 
Measures 
Height 100% 100% 100% 
Bioimpedance Measurements (Weight, 
BMI, Body Fat%, Body Fat Mass)  
100% 100% 99% 
Waist Circumference 94% 100% 100% 
Knee Function 
Measures 
Timed Up and Go 100% 100% 100% 
Questionnaires VAS 100% 100% 100% 
WOMAC 100% 100% 100% 
SF-36 100% 100% 100% 
Blood Samples Venous Sample 100% 99% 100% 
Dried Blood Spot Sample 88% 94% 88% 
Table 4.1: Compliance to study measures at baseline, week 6 and week 12 of pilot 
intervention study across all participants 
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Compliance to anthropometric study measurements was high, with only 1/17 
participants missing body fat mass data at the 12 week visit and 1/17 participants 
missing waist circumference data at the baseline visit, due to investigator error. 
Compliance in completing questionnaires was 100% across all time points. Compliance 
for venous blood samples was high, with only 1/17 participants missing a blood sample 
at 6 weeks due to difficulty in accessing a vein. Compliance to the fingerprick DBS 
blood sample method was lower than the venous method at 88% (15/17 participants) 
at baseline, 94% (16/17 participants) at week 6 and 88% (15/17 participants) at week 
12. One participant refused to give a DBS sample at all time points due to a dislike of 
having blood taken. At baseline one other participant sample was not taken due to 
investigator error and at week 12 another participant refused consent for the DBS 
sample due to side effects (pain and bruising at the site of fingerprick) from the DBS 
procedure at their previous study visit. 
4.3.1.3 Activity Monitor compliance and Data Retrieval 
All activity monitors were returned and data downloaded and retrieved at each time 
point (baseline, week 6 and week 12) of the pilot intervention study. 
4.3.1.4 Wear Time Analysis 
 Mean Baseline 
(n=17) 
Mean (SD) 
Mean Week 6 
(n=15) 
Mean (SD) 
Mean Week 12 
(n=17) 
Mean (SD) 
Change in 
measures 
(n=17) 
Mean (95% CI)  
Mean Age (years) 62 (±5.5) N/A 
Mean BMI (kg/m2) 34 (±3.7) 33 (±2.4) 34 (±3.9) -0.11 (-0.73, 
0.51) 
Mean Wear Time (mins) 3093 (±824.6) 3990 (±400.0) 3728 (±630.8) 636 (198, 1073) 
Total Wear time (% of 
total monitoring time) 
60 (±6.0) 59 (±6.0) 55 (±9.4) 0.4 (-5.5, 6.2) 
Total Non-Wear Time (% 
of total monitoring time) 
40 (±6.1) 41 (±6.0) 45 (±9.4) 5.3 (0.1, 10.4) 
Table 4.2: Mean wear time of accelerometers over the activity monitoring period at baseline, 
week 6 and week 12 of the pilot intervention study. Data only refers to participants with 
valid data (>10hours wear time/day) (n= 15) 
Compliance to PA measurement by accelerometry was analysed by study visit, results 
of which are summarised in Table 4.2. As with the cross-sectional study, a mean of >10 
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hours/day of monitor wear was determined as an acceptable length of daily wear to 
provide valid PA data [219]. For baseline and week 12 study visits, valid data 
(calculated from average wear time/day over the monitoring period) was obtained for 
all pilot study participants (n=17). At week 6 study visit, valid data (calculated as 
described above) was not obtained for two participants, leaving 15 participants with 
valid data. When analysed by individual day, of the nine participants monitored for 3 
days at baseline, 89% and 11% of participants achieved three or two days of valid data 
respectively and of the seven participants monitored for five days at baseline, 71%, 
14% and 14% achieved valid data for five, four and 3 days respectively. At week 6 
(during which all participants were monitored for five days) 63%, 25% and 13% of 
participants achieved five, four and three days of valid data respectively. At week 12 
(during which all participants were monitored for five days) 56%, 25%, 13% and 6% of 
participants achieved five, four, three and one day valid data respectively.  
Mean total wear time increased from baseline to week 12 by a mean 636 mins (95% CI: 
198, 1073) of the pilot intervention study. There was a slight mean increase in % wear 
time from baseline to week 12 of 0.4% (95 CI: -5.5, 6.2) and a mean increase in non-
wear time of 5.3% (95% CI: 0.1, 10.4) from baseline to week 12 study visits. 
4.3.1.5 Vitamin D Supplementation Intervention 
78% (7/9) participants took 100% (168/168 tablets) of the Vitamin D supplements. 1/9 
(11%) took 99% (167/168) vitamin D supplements and 1/9 participants (11%) took 93% 
(156/168). Averaged across all participants, Vitamin D supplement compliance was 
99% (1499/1512).  
4.3.1.6 Online Physical Activity Intervention 
Compliance with the POW! Website was measured by frequency of website usage. 
Those who did not log on to POW! After the initial registration visit were considered 
‘non-compliers’. 3/9 (33%) PA intervention participants were POW non-compliers. 
There were no differences in baseline measurements between POW compliers and 
non-compliers. 
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Use of the POW website by intervention participants was analysed using website 
analytics programme PiWik. We a variety of POW! Website usage outcomes, which are 
summarised below in Table 4.3. 
POW! Usage Outcomes Mean (SD) 
No. of POW! visits 11.3 (±6.28) 
Total time (secs) spent on 
POW! 
5820.2 (±4694.52) 
Mean number of actions 
per visit 
9.1 (±3.24) 
Total number of website 
actions 
112.3 (±75.86) 
Average time (days) 
between visits 
4.0 (±2.09) 
Table 4.3: Table summarising POW! Website usage outcomes amongst PA 
intervention compliers (n=5). 
The usage of the primary individual web pages within the POW Website were analysed 
as % of total POW Usage (see Table 4.4).The most frequently visit page on the POW 
website was the step graph (54%) followed by the dashboard (9%) and the goal setting 
page (5.4%).  
POW Web Page % of overall usage 
Introduction 3.1 
Activity Questionnaire 1.5 
Step Graph  54.0 
Goal Setting 5.4 
Activity Planning 4.3 
Activity Barriers 2.3 
Diary 2.8 
Dashboard 9.0 
Other 17.6% 
Table 4.4: Table summerising the % of usage of each web page on the POW 
website by PA participants 
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4.3.2 Participant Characteristics 
4.3.2.1 Cross-sectional study group vs. Pilot intervention study group 
Study Measurements Cross-sectional Study 
Cohort (n=45) 
Pilot Interventional Study 
Cohort (n=17) 
Age (years) 61(±5.3) 61(±5.4) 
Height (cms) 170 (± 8.8) 170 (±9.7) 
Weight (kgs) 106 (±23.2) 98 (±12.4) 
BMI (kg/m2) 34 (±4.8) 34 (±3.9) 
Body Fat (%) 40 (±8.1) 40 (±8.6) 
Body Fat Mass (kg) 40 (±11.9) 39 (±10.1) 
Waist Circumference (cms) 113 (±12.1) 111 (±8.8) 
Timed Up and Go (secs) 9.5 (±2.2) 9.9 (±2.6) 
VAS Daily Score (0-10) 4.3 (±1.8) 4.3 (±2.1) 
WOMAC Pain 8.4 (±3.4) 7.5 (±3.5) 
WOMAC Stiffness 4.4 (±1.9) 3.7 (±2.4) 
WOMAC Activities of Daily 
Living (ADL) 
28.1 (±10.7) 25.5 (±12.7) 
WOMAC Total 40.8 (±15.2) 36.7 (±17.8) 
SF-36 MCS (Mental Capacity 
Score) (0-100) 
48.6 (±11.5) 46.8 (±9.2) 
SF-36 PCS (Physical Capacity 
Score) (0-100) 
38.6 (±9.5) 41.9 (±9.9) 
Serum 25(OH)D (nmol/L) 44 (±23.4) 43 (±20.5) 
Serum Calcium (mmol/L) 2.2 (±0.3) 2.3 (±0.2) 
% 25(OH)D Deficient 
(<25nmol/L) 
27 (12/45) 12 (2/17) 
% 25(OH)D Insufficient (26-
50nmol/L) 
36 (16/45) 65 (11/17) 
% 25(OH)D Sufficient 
(<51nmol/L) 
36 (16/45) 18 (3/17) 
% time in sedentary activity 63 (±10.6) 69 (±9.7) 
% time in light activity 33 (±9.35) 29 (±9.5) 
% time in moderate activity 3.5 (±3.1) 2.7 (±2.7) 
Average daily time in 
sedentary activity (mins) 
1027(±2247.6) 591 (±21.3) 
Average daily time in light 
activity (mins) 
273 (±81.3) 241 (±75.3) 
Average daily time in 
moderate activity (mins) 
29 (±25.5) 21 (±19.6) 
Table 4.5: Means and SD of participant characteristics of cross-section and pilot intervention 
study participants. 1 = non parametric data. 
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Baseline participant characteristics for the cross-sectional study and the pilot 
intervention study cohorts are summarised in Table 4.5. There were n=45 participants 
in the cross-sectional study 49% of which were female and n=17 participants enrolled 
into the pilot intervention study of whom 44% were female. Overall, participants in 
both studies were very similar between the cross-sectional study and pilot 
interventional study cohort. Measurements were similar between the cross-sectional 
and pilot intervention study participants. However baseline WOMAC Pain (0-20) 0.9 
points higher in the cross-sectional participants compared to the pilot intervention 
participants. Physical activity measures were also different between the groups, with 
% sedentary time 6% higher and % light and moderate time 4% and 0.8% lower in the 
pilot intervention participants compared to the cross-sectional study participants.   
 
 
 
 
 
 
 
 
 
 
 
 
 175 
4.3.2.2 Vitamin D Intervention group vs. Online PA Intervention group 
Study Measurements Vitamin D 
Intervention 
Cohort (n=9) 
Online PA 
Intervention Cohort 
(n=9) 
Age (years) 60.4 (±4.7) 61.9 (±5.4) 
Height (cms) 173.4 (±8.6) 169.3 (±11.6) 
Weight (kgs) 99.2 (±9.2) 98.6 (±14.6) 
BMI (kg/m2) 33.2 (±4.2) 34.5 (±3.5) 
Body Fat (%) 39.1 (±9.7) 38.3 (±8.0) 
Body Fat Mass (kg) 38.8 (±10.7) 37.6 (±9.3) 
Waist Circumference (cms) 110.3 (±6.5) 112.9 (±9.9) 
Timed Up and Go (secs) 9.6 (±2.9) 9.8 (±2.2) 
VAS Daily Score (0-10) 4.4 (±1.8) 4.1 (±2.2) 
WOMAC Pain 7.4 (±3.8) 7.7 (±3.2) 
WOMAC Stiffness 3.4 (±2.4) 3.3 (±2.5) 
WOMAC Activities of Daily Living (ADL) 24.6 (±13.5) 25.7 (±12.1) 
WOMAC Total 35.4 (±18.8) 36.7 (±17.1) 
SF-36 MCS (Mental Capacity Score) (0-100) 47.0 (±10.1) 49.0 (±9.0) 
SF-36 PCS (Physical Capacity Score) (0-100 41.63 (±10.1) 40.9 (±11.0) 
Serum 25(OH)D (nmol/L) 38.3 (±9.1) 47.0 (±26.0) 
Serum Calcium (mmol/L) 2.3 (±0.3) 2.3 (±0.2) 
% 25(OH)D Deficient (<25nmol/L) 0 (0/9) 22.2 (2/9) 
% 25(OH)D Insufficient (26-50nmol/L) 100 (9/9) 44.9 (4/9) 
% 25(OH)D Sufficient (<51nmol/L) 0 (0/9) 33.3 (3/9) 
% time in sedentary activity 64.5 (±9.6) 74.2 (±6.1) 
% time in light activity 31.6 (±7.9) 24.4 (±6.0) 
% time in moderate activity 3.8 (±3.4) 1.4 (±0.6) 
Average daily time in sedentary activity 
(mins) 
539.8 (±105.8) 647.4 (±179.8) 
Average daily time in light activity (mins) 259.4 (±72.5) 208.7 (±55.8) 
Average daily time in moderate activity 
(mins) 
30.4 (±23.7) 11.8 (±5.3) 
Table 4.6: Mean and SD of study outcomes for the Vitamin D supplementation and web-
based PA interventions. 
Baseline participant characteristics for both intervention modality groups are 
summarised in Table 4.6. Of the n=9 participants enrolled in the Vitamin D 
supplementation intervention, 44% were female, and of the n=9 participants enrolled 
into the web-based PA intervention 33% were female.  The Vitamin D supplementation 
intervention group had a mean 25(OH)D concentration which was 8.7nmol/L lower 
than the  Online PA intervention group. Mean % sedentary activity in the Online PA 
group was 9.7% higher than the Vitamin D supplementation group. Mean % light and 
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moderate activity was -7.2% and 2.4% lower respectively in the Online PA intervention 
group compared to the Vitamin D supplementation group. These differences in 
baseline Vitamin D and PA measures between intervention modalities is likely 
reflective of the eligibility criteria for each intervention, e.g. a low 25(OH)D 
concentrations (25-50nmol/L) were required for the Vitamin D intervention and low PA 
levels (<60mins/week of moderate intensity activity) were required for the Online PA 
intervention. 
4.3.3 Secondary Outcomes 
4.3.3.1 Changes to Anthropometric Measures 
 
Anthropometry 
Measures  
Vitamin D supplementation 
N= 9 
Online PA programme 
N= 9 
Baseli
ne 
Mean 
(SD) 
Week 12 
Mean 
(SD) 
Change in 
measurement 
Mean (95% CI) 
Baseline 
Mean 
(SD) 
Week 12 
Mean 
(SD) 
Change in 
measurement 
Mean (95% CI) 
Weight (kgs) 101.7 
± 11.4 
102.6 ± 
10.4 
1.4 (-0.4, 3.1) 98.6 ± 
14.6 
96.9 ± 
14.8 
-1.8 (-4.6, 1.1) 
BMI (kg/m2) 33.4 ± 
10.4 
33.8 ± 4.1 0.6 (-0.05, 1.2) 34.5 ± 3.5 33.8 ± 3.7 -0.7 (-1.7, 0.4) 
Body Fat (%) 38.5 ± 
9.2 
38.6 ± 9.6 0.1 (-1.1, 1.2) 38.3 ± 8.0 36.5 ± 7.2 -2.0 (-5.2, 1.2) 
Body Fat Mass 
(kg) 
39.1 ± 
10.0 
39.5 ± 
10.6 
0.7 (-0.6, 2.1) 37.6 ± 9.3 34.6 ± 
10.0 
-2.4 (-6.2, 1.5) 
Waist 
Circumference 
(cms) 
110.3 
± 6.5 
111.4 ± 
6.1 
0.1 (-2.8, 3.0) 112.9 ± 
9.9 
111.7 ± 
7.8 
-1.1 (-4.1, 2.0) 
Table 4.7: Change in anthropometric measurements from baseline to week 12 of pilot 
interventions 
Participants in the Vitamin D intervention group had slight mean increases in 
anthropometric measurements. However, there were mean decreases in all 
anthropometric measurements in the Online PA intervention group. Online PA 
intervention participants lost an average 1.8kg over the 3 month intervention 
compared to the average 1.4kg increase in body weight in the Vitamin D intervention 
group. Body Fat % decrease by 2.4% on average in the Online PA intervention in 
contrast to the Vitamin D supplementation group who increased body fat % by 0.7%. 
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Measures of 
KOA 
symptoms 
Vitamin D supplementation 
N= 9 
Online PA programme 
N= 9 
Baseline 
Mean 
(SD) 
Week 12 
Mean 
(SD) 
Change in 
measurement 
Mean (95% CI) 
Baseline 
Mean 
(SD) 
Week 12 
Mean 
(SD) 
Change in 
measurement 
Mean (95% CI) 
Timed Up 
and Go (secs) 
9.7 ± 2.7 8.3 ± 2.5 -1.4 (-2.2, -0.5) 9.8 ± 2.2 7.8 ± 1.4 -2.0 (-3.0, -
0.88) 
VAS Daily 
Score (0-10) 
4.4 ± 1.7 4.8 ± 1.8 0.4 (-0.3, 1.2) 4.1 ± 2.2 3.8 ± 2.4 -0.2 (-1.2, 0.8) 
WOMAC 
Pain (0-20) 
7.6 ± 3.6 7.7 ± 4.6 0.1 (-2.4, 2.6) 7.7 ± 3.2 5.6 ± 3.9 -3.0 (-5.2, -0.8) 
WOMAC 
Stiffness (0-
8) 
3.7 ± 2.4 3.4 ± 2.0 -0.2 (-1.3, 0.8) 3.3 ± 2.5 2.6 ± 1.7 -0.8 (-1.9, 0.4) 
WOMAC 
Activities of 
Daily Living 
(ADL) (0-68) 
24.8 ± 
12.7 
24.8 ± 
11.4 
0.0 (-5.2, 5.2) 25.7 ± 
12.1 
18.3 ± 
12.9 
-7.3 (-13.7, -
1.0) 
WOMAC 
Total (0-92) 
36.0 ± 
17.7 
35.9 ± 
17.4 
-0.1 (-7.7, 7.5) 36.7 ± 
17.1 
26.8 ± 
17.6 
-9.9 (-17.6, -
2.2) 
SF-36 MCS 
(0-100) 
57.0 ± 
3.8 
59.3 ± 0.5 5.1 (0.7, 9.4) 57.0 ± 
3.8 
59.3 ± 0.5 5.6 (-1.2, 12.3) 
SF-36 PCS (0-
100) 
36.3 ± 
16.5 
35.9 ± 
10.9 
-2.7 (-7.5, 2.0) 36.3 ± 
16.5 
35.9 ± 
10.9 
0.9 (-9.7, 11.4) 
Table 4.8: Changes in KOA symptoms from baseline to week 12 of pilot intervention 
Comparison of KOA symptoms at baseline and week 12 in the Vitamin D 
supplementation group (see Table 4.8) showed a mean decrease of 1.4 seconds to 
complete the TUG test, indicating improved function. Changes in WOMAC measures 
were similar at baseline and week 12. SF-36 MCS (0-100) increased mean 5.1 points in 
the Vitamin D supplementation group to mean 59.3/100 points, indicates an 
improvement of mental quality of life throughout the study. Conversely physical health 
related scores (SF-PCS) improved throughout the Vitamin D supplementation 
intervention, decreasing by 2.7 points from a mean 36.3/100 at baseline to a mean of 
35.9/100 at week 12 suggesting a worsening of physical health during the study.    
Comparison of KOA symptoms at baseline and week 12 in the online PA programme 
group (see Table 4.8) also showed decreases in time taken to complete TUG by mean 
2.0 secs, indicating improved function. Decreases in WOMAC Pain (0-20), WOMAC ADL 
(0-68) and WOMAC Total scores of an average of 3.0, 7.3 and 9.9 points respectively 
were observed in the Online PA intervention indicating improved self-reported pain, 
function and overall KOA symptoms. An increase in mean SF-36 MCS of 5.6 points was 
seen in the online PA intervention, indicating an improvement of mental quality of life.  
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4.3.3.2 Changes to 25(OH)D Levels 
Mean change in 25(OH)D concentration from baseline to week 12 in the Vitamin D 
supplementation group was 51 ±23.1nmol/L (95% CI 33.2, 68.8) (see Figure 4.10). 
Change in 25(OH)D concentration from baseline to week 6 was 39.9nmol/L ±17.0 (95% 
CI: 26.8, 52.9) and change in 25(OH)D concentration from week 6 to week 12 was 
smaller at 11.1 ±11.6 nmol/L (95% CI: 2.2, 2.0.0). 
Mean change in 25(OH)D concentration from baseline to week 12 in the Online PA 
group was smaller than the Vitamin D supplementation group at 14.9 ±41.1 (95% CI: -
16.7, 46.5) (see Figure 4.11). Change in 25(OH)D concentration from baseline to week 
6 was 11.0 ±39.0 (95% CI: -19.0, 41.0) and change in 25(OH)D concentration from week 
6 to week 12 was smaller at 3.9 ±4.5 (95% CI: 0.4, 7.4). 
 
Figure 4.10: Individual participant 25(OH)D concentrations (y axis) by time point in the pilot 
intervention study (x axis) in the Vitamin D supplementation group 
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Figure 4.11: Mean (SD) 25(OH)D concentrations (y axis) by time point in the pilot 
intervention study (x axis) in the Vitamin D and PA intervention groups. 
 
Vitamin D Status Vitamin D Group PA Group 
Baseline Week 12 Baseline Week 12 
Vitamin D deficient 
(<25nmol/L 25(OH)D)  
N= 0 
0% 
N= 0 
0% 
N= 2 
22.2% 
N= 0 
0% 
Vitamin D Insufficient 
(26-50nmol/L 
25(OH)D) 
N= 9 
100% 
N= 0 
0% 
N= 4 
44.4% 
N= 2 
22.2% 
Vitamin D sufficient 
(>50nmol/L 25(OH)D) 
N= 0 
0% 
N= 9 
100% 
N= 3 
33.3% 
N= 7 
77.8% 
Table 4.9: Change in Vitamin D status by intervention group 
In the Vitamin D intervention group there was 100% change from Vitamin D 
insufficiency to Vitamin D sufficiency (see Table 4.9: Change in Vitamin D status by 
intervention group). In the PA group there was a 45% increase in Vitamin D sufficiency 
with 3/9 people moving from insufficiency to sufficiency and 2/9 people moving from 
deficiency to sufficiency (see Table 4.9). 
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4.3.3.3 Changes to objective PA 
 
 
PA Measures 
Vitamin D supplementation 
N=9 
Online PA programme 
N=9 
Baseline 
Mean 
(SD) 
Week 12 
Mean 
(SD) 
Change in 
Measures` 
(95% CI) 
Baseline 
Mean 
(SD) 
Week 12 
Mean 
(SD) 
Change in 
Measures 
(95% CI) 
% time in sedentary 
activity 
62 (±10.9) 62 (±13.6) -0.1 (-5.9, 
5.6) 
74 (± 6.1) 68 (±7.3) -5.0 (-9.7, -
0.2) 
% time in light 
activity 
34 (±9.5) 34 (±11.8) 0.1 (-5.9, 
6.1) 
24 (±6.0) 29 (±7.0) 4.7 (0.4, 
9.1) 
% time in moderate 
activity 
3.9 
(±3.16) 
3.9 
(±3.55) 
0.0 (-1.1, 
1.1) 
1.4 
(±0.65) 
2.4 
(±1.28) 
1.0 (-0.1, 
2.1) 
Average daily time in 
sedentary activity 
(mins) 
516 
(±121.4) 
507 
(±139.2) 
-8.8 (-91.1, 
73.4) 
647 
(±179.8) 
540 
(±157.7) 
-107.4 (-
259.8, 
45.0) 
Average daily time in 
light activity (mins) 
303 
(±148.8) 
270 
(±86.1) 
-33.1 (-
130.7, 
64.5) 
209 
(±55.8) 
199 
(±38.1) 
-9.5 (-44.3, 
25.2) 
Average daily time in 
moderate activity 
(mins) 
31 (±22.2) 33 (±30.9) 1.9 (-11.5, 
15.2) 
12 (±5.3) 16 (±7.7) 4.4 (-3.0, 
11.8) 
Table 4.10: Changes in PA measures from baseline to week 12 of pilot intervention. 
Comparison of PA measures in the Vitamin D supplementation group (see Table 4.10) 
showed similar % time in sedentary, light and moderate intensity activity at baseline 
and week 12.  Average daily time (mins) in sedentary and light activity decreased by 
8.8 (95% CI: -91.1, 73.4) mins and 33.1 (95% CI: -130.7, 64.5) mins respectively. 
Average moderate activity increased by 1.9 mins (95% CI: -11.5, 15.2) from baseline to 
week 12 in the Vitamin D supplementation intervention group. 
Comparison of PA measures at baseline and week 12 in the Online PA programme 
group showed a decrease in % time in sedentary activity of -5.0% (95% CI: -9.7, -0.2) 
and an increase in % time in light and moderate activity of 4.7% (95% CI: 0.4, 9.1) and 
1.0% (95% CI: -0.1, 2.1) respectively (see Table 4.10). Average daily time (mins) in 
sedentary and light intensity activity decreased throughout the PA intervention by -
107.4 (95% CI: -259.8, 45.0) and -9.5 (95% CI: -44.3, 25.2) respectively from baseline to 
week 12 measures (see Table 4.10). 
At the end of the 3 month intervention, % time in sedentary activity was 6% higher in 
the online PA intervention group compared to the Vitamin D supplementation group. 
 181 
% time in light activity and % time in moderate activity was 5% and 1.5% lower 
respectively in the Online PA intervention group compared to the Vitamin D 
supplementation group. These differences in the PA measures between intervention 
groups at 12 weeks may reflect differences in baseline PA measures between the 
intervention groups which showed significant differences between baseline % time in 
sedentary, light and moderate activity and average daily time in light and moderate 
activity (see Table 4.6). However the differences in physical activity between the two 
intervention groups reduced at week 12 compared to baseline, which considering the 
change observed in PA measures in the online PA intervention group, suggest an 
overall improvement in physical activity in the online PA intervention group. 
 182 
 
 
Figure 4.12: % time in sedentary intensity activity by pilot intervention study time point in 
Online PA and Vitamin D supplementation intervention groups. 
 
Figure 4.13: % time in light intensity activity by pilot intervention study time point in Online 
PA and Vitamin D supplementation intervention groups. 
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Figure 4.14: % time in moderate intensity activity by pilot intervention study time point in 
Online PA and Vitamin D supplementation intervention groups. 
4.3.3.4 PA Measures by Online PA intervention compliance 
Differences were observed between POW Compliers (participants who logged onto the 
POW website beyond the registration visit) and non-compliers (participants who did 
not log on to the POW website beyond the registration visit) in PA outcome change 
during the 3 month PA intervention (see Table 4.11). This analysis showed that POW 
compliers had substantially reduced their average sedentary time during the 3 month 
intervention by -169.71 (±215.3) min compared to POW non-compliers who increased 
their sedentary time during the intervention by 17.1 (±80.27). However interestingly 
POW non-compliers increased their moderate activity by 7.2mins more than the POW 
compliers, which may be an example of study participation effect (otherwise known as 
the Hawthorne effect in which awareness of being studied can impact behaviour 
[256]).  
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PA Measure 
POW Compliers 
(n=5) 
POW Non 
compliers 
(n=4) 
 
Mean Difference 
Change in % time in 
sedentary activity 
-5.6 (±7.01) -3.7 (±5.24) 1.9 
 
Change in % time in light 
activity 
4.9 (±6.18) 4.5 (±5.60) -0.4 
Change in % time in 
moderate activity 
0.7 (±1.66) 1.5 (±0.89) 0.8 
Change in Average daily 
time in sedentary activity 
(mins) 
-169.71 (±215.3) 17.1 (±80.27) 186.81 
Change in Average daily 
time in light activity 
(mins) 
-3.7 (±27.43) -21.3 (±77.42) -17.6 
 
Change in Average daily 
time in moderate activity 
(mins) 
2.0 (±10.37) 9.2 (±7.28) 7.2 
Table 4.11: Table summarising the change in PA measures during the PA intervention 
between POW compliers and non-compliers. 
4.4 Discussion 
This pilot intervention study was designed to test the feasibility and acceptability of 
two interventions, daily vitamin D supplementation and online PA programme 
interventions, in older obese adults with KOA. As part of this pilot intervention study 
we tested study arm allocation procedures, study retention and intervention 
compliance and effect. The results of this pilot study are discussed below according to 
study design and procedures, study compliance and intervention effect. 
4.4.1 Study Design and Procedures 
As part of the original design of this pilot study, eligible participants would be 
randomised to one of 4 study arms; daily vitamin D supplementation of 2000IU (50µg) 
D3, access to an online PA programme (POW), both or standard care, as part of a 2x2 
factorial randomised control trial design. However due to the low numbers (six 
participants) of cross-sectional study participants eligible for inclusion into the random 
study arm allocation (requiring participants to meet the eligibility criteria for both the 
Vitamin D and Online PA intervention), the decision to unrandomise the study arm 
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allocation process was made. This decision meant 17 participants were deemed 
eligible to receive one of the study interventions and who were entered into the pilot 
intervention study. This allowed sufficient participant numbers to test the pilot 
intervention study aims of assessing the feasibility and acceptability of the pilot 
interventions. 
Another consequence of the unrandomised study design was that we could not assess 
the effect of the vitamin D supplementation and online PA interventions in 
combination, as originally planned. Additionally because of the different eligibility 
criteria employed for each intervention group, there were differences in baseline 
measurements between groups, as demonstrated in Table 4.6. The PA intervention 
group had 12% higher sedentary time and 10% and 2.5% lower % light and moderate 
time at baseline compared to the Vitamin D intervention group. There was also a 
difference in baseline 25(OH)D concentrations between intervention modalities, with 
the Vitamin D supplementation group having 8.7nmol/L lower baseline 25 (OH)D 
concentrations than the Online PA intervention group. 
However, as a pilot intervention study, it is important to highlight the feasibility of 
randomisation and study arm allocation procedures, and how many participants are 
required to screen in order to recruit sufficient participants into a RCT. Therefore, the 
information collected by this pilot study on the number of participants eligible for 
randomisation (6 [0.8%] of an original 791 originally identified potential participants) 
based on our eligibility criteria and recruitment rates (5.7%) will be important in 
informing recruitment targets for future RCTs using this study population and 
interventions. For example, if this data is extrapolated to the entire older obese KOA 
population of north east England (n= 1,203,453) according to data on prevalence 
published by ARUK[17]), we could expect approximately 9627 participant to be eligible 
for and participate in a randomised control trial of Vitamin D supplementation and 
Online PA programme interventions. 
4.4.2 Study Compliance 
4.4.2.1 Study Visit and Measurement Compliance 
As discussed in section 4.3.1, study visit retention was 100% at each time point. As 
with the cross-sectional study, compliance to study measures was very high at each 
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time point of the pilot intervention study for anthropometric and questionnaire data. 
Compliance to blood samples was high for venous blood samples with only one blood 
sample missing at week 6 due to difficulty in accessing the participant’s vein. 
Compliance with DBS blood samples was lower than venous samples, with one 
participant refusing to give DBS samples at all time points due to a dislike of needles, 
one participant refusing DBS samples at week 12 due to side effects (bruising and pain) 
and one DBS sample missing at baseline due to investigator error (no DBS kit 
available). However, despite the lower level of compliance with the DBS blood 
collection method compared to venous collection, there are many potential benefits to 
collecting blood samples by the DBS method. The DBS method is minimally invasive, is 
easy to conduct (not requiring specially trained medical staff), is easy to transport and 
store and are low in cost [257]. This makes DBS ideal for use in clinical trials and 
population based studies for screening and collecting baseline measurements [258]. 
The use of DBS has been validated for use in many biomarkers, including for the 
detection of 25(OH)D [259], which has been previously applied in a large multisite 
population based nutrition study, Food4Me [260]. 
Compliance to accelerometer use was analysed using wear time in minutes and as a % 
of the total 24hr day. Valid data was classed a day with >10hrs wear time [219]. Over 
our five day accelerometer monitoring period, we found 71%, 63% and 56% of pilot 
intervention study participants had valid data for all 5 days at baseline, week 6 and 
week 12 time points respectively. This was slightly lower than the compliance found in 
the NHANES (National Health and Nutritional Examination Survey) 2003-2004 dataset, 
with 74% of men and 68% women aged 40-59 years achieving 5 days valid data 
(classed as >10hours wear time/day) and 80% of men and 77% of women aged 60+ 
years achieving 5 days valid data [261]. 
4.4.2.2 Intervention Compliance 
Compliance to the Vitamin D supplementation was measured using pill counting at 6 
and 12 week study visits, which showed compliance was high in this pilot study at 99% 
over the 3 months intervention period. This is comparable with the 2013 RCT by 
McAlindon [147] which showed 96% adherence to vitamin D supplementation over 24 
months. 
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Compliance to the Online PA intervention (defined as repeated use of the POW 
website beyond the initial registration visit) in the pilot intervention study was 66% 
(6/9 participants) over the 3 month intervention period. Similarly on the only currently 
available online PA intervention for older obese adults with KOA, the 'Join2Move' 
intervention, which concluded of the 100 participant assigned to the online 
'Join2Move intervention', 94% started the programme and 46% adhered to the set 
adherence level (completion of 6/9 online 'modules')[262]. 
4.4.3 Intervention Effect 
In this pilot study, we administered Vitamin D supplementation and Online PA 
interventions to an older obese KOA population and tracked subsequent changes in 
25(OH)D concentrations and objective PA measures.  
During the 3-month Vitamin D supplementation intervention, a mean increase of 51 
±23.1nmol/L (95% CI 33.2, 68.8) was observed in the Vitamin D supplementation 
group, from 38.3 (±9.1) at baseline to 88.1 (17.2) at week 12. Increases in 25OHD 
concentrations were higher in this pilot intervention study than those reported in 
another D3 supplementation study [263], which also supplemented deficient 
participants (defined as <50nmol/L 25(OH)D concentration, mean 25(OH)D 
41.2nmol/L) to receive 2000IU (50µg) of cholecalciferol/day for 3 months, and found 
an increase of 34.1 nmol/L 25OHD. The disparity in 25OHD may be due to cutaneous 
Vitamin D synthesis as the supplementation regime ran into the ‘summer months’ 
(April-September) when exogenous synthesis of Vitamin D in the UK occurs [110]. 
However when mean 25OHD concentration change was analysed according to those 
who finished D3 supplementation before (46 [95%CI -195.4, 2.87.4]) and after (52.4 
[30.1, 74.7) April 2016 there was little difference observed. 25(OH)D concentrations 
also increased by 14.9 ±41.1 (95% CI: -16.7, 46.5) (see Table 4.9) in the Online PA 
intervention group despite not being supplemented as part of the study and being 
instructed not to take supplement containing Vitamin D at home. It is therefore likely 
to be a result of cutaneous synthesis as this intervention also ran into the summer 
months. Seasonal variation in Vitamin D synthesis are summarised in the introduction 
chapter, however briefly a British cohort study showed average 25OHD varied  by 
20.8nmol/L in men and 17.4nmol/L in women between Winter/Spring (December-
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May) and Summer/Autumn (June-November) [129]. As this pilot intervention took 
place January-June, it is likely this change in 25(OH)D in the Online PA intervention 
group reflects this previously reported season variation in 25(OH)D production 
between Spring and Summer.  
No trends for change in self-reported KOA symptoms (assessed using WOMAC 
Questionnaire and VAS in this pilot intervention study) were observed in the Vitamin D 
supplementation group after 3 months (see Table 4.8). This is consistent with the 
results of more recently released published RCTs [146, 147] which supplemented 
symptomatic KOA participants with 24,000-50,000IU (600-1250µg) Vitamin D/per 
month for 2-3 years showed no significant improvements in KOA symptoms measured 
by the WOMAC Questionnaire. However one Vitamin D supplementation study [147] 
did see a statistically significant improvement in knee pain measured by Visual 
Analogue Scale (0-100) (p=0.48) in the Vitamin D supplemented group compared to 
the placebo group at 2 years. The benefit of this RCT was that, like this pilot 
intervention study, only those considered Vitamin D insufficient were included in the 
study, ensuring those supplemented would be those most likely to benefit from 
supplementation. Despite these similarities with this pilot intervention study, we were 
unable to replicate this previously improvement in knee pain VAS and we saw no trend 
for improvement in VAS (0-10) (change of 0.4 [95%CI -0.3, 1.2]) over 3 months of 
Vitamin D supplementation. 
The Online PA intervention (POW) aimed to increase PA among older obese adults 
with KOA using a goal orientated lifestyle changes to increase PA. This was based 
previous work as part of the LEAP (Living, Eating, Activity and Planning in Retirement) 
intervention that formed part of the ‘Livewell’ project, developed at Newcastle 
University [182]. As part of the online PA intervention, various behaviour change 
techniques (BCT)[264], such as goal setting, action planning, barrier identification and 
problem solving, setting of graded tasks and self-monitoring of physical activity (using 
the pedometers provided), were delivered as an online programme. The evidence 
regarding which BCTs are most effective in promoting physical activity change are 
mixed. A systematic review [265] of BCTs in obese individuals with the aim of 
increasing PA concluded many BCTs when present as part of a physical activity 
intervention were associated with significantly higher PA. The strongest associations 
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were found in interventions incorporating teaching to use prompts and cues (where 
participants are taught environmental prompts/cues which remind them to perform a 
behaviour [264]), prompt practice (where the participant is prompted to repeat a 
behaviour [264]) and prompt rewards contingent on effort or progress towards 
behaviour (using praise/rewards for attempts at achieving behavioural goal [264]) 
[265]. However another systematic review [266] of BCTs in physical activity 
interventions observed only 3 BCTs which were significantly associated with higher PA 
when present in an intervention. These BCTs included barrier identification and 
problem solving, providing rewards contingent on successful behaviour and 
demonstrating the behaviour[266]. The effect of BCTs on physical activity was not 
specifically explored as an outcome of this pilot intervention study, however 
participants views on some of the BCT used in the intervention were discussed as part 
of the qualitative interview study (see chapter 6). 
The effect of the Online PA intervention on objective PA measures was assessed as 
part of this pilot intervention study. Due to the variable nature of physical activity 
interventions, the ability of the intervention to change physical activity in the target 
population can be considered a measure of effectiveness and feasibility. During the 12 
week intervention, the Online PA group experienced changes in % time in sedentary, 
light an moderate intensity PA of -5.0% (95% CI: -9.7, -0.2), +4.7% (95% CI: 0.4, 9.1) and 
+1.0% (95% CI: -0.1, 2.1) respectively. Comparatively the Vitamin D intervention groups 
experience minimal change in % time in sedentary, light an moderate intensity PA 
throughout the intervention at  -0.1% (95% CI: -5.9, 5.6), +0.1% (95% CI: -5.9, 6.1) 0.0% 
(95% CI: -1.1, 1.1) respectively. This disparity in PA change between intervention 
modalities suggests the Online PA intervention was successful in promoting increased 
PA in the participants. In a published  online based PA intervention study [262] in older 
obese individuals with KOA, objective PA levels (measured as mean total mins/day in 
PA light, moderate and vigorous intensity activity) were not significantly different 
between the PA intervention group and controls (361 [95% CI: 312-411] vs 358 [95% 
CI: 310-407] respectively) at 3 months. Indeed average mins/day in PA between 
baseline and 3 months (369 [95%CI: 299-439] vs 361 [95% CI: 312-411] respectively) 
decreased in this PA intervention group [262]. This suggests that compared to the only 
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other published Online based PA intervention for KOA patients, this pilot intervention 
was more effective in increasing PA in this population over 3 months.  
Changes in self-reported KOA symptoms were observed from baseline to week 12 of 
the Online PA intervention. Changes in WOMAC pain (0-20) and activities of daily living 
(0-64) of -3.0 (95% CI: -5.2, -0.8) and -7.3 (95% CI: -13.7, -1.0) were seen respectively. 
Change in time taken to complete TUG (secs) also changed from baseline to week 12 of 
the Online PA intervention by -2.0 (95% CI: -3.0, -0.88). Overall, the existing research 
literature support the observation that increasing PA improves self-reported KOA pain 
and disability. A systematic review of four RCTs of aerobic walking exercise 
interventions on KOA symptoms showed weighted pooled effect sizes of 0.52 (95% CI: 
0.34-0.70, n=449) for pain and 0.46 (95% CI: 0.25-0.67, N=385) for disability [103]. A 
RCT of exercise and dietary weight loss interventions of 316 obese adults >60 years 
with KOA showed there were also improvements in mean WOMAC Pain and Function 
over 18 months of −0.40 (95% CI: −1.32-0.52) and -3.07 (95% CI: 1.91-6.13) 
respectively  within the exercise group, however these improvements were not as 
large as recorded in this pilot intervention study [157]. 
4.5 Conclusions 
During this three month pilot intervention study, we aimed to assess the feasibility of 
delivering a Vitamin D supplementation and Online PA intervention to obese older 
people with symptomatic KOA. Secondary aims were to assesses the effect of the 
interventions delivered on anthropometric measures, self-reported KOA symptoms, 
serum 25(OH)D concentrations and objective PA measures. From this study, we have 
concluded: 
 There were insufficient numbers (n=6) of participants eligible to participate in 
both of the pilot interventions. Therefore, only 6 participants were randomised 
according to the original RCT design. After un-randomisation, an additional 11 
participants were recruited. This highlights the feasibility of randomisation and 
study arm allocation procedures, which will inform how many participants are 
required to screen in order to recruit sufficient participants into a RCT design 
trial. Extrapolation to the older obese KOA population of north east England (n= 
1,203,453) according to data on prevalence published by ARUK[17]), estimates 
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9627 participants to be eligible for and participate in a randomised control trial 
of Vitamin D supplementation and Online PA programme interventions. 
 Study retention was excellent in this study at 100% at week 6 and week 12. 
Compliance with study measurements was high (see Table 4.1). Assessing 
compliance with the accelerometry data was particularly important to ensure 
valid PA data (classed as >10hours wear/day) was used in our analysis. We 
found total days of valid PA wear reduced from baseline (71%, 14% and 14% 
achieved valid data for five, four and three days respectively) to week 12 (56%, 
25%, and 13% of participants achieved five, four and three day valid data 
respectively) of the pilot intervention study. 
 Compliance to the Vitamin D supplementation intervention showed high 
compliance in this pilot study at 99% over the 3 months intervention period, 
comparable with the vitamin D supplementation study by McAlindon [147] 
which showed 96% adherence to vitamin D supplementation over 24 months. 
Compliance to the Online PA intervention was 66% (6/9 participants) over the 3 
month intervention period, higher than the ‘Join2move’ online PA intervention 
for older obese people with KOA [262], with 46% adhering to the studies set 
adherence level (completion of 6/9 online 'modules'). 
 Participation in the Vitamin D supplementation intervention led to substantial 
increases in serum 25(OH)D levels over 3 months of a mean 51 ±23.1nmol/L 
(95% CI 33.2, 68.8). Increases in 25(OH)D were also seen in the Online PA 
intervention group, however this change was not as large as the Vitamin D 
intervention group, at a mean 14.9 ±41.1 (95% CI: -16.7, 46.5). This was 
possibly a result of cutaneous Vitamin D synthesis as the study ran into the 
‘summer’ months when Vitamin D production was possible in UK. No trends for 
change in self-reported KOA symptoms (assessed using WOMAC Questionnaire 
and VAS in this pilot intervention study) were observed in the Vitamin D 
supplementation group after 3 months (see Table 4.8). This is consistent with 
the results of more recently released published RCTs [146, 147] no significant 
improvements in KOA symptoms measured by the WOMAC Questionnaire. 
 Changes in objective PA were seen in the Online PA intervention group from 
baseline to week 12 in % time in sedentary, light an moderate intensity PA of -
5.0% (95% CI: -9.7, -0.2), +4.7% (95% CI: 0.4, 9.1). This change in objective PA 
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was not observed in the Vitamin D supplementation group with % time in 
sedentary, light an moderate intensity PA throughout the intervention at  -0.1% 
(95% CI: -5.9, 5.6), +0.1% (95% CI: -5.9, 6.1) 0.0% (95% CI: -1.1, 1.1) respectively. 
This suggests the Online PA intervention was successful in promoting increased 
PA in the Online PA intervention participants. Changes in self-reported KOA 
symptoms were observed from baseline to week 12 of the Online PA 
intervention in WOMAC pain (0-20) (mean difference -3.0 [95% CI: -5.2, -0.8]) 
and activities of daily living (0-64) (mean difference -7.3 [95% CI: -13.7, -1.0]). 
This observation has also been observed in other clinical trials of PA 
interventions [103, 157]. 
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Chapter 5. : Assessing acceptability and feasibility of study procedures 
and interventions: A Qualitative Interview study 
5.1 Introduction 
Chapter 1 presented the aims and objectives of the pilot study, i.e. to explore the 
issues around design, planning, recruitment, conduct and logistical management to 
potentially inform a future trial [194]. This can be achieved using quantitative and/or 
qualitative data collection techniques. The advantage of collecting qualitative data is 
that it can provide  context and meaning and can raise unanticipated ideas or insights 
regarding the study and its participants [267]. 
A qualitative interview study was selected to explore participant views on the cross-
sectional and pilot study presented earlier in the thesis (chapters 3 and 4). Detailed 
aims and objectives are summarised in section 5.2. 
5.2 Aims and Objectives 
The aim was to assess the acceptability and feasibility of several aspects of the cross-
sectional and pilot studies, in particular: 
1) Recruitment: 
a. Are GP surgeries an effective setting for recruitment 
b. What were people’s reasons for participating in the study? 
2) Study Measurements and Study Visits  
a. What were the participant’s views on the organisation, timing and 
structure of study visits?  
b. What were the participant’s views on the measurements taken during 
study visits?  
3) Study materials 
a. What were the participants opinions on the information provided at the 
beginning of the study (i.e. the participant information sheet) 
b. What were the participant’s opinions on the materials provided as part 
of the interventions?  
4) Pilot Study Interventions:  
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a. Were the interventions usable and acceptable to participants? 
b. Were there any issues with using the interventions?  
5) Study Experience: 
a. What was the participant’s experience of taking part in the study? In 
particular would they recommend any changes to study interventions or 
procedures? 
b. Were there any recommendations/changes the participants could offer 
regarding the study? 
c. How acceptable in general was participation in the study? 
5.3 Methods 
5.3.1 Ethical Considerations 
A favourable ethical opinion was provided by London City and East Research Ethics 
Committee (REC)prior to commencement of the study (see Appendix A).Written 
informed consent to conduct and audio record interviews was obtained at the 
beginning  of the study as part of the overall study consent procedure (see appendix 
F).The consolidated criteria for reporting qualitative research (COREQ) checklist was 
used to guide to the development and reporting of the qualitative research study 
[268]. 
Verbal consent for participation in qualitative interviews was obtained prior to the 
interviews taking place. Participants were informed that they had the right to 
withdraw from the interview at any point and that interview recordings would be 
transcribed verbatim and audio recordings would be deleted. 
5.3.2 Study Design 
Semi-structured, one to one, face to face interviews, lasting between 35-80 minutes 
were conducted with the aim of assessing the acceptability and feasibility of study 
procedures and interventions and providing recommendations for a future trial.  
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5.3.3 Study Participants 
5.3.3.1 Inclusion Criteria 
 All Pilot Intervention study participants were eligible to take part in an 
interview 
5.3.3.2 Exclusion Criteria 
 Participants who did not take part in the pilot intervention study 
 Participants who refused to provide consent to take part in a qualitative 
interview 
 Participants who refused to provide consent to having the interview audio 
recorded 
5.3.3.3 Sampling Strategy 
A purposive sample of those who participated in the pilot intervention study were 
invited to be interviewed. This sample could be split into two sub-samples according to 
the study interventions to which the participants were allocated (i.e. Vitamin D 
supplementation and Online PA programme).  
5.3.4 Materials and Measures 
Prior to the commencement of the qualitative study, a topic guide was developed with 
the advice from two health psychologists with expertise in health behaviour change 
(NO'B and LA). The topic guide comprised of a set of questions designed to assess 
acceptability and feasibility of study procedures and interventions and was used to 
guide each interview (see appendix Q). A qualitative interview protocol was developed 
which outlined and standardised all procedures for setting up and conducting 
qualitative interviews, ensuring essential equipment and procedures (e.g. consenting) 
were adhered to and that all interviews were consistent (see appendix R). 
5.3.5 Study setting 
The interviews took place within North Tyneside General Hospital. 
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5.3.6 Study Procedure 
The interviews took place directly following the pilot intervention 12 week study visit 
and were all conducted by the author of this thesis (RB). 
The interview adhered to the interview protocol (see appendix R). The topic guide and 
prompts were used to encourage and probe participant responses. At the end of the 
interview, the recording was stopped and the participant thanked for their 
involvement. 
5.3.7 Methodological Quality 
As part of the qualitative approach undertaken, issues affecting methodological quality 
were taken into consideration during the design, conduct and analysis of the 
qualitative interview study with the aim increasing the trustworthiness of the 
qualitative data. 
We employed many methodological techniques to improve different quality concepts 
regarding the overall trustworthiness of the data, as described below. 
5.3.7.1 Dependability and confirmability 
In order to ensure this data was dependable (that methods of obtaining study findings 
are clear [269]) and confirmable (that the findings of the study a representative of the 
study aims and topic rather than the researchers beliefs [269]), we ensured the 
following: 
Clear audit trails were maintained throughout this qualitative study. Rationale for 
study aims, design, participant sample, data collection and analysis are clearly detailed 
as part of this thesis.  
Data was analysed and coded by the primary researcher (RB), with a subsection of 
interviews (n=4) also analysed and coded by a second researcher (LA). After each of 
the first four interview transcripts were analysed and coded, RB and LA met to 
compare and discuss the resulting themes (defined as prevalent ideas or concepts 
expressed by participants and identified from the transcripts), with any discrepancies 
resolved through discussion (triangulation [269]). 
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5.3.7.2 Credibility  
To ensure the themes derived from the data were reflective of the participants 
opinions and experiences, direct quotes from participants on which themes and 
subthemes have been based have been presented in Appendix S. The relevant direct 
quotes are used as supporting evidence for the interpretation of themes and 
subthemes throughout the results section of this chapter. 
Another aspect of the study, which may have increased the credibility of the data 
collected, was the participant’s relationship with the interviewer. As RB had conducted 
all study visits (3 face-to-face visits before the qualitative interview was conducted) 
and was the primary contact for participants therefore familiarity and rapport with 
participants was established before the interview. This important as it has been 
recognised it may help participants to relax, leading to a more productive interview 
[270]. 
5.3.7.3 Transferability 
In order to ensure this qualitative data is transferable (to other studies and contexts) 
details of the characteristics of the study population are reported in the results of this 
chapter. The context of the subject matter of this interview (involvement in the cross-
sectional and pilot intervention studies) are described in detail in chapter 3 and 4.  
Another aspect worthy of note when considering context is the environment in which 
the interviews were conducted.  Interviews were conducted in a clinical room (Jubilee 
Day Hospital, NTGH), following the participants final study visit. This was done 
primarily to reduce participant burden (i.e to keep number of visits to a minimum that 
would hopefully maximise recruitment to the study). As the interview took place in the 
same room and environment participants had completed their previous study visits, it 
was a familiar environment which may have been helpful when discussing procedures 
which had occurred previously (i.e. recall). However, as a clinical environment, this 
may have influenced the participant’s responses to what they believed appropriate to 
that environment.  
It has been recognised that many of the researcher’s personal characteristics (e.g. 
background, experience and training, and preconceptions) can have an effect on the 
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research process, and that these characteristics should be acknowledged (reflexivity) 
[271]. 
5.3.8 Data Processing and Analysis 
5.3.8.1 Data Processing 
All interviews were audio recorded and transferred to a Newcastle University 
password protected computer. All recordings were transcribed verbatim into word 
documents by an approved external transcription service (Type it Write). 
All transcripts were checked against the audio recordings and any errors or gaps in 
transcription were corrected. Transcripts were stored in electronic form in files on a 
Newcastle University password protected computer, identifiable only by participant ID.  
5.3.8.2 Data Analysis 
All data were analysed by the author of this thesis [RB] and 25% (4/16 transcripts) 
analysed by LA. Transcripts were analysed using a structured thematic analysis. [269] 
Briefly, the main themes were determined based on the responses of participants to a 
standardised topic guide asking questions in relation to recruitment, study materials, 
study visits, pilot interventions and study experience.  
A random selection of four transcripts were selected initially and independently coded 
by RB and LA. Opinion on preliminary themes identified were discussed until 
agreement was reached. This process allowed early themes to be reviewed and agreed 
before the remaining transcripts were analysed by RB.  
Remaining data from the interview transcripts were coded into these themes and 
themes were redefined/revised where appropriate. In some instances, it was 
appropriate to generate sub-themes[272]. Themes and sub themes were summarized 
in table form along with supporting quotes (with appropriate participant ID) from 
transcripts. A narrative description of the themes and subthemes were then discussed 
as part of the results section of this chapter. 
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5.4 Results 
5.4.1 Participants 
17 participants who took part in the pilot intervention study, and of these 16 (nine 
men and seven women) provided informed written consent to take part in an audio 
recorded qualitative interview. One participant refused to participate due to lack of 
available time. Of those participating, eight took part in the online PA intervention and 
eight took part in the Vitamin D supplementation intervention. Of those who took part 
in the Vitamin D intervention, four were female and four were male, with a median 
age of 62 years (range: 51-68 years), median BMI of 31.5 (range: 29-41) and median 
WOMAC Pain (0-20) of 7.8 (range: 1-12) at baseline and 7.8 (range: 2-16) at week 12. 
Of those who took part in the Physical activity intervention, three were female and five 
were male, with a median age of 63 years (range: 52-69), median BMI of 34 (range: 30-
41) and median WOMAC Pain (0-20) of 7.9 (range: 3-12) at baseline and 5.4 at week 12 
(range: 0-11). 
5.4.2 Qualitative Interview Findings 
The qualitative interview data were analysed according to each of the main study aims 
(see section 5.2) relating to study recruitment, study visits and procedures, study 
materials, pilot interventions and overall study experience. The results, including 
themes and sub-themes are summarised below. Since responses given by males and 
females were similar, they are presented together. A table summarising all of the 
themes and subthemes identified can be found in Appendix S. 
5.4.3 Theme 1: Study Recruitment 
5.4.3.1 Sub theme 1.1: Motivations to recruitment 
Two main motivations for participation in the study were identified, both regarding 
improving health. The first motivation regarded personal benefit, primarily the hope 
that participation in the study would improve their KOA and the willingness to try 
anything to improve their health condition and symptoms. 
“I thought I would try anything. If anything works, I will try it. I know 
it’s just a test at the minute [the study interventions], but…Only to 
get rid of the pain. (Participant 033, Male, Vitamin D Intervention) 
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A subset of participants also hoped the study may aid them in increasing their activity 
levels and to lose weight  
“I was hoping my weight would go down.” (Participant 004, female, 
Online PA Intervention) 
The second main motivation for participation was the desire to help other individuals 
with KOA by contributing to medical research. The hope was that in the future the 
information gained from this study would be used to treat and improve KOA. 
“I thought, well, what the hell, because, if I’m not mistaken, on the 
first letter [participant information sheet] it said it [study] will be for 
future references, for people that have got arthritis, and it may be 
beneficial, the findings, to help somebody else, so I thought why not 
(participate in study).” (Participant 032, male, Online PA intervention) 
Interestingly, for those who did not comply with the PA intervention, the main 
motivations for participations seemed to be altruism (help other in the future by 
contributing to research) and 'disproving the research team' in reaction to being 
labelled 'obese', which the participant found personally offensive.  
"Yes, because, relating back to the first one, [cross-section study] on 
the letter, in my words to my wife, "I'll bloody show her who's 
obese', and that's what I've been trying to do, I've been trying 
too...you were the cause of it. So I did take part in the second one 
[pilot intervention study], and I was determined to lose some weight, 
and I feel better for it. (Participant 032, male, Online PA intervention) 
Compliers to the PA intervention were more likely to be motivated to part for personal 
benefit, with no non-compliers stating this as a motivator for participation. 
5.4.3.2 Subtheme 1.2: Barriers to recruitment 
In addition to identified facilitators, several potential barriers to study recruitment 
emerged. The use of specific terms within the study information provided and used to 
screen for eligibility were sometimes viewed negatively by participants such as the use 
of terms relating to age, particularly ‘older’, and the use of the term ‘obese’ which 
were viewed as potentially offensive. For some participants, being identified as obese 
was also surprising and unexpected and one participant particularly expressed they 
would have preferred to have discussed their weight with the GP before recruitment 
to the study: 
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Well a bit cross that somebody had the nerve to call me obese, that 
was the first thing…I think if one had been prepared, if the GP had 
talked it through and said, ‘You know you’re a little bit overweight 
and they are looking for people who might join this thing [study]. 
(Participant 026, female, Vitamin D intervention) 
One participant, a non-complier to the online component of the PA intervention, 
explained that their family had discouraged their involvement in the study due to a 
distrust of medical research and concern that it may be harmful. Although this did not 
prevent the individual taking part it does highlight the perception of some members of 
the public that medical research is unregulated and potentially harmful. 
I was advised by my daughter and son in law not to take part in it 
[study], because I think the word was, ‘don’t let them get their claws 
in you, or you might not come out alive’, you know…it’s common 
knowledge that, sometimes, doctors get their hands on you, and 
they start feeding you all kinds of things, and you end up a zombie.” 
(Participant 032, male, Online PA intervention) 
5.4.3.3 Subtheme 1.3: Facilitators to recruitment  
Various facilitators, which mediated motivation to participate or retention in the 
studies, were identified. The main facilitator to recruitment was the involvement of GP 
surgeries. The majority of participants (including compliers and non-compliers to the 
interventions) expressed that they felt recruitment from the GP surgery was a good 
method of recruitment. Recruitment through GP surgeries was also viewed as a form 
of ‘endorsement’ from a professional medical body. This was important for facilitating 
participation into the study as this ‘endorsement’ seemed to reassure participants that 
the study was safe and legitimate:  
“I felt it [the study] was important because the GP was behind it, it 
was authentic, it had the authority. It was women my age who had 
these problems [knee osteoarthritis], and because the doctor’s 
names and surgeries was on it, that gave it a good okay.” 
(Participant 022, female, Online PA intervention) 
Alternatively, it was felt by two participants that recruiting from GP surgeries by 
screening patient records, that they had been nominated for the study without their 
permission to be referred or recommended to the university study team.  
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“The doctor hadn’t asked my permission or done anything in that 
nature about the referral [for study recruitment]. She’d [GP] just 
done it. (Participant 026, female, Vitamin D Intervention) 
It was suggested that discussions with GPs about the patient’s willingness to be 
recommended for participation in research studies may be preferable regarding 
recruitment from GP surgeries. 
“I think possibly if the GP had have mentioned it [research study] 
beforehand rather than a letter coming, you know, if I had been at 
the GP or something like that and he’d [GP] said, ‘how do you feel 
about taking part in these things [research studies]’” (Participant 
007, male, both interventions) 
As well as identifying motivators to participation in the study, several other facilitators 
(factors aided study recruitment and retention) emerged. These included personal 
interest in the study topic, the hope that study results will inform primary care practice 
(i.e. to improve care provision) and study appointment flexibility. Provision of 
transport was an important facilitator for study participation in non-compliers to the 
online PA intervention who saw arranging travel to the study site as a barrier to their 
participation. 
“…I didn’t think I would be accepted [recruited to the study] because 
I didn’t drive, and I was worried about getting to this place, and you 
explained that you would provide transport, and I was relaxed after 
that, because my major…I didn’t want the worry of trying to jump on 
two buses to get here, getting home, and as soon as you said 
transport, I thought, well, there’s no problem.” (Participant 032, 
male, Online PA intervention) 
One participant’s views deviated from that of the majority and it was likely due to 
having been a medical researcher. They highlighted their previous career had 
increased the likelihood of them taking part in the study because they felt that they 
could not reasonably decline participation as they were aware of the importance of 
participants. 
“how could I possibly disagree (taking part in the study) having had a 
career that is related to medical research myself? I wouldn't dream 
of standing in anybody's way if there was any way that I could help 
out by being a participant although (Participant 026, female, Vitamin 
D intervention)” 
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5.4.4 Theme 2: Study Visits and Measures 
5.4.4.1 Sub theme 2.1: Study Setting 
The use of the hospital as a setting for the study was discussed with mixed opinions. It 
was generally agreed that the hospital was an appropriate setting for the study. For 
some attending a hospital for a research study was reassuring and gave the study 
credibility and for others it evoked anxiety over what the visit may involve. 
“At first you think ‘hospital’ what are they going to do, but once 
you’ve been here, and you’ve been through the first session, there 
wasn’t a problem with it.” (Participant 032, male, Online PA 
intervention) 
It emerged that the participant who expressed anxiety over the study setting was also 
the participant whose family members expressed distrust of medical research and a 
non-complier to the online PA intervention. 
Accessibility to the hospital was discussed and opinions were mixed. A reoccurring 
theme was issues with parking (i.e. lack of parking space) and in particular parking 
charges. This led to some participants parking outside of the hospital grounds or 
seeking alternative travel arrangements.  
Sometimes I brought the car down and parked in the local housing 
estate because I refuse point blank to pay parking in a hospital, even 
if you were going to pay it back, which I haven’t asked you to do 
with any of it.” (Participant 026, female, Vitamin D Intervention) 
Most participants preferred to travel to their study appointment by car. Problems with 
using public transport were identified by one participant. 
I don’t live on a METRO route, and I’ve got quite a walk to get to a 
bus which, because of the condition I’ve got, and getting on and off 
[the bus]…fair enough, one of the buses that lower down, they’re 
alright, but using public transport is a problem for me because, even 
having to stand up, in preparation to get off, the bus is moving, and 
my knees aren’t steady enough. I just very, very rarely use public 
transport” (Participant 029, female, Online PA intervention) 
5.4.4.2 Sub theme 2.2: Wearing the accelerometer 
Wearing an accelerometer or activity monitor presented as a challenge for some 
participants who reported that they found wearing the device (worn on an elasticated 
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belt) irritating, noting the belt seemed to move around and the elastic belt as 
uncomfortable to wear.  
It kept slipping up and down, I don’t know why. Then I couldn’t 
sometimes tell whether I was putting it in the right place. I just 
found it just irritating. That’s the only bit I didn’t really enjoy.” 
(Participant 003, female, Vitamin D intervention) 
Alternately, some participants reported noted after wearing the activity monitor that 
they did not realise it was there. Some concern also revolved around the concept of 
being monitored. These concerns primarily regarded being perceived as lazy when 
participants were not being active and embarrassment over the monitor recording 
personal activities such going to the toilet, which seemed to stem from a 
misunderstanding of what the activity monitor was able to record.  
“It’s embarrassing actually if you’re on the loo and so on, you think 
they might know what you’re doing…It’s probably handy for you to 
know that I can get on and off the loo or not but it’s a bit 
embarrassing. It’s like having someone watching you.” (Participant 
026, female, Vitamin D intervention) 
5.4.4.3 Sub theme 2.3: Completing the consent form 
Views on the measurements taken during the study visits was discussed. One study 
procedure which generated a range of opinions was completion of the consent form at 
the start of study visit 1. Many participants reported preferring to complete the 
consent form with the researcher because this provided them with an opportunity to 
ask questions face to face. 
“No I think it was easier doing it [consent form] here [study 
appointment], because if you’re unsure about some of the 
questions, you’d [researcher] be able to help us answer them, 
whereas if you’re at home on your own, you’re on your own, 
unsure.” (Participant 037, male, Vitamin D intervention) 
However, there was some confusion amongst participants as to why the consent form 
was required. Most participants correctly assumed that consenting was a necessary 
part of the research study process. Some participants viewed completion of the 
consent form as confirmation of the participants understanding and to outline what 
was to happen in order to prevent any abuses of power by the study team. 
Alternatively, anxiety was expressed by one individual about the need to complete a 
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consent form which seem to suggest to them that the study would involve invasive or 
unpleasant procedures. However, following consent and once the study visit was 
completed the same individual expressed confusion over why consent was required for 
the measurements taken.  
“…bit it’s funny, when you start talking about consent forms, then 
what the wife was saying, and what the daughter was saying, ‘hold 
on, are they going to take your leg off you’, you know what I mean? 
Consent you know, it’s in the back of your mind, ‘hold on, I’m signing 
a consent form, why?’. Once it was all explained, it was no 
problem…Well, I mean, for what treatment I’ve had, I don’t know 
why we had a consent form. I mean, basically, I’d already been doing 
it, taking a weight, height and a little bit of blood, and monitoring my 
activities, but I don’t know what the law is.” (Participant 032, male, 
Online PA intervention) 
This particular participant seem to express anxiety and distrust of medical research 
and seemed wary regarding the concept of medical research. However this did not 
deter his participation within the study although he did not comply with the online PA 
intervention. 
5.4.4.4 Sub theme 2.4: Questionnaire completion 
Several problems with the completion of questionnaires were identified by 
participants including concern over unintentional variation in their answers to 
questions between study visits which are not due to any perceived variation in their 
condition or wellbeing. For example, one participant described what they perceive to 
be a ‘mild’ symptom may change between study visits depending on external factors 
such as sleep or mood. 
“I'm never terribly sure because we never keep a record, whether 
mine are consistent answers or not from one period to the next. 
That slightly worries me because in my head I might be using a 
different understanding of mild each time I come in, slightly 
depending on my mood or slightly depending on whether I had a 
good night's sleep or something like that.” (Participant 026, female, 
Vitamin D Intervention) 
Other issues emerged regarding confusion over the wording of questions in the 
questionnaires. They were described as ambiguous or and sometimes difficult to 
 206 
understand, e.g. it was felt some questions were phrased as double negatives and 
therefore the true meaning of the question was difficult to decipher. 
“Yes, there were two questions when I did it [questionnaires] 
today…but they were almost like double negatives, I thought, “I 
don’t know if I’m reading this properly or not.”(Participant 038, 
female, Vitamin D intervention) 
A further issue that emerged was the dislike of admitting perceived personal 
limitations and accepting there are activities oneself cannot do anymore. 
“No, the only bad point is me; I don’t like accepting what I can and 
can’t do, so I sometimes think, well, it’s really that but I’m going to 
say this, but that’s my problem. Even after all these years, I still don’t 
like saying, ‘I can’t do’…”(Participant 029, female, Online PA 
intervention) 
However, having the researcher present during completion of the questionnaires was 
reported to encourage participants to answer more honestly. 
Yes, and discuss [the questions], and then you’re sitting there 
thinking, ‘I want to say I’m that good, but I’m really not that good’, 
so I think, for me personally, it helped me be more honest, with 
which one [answer] to tick.” (Participant 029, female, Online PA 
intervention) 
5.4.4.5 Sub theme 2.5: Taking blood Samples 
Giving venous blood samples was reported as acceptable by all participants and most 
were familiar with the process of having blood taken due to previous experience in 
donating blood or having blood taken in other contexts.  
“I am a blood donor any way so it wasn’t a problem. (Participant 
033, male, Vitamin D intervention)” 
5.4.4.6 Sub theme 2.6: External factors on study measurement performance 
Participants also highlighted the importance of external factors affecting physical 
activities which may not be taken into account by the activity monitors such as other 
health conditions, e.g. arthritis at other sites, which restricted movement or illness.  
The last time [participant wore the activity monitor] I wasn’t very 
well so I was in bed so I didn’t probably use it [activity monitor] as 
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much as I could have done but I was ill in bed at the time.” 
(Participant 003, female, Vitamin D intervention) 
The impact of movement restrictions due to other medical problems including pain 
and arthritis at other anatomical sites and time of day was also highlighted concerning 
performance during the timed up and go function test performed during the study 
visit. This highlighted the need to record and consider such contextual factors when 
carrying out this test. 
“ That was fine [time up and go test], except I think, the last one I 
came to, when my back was still a problem, and I couldn’t…I think I 
only managed one walk.” (Participant 029, female, Online PA 
intervention) 
5.4.4.7 Sub theme 2.7: Uncertainty over what was being measured 
There was some isolated instances of uncertainty over exactly what a measurement 
was measuring and why it was being measured. One participant was unclear as to why 
some measurements (e.g. height and waist circumference) was repeated and taken 
three times. 
“Basically, you took my height three times, you took my waist 
measurement three times. Well, either you’re very insecure, or is 
that because of the study, you’ve got to do it three times? I mean, 
I’m not going to get any smaller… (Participant 032, male, Online PA 
intervention)” 
One other participant described a misunderstanding of what the accelerometer was 
able to measure, thinking that it was able to record activities such as going to the 
toilet, which they found embarrassing. 
“It's embarrassing actually if you're on the loo and so on, you think 
they might know what I'm doing. It's a bit of an embarrassment, 
especially for older ladies I would say, yes. I took it off for showers 
and baths and things. I might have been tempted to take it off for 
other things but I didn't. It's probably handy for you to know that I 
can get on and off the loo or not but it's a bit embarrassing. It's like 
having someone watching you.” (Participant 026, female, Vitamin D 
intervention) 
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5.4.4.8 Sub theme 2.8: Embarrassment over terminology used during study visits  
There was some embarrassment over terminology used during the study visits, 
particularly terms relating weight such as ‘obese’. One participants highlighted their 
relief that the subject of their weight was not discussed explicitly during the study visit. 
“I'm pleased you didn't say that I was overweight because normally 
they do. That was a plus, that you didn't make any comment at all 
actually. I don't need to be told I need to lose weight because I know 
that.” (Participant 003, female, Vitamin D intervention) 
5.4.4.9 Sub theme 2.9: Study Visit length 
Most people felt that the duration of the study visits was acceptable and as they 
expected. 
“You have certain things that you want to do as part of your study 
then I don’t think it’s probably unreasonable. It’s normally about an 
hour, I think, isn’t it, so that’s not a huge amount of time out of my 
day.” (Participant 043, male, Online PA intervention) 
However, one participant highlighted they found the study visits were more time 
consuming than they anticipated. They also expressed the idea that just because they 
were retired, that did not mean they had a lot of free time to be called upon to attend 
study visits. 
“Just because we’re retired, we’re not sitting around waiting to be 
called into the hospital and entertained for a whole morning. We 
have plenty of other things to do, like everybody does. So it was 
probably more time consuming, these little sessions than I thought 
from the outset. (Participant 026, female, Vitamin D intervention) 
5.4.4.10 Sub theme 2.10: Concern over investigator qualification 
One participant expressed concern about a student researcher taking blood samples, 
feeling it would be more appropriate for medically trained professional, such as a 
nurse, to carry out what was viewed as a medical procedure. 
I would have expected a trained medical worker to do those [take 
blood samples], a nurse. You tell me you’ve done a course to enable 
you to do that and I take that at face value…I would have probably 
stayed with the nurse doing it throughout.” (Participant 026, female, 
Vitamin D intervention) 
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5.4.5 Theme 3: Study Materials 
5.4.5.1 Sub theme 3.1: Acceptability of patient information sheet  
When asked about the materials mailed to participants regarding recruitment to the 
study (study invitation pack containing invitation letter from GP surgery, patient 
information sheet and consent form) most felt that the information was easy to 
understand, straightforward and helpful. However, as discussed earlier in the context 
of study recruitment, there were objections to some of the terminology used in the 
patient information sheet, particularly terms relating to weight (‘obese’) and age 
(‘older’), which were viewed by some as offensive and carried a stigma.  
“ I read it [patient information sheet], but that was good; if that word 
hadn’t have been on…’overweight’, I would have said…but ‘obese’ 
has got that tinge to it, that meaning…it just hits you where it hurts.” 
(Participant 032, male, Online PA intervention) 
“So I didn’t know what to be more offended by, being called older or 
being called obese [laughter]…It’s the fact that when you see it just 
written like that, it’s quite stark, isn’t it?” (Participant 038, female, 
Vitamin D intervention) 
Some participants expressed shock at being labelled as obese or older as they had not 
previously considered themselves to be either. 
…And actually, I mean I just don’t consider myself an older person 
but maybe I am you know…” (Participant 038, female, Online PA 
intervention) 
“Well, being selected on that criteria. I’ve never thought of myself as 
being obese…but it just came out of the blue, the letter.” 
(Participant 007, male, Online PA intervention) 
5.4.5.2 Sub theme: Provision of appointment letters 
One participants mentioned the advantages of being provided with appointment letter 
for remembering the appointment date and time and in being provided with evidence 
to present to their employer so they could leave work early to attend a study visit.  
“So a letter is good for me because I can show my boss and I’m not 
just, you know, having a sneaky early finish. So the letter is useful for 
me to show him, rather than just tell him. So that was fine. Plus, I 
think, if you’ve got something tangible, you know, you can put in 
your handbag and you remember. Whereas, if you’ve just had a 
 210 
phone call, you write it in your diary or you stick it on a calendar or 
something like that, but you could forget.” (Participant 004, female, 
Online PA intervention) 
5.4.5.3 Sub theme 3.3: Participant feedback 
There was great interest in study feedback amongst participants, with a number of 
reasons for this emerging. Participants felt generally that in receiving feedback on their 
results from the measures taken during the study visit, they were ‘getting something 
back’ from participating and that research studies should be a two way process, with 
information benefiting both the research team and participant.  
Really important [feedback], I think. As I say, it’s a two way process I 
believe, so I’m happy to participate and it’s always very interesting 
to see what the results have actually brought up.” (Participant 043, 
male, Online PA intervention) 
Participants were also interested in receiving individual feedback in order to inform 
them on their current health status with a view to improving their condition and 
overall health. Particular emphasis was placed on the role of feedback in not only 
providing results from the study visits but in providing advice on how to ‘improve’ their 
results in the future. 
“ But as long as it’s a coherent set of information with some possible 
pointers and what one might do to continue to manage the 
condition.” (Participant 022, female, Online PA programme) 
“…[feedback] telling me how much exercise I did or didn't do. Well I 
could have told them that. That was foolish. I mean that's a piece of 
information. More to the point, it's how can you do some more or 
whatever you can do. (Participant 026, female, Vitamin D 
intervention) 
It was suggested that the feedback from the study could also be potentially feedback 
to and inform primary care (GP surgeries), with the aim of improving the participants 
future health. 
“Obviously any diet warnings, if you picked something really foul up 
you would have obviously contacted the GP and put matters in hand 
to do something about it. So it’s a good thing“(Participant 026, 
female, Vitamin D intervention) 
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There was also interest in feedback of the results from the study as a whole, 
particularly regarding comparing different intervention groups (Vitamin D 
supplementation and Physical Activity groups) to establish whether there were any 
differences in outcomes at the end of the study according to intervention group. 
“…people who’ve had the placebo, people who’ve had the Vitamin D 
and then the people who’ve had the activity programme, I think it 
will be interesting to see how to results differ, if at all.” (Participant 
004, female, Online PA intervention) 
5.4.5.4 Sub theme 3.4: Intervention study pack and instructions 
Materials provided as part of the pilot interventions were also discussed with 
participants. It was felt that the pilot intervention starter pack (containing the pilot 
intervention study invitation letter, study intervention manual and study materials) 
was generally clear and easy to understand. This promoted an understanding and 
confidence in conducting the interventions and using the intervention materials 
provided.  
“I thought they were quite good [study intervention manual]. They 
were concise and I knew what I was doing” (Participant 003, female, 
Vitamin D intervention) 
“That was really useful to read through all of that (study intervention 
instructions). I found the whole thing really helpful. I had my 
pedometer and I read that, knew how to work that. So that was fine. 
I was raring to go really.”(Participant 004, female, Online PA 
intervention) 
The mode of delivery of the pilot intervention starter pack (posted to the participant’s 
home address at the start of the pilot intervention study) also seemed preferable to 
collecting the pack in person 
“Yes, obviously it’s a cheaper way for me [to have pack posted] 
because I don’t have to come down [to collect the pack]. (Participant 
033, male, Vitamin D intervention) 
5.4.5.5 Sub theme 3.5: Use of the pill cases 
Intervention specific materials delivered as part of the study intervention starter pack 
were also discussed. As part of the Vitamin D supplementation intervention, six-week 
supply pill cases containing the vitamin D supplements were provided to participants. 
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With the exception of one participant who reported difficulty in opening and closing 
the pill cases, all participants found the pill cases easy to use.  
“…the whole thing has been a disaster as far as my thumb nails have 
been concerned. That’s why I don’t want those things [pill boxes] 
back. They’re the most…if you honestly think that people with any 
degree of arthritis in their hands could possibly manage those, they 
can’t. It was awful.” (Participant 026, female, Vitamin D intervention) 
In addition to being generally easy to use, the use of pill cases in delivering Vitamin D 
supplements was reported to facilitate compliance to the intervention by reminding 
participants if they had taken their supplements every day (i.e. it worked as a 
behavioural prompt). 
“Like I said, if you didn’t know whether you had taken a tablet, you 
would know as soon as you opened the box. I mean I didn’t miss 
one.” (Participant 033, male, Vitamin D intervention) 
5.4.5.6 Sub theme 3.6: Pedometer as an incentive to increase PA 
As part of the physical activity intervention, a pedometer was provided to enable 
participants to track and monitor their daily steps if desired. All participants in the 
online PA intervention used the pedometers provided to monitor their activity. It was 
reported to work as an incentive to motivate people to monitor and increase their 
activity when using the POW website.  
…I thought they [pedometer] were a tool, and it was an incentive for 
me to have around.” (Participant 032, male, Online PA intervention) 
No I think the pedometer is the key thing. It’s a daily thing that I 
check up on. That’s really important.” (Participant 022, female, 
Online PA intervention) 
Interestingly, the participants who reported that the pedometer was effective as an 
incentive to increase their PA were mostly non-compliers to the online component of 
the PA intervention. 
 213 
5.4.6 Theme 4: Pilot Intervention 
Themes emerging with regards to the acceptability of the pilot intervention study 
related to the acceptability of study procedures and the interventions themselves 
including specific issues. 
5.4.6.1 Sub theme 4.1: Study arm allocation 
Themes regarding the acceptability of study procedures such as study arm allocation 
and study retention was discussed. Views on study arm allocation varied with some 
participants expressing a preference for participation in a particular study arm, 
specifically for either of the intervention arms. However, participants did not suggest 
they would withdraw from the study if they were allocated to a study arm which was 
not preferred by themselves. The study arm allocation procedure was unclear to one 
particular participant. 
“Well, I’m not sure why, or how, you selected who does what [which 
study arm participant is allocated to]; you must have your reasons, 
but I just took it as this is the way you wanted it, that I would be 
taking part in this.” (Participant 032, male, Online PA intervention) 
One participant who had taken part in the Vitamin D intervention expressed their 
preference for this study arm because it was perceived as being ‘easier’ in terms of 
fitting into everyday life when compared to the PA intervention.  
“As I say, it’s easy to take. If you have got to do some sort of exercise 
before you go to bed and you are tired you just say, ‘I will miss it 
tonight’, whereas with a tablet you just take it and because I was 
taking the statin as well, it made sure that I was taking that 
regularly…It was easier taking them than doing an activity one 
because, you know, I can’t be bothered.” (Participant 033, male, 
Vitamin D intervention) 
However overall the majority of participants expressed a preference for participation 
in the online PA intervention. This was due to them seeing it as motivation to start 
increasing their activity levels or as giving them a feeling they were ‘doing something’ 
or achieving something as part of participating in the study. 
“I was hoping I would be in one of the groups that did more of the 
exercise than just take the pills…Yes I thought it might give me a kick 
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start in doing something” (Participant 003, female, Vitamin D 
intervention) 
“Well I suppose you just would feel you were not doing anything 
differently, whereas if you were in one of the others, provided with 
an exercise programme or…so you were just doing something 
differently I suppose.” (Participant 038, female, Vitamin D 
intervention) 
One participant also expressed relief at not being allocated to a placebo or standard 
care group, claiming they would have been disappointed to be allocated to this group. 
However, they did not suggest they would withdraw from the study if they were 
allocated to the placebo/standard care arm. 
“Because one of them [study arm] was no intervention, wasn’t it? 
Yes I’d have been a bit disappointed if I’d been given…you know, so I 
was glad to get…” (Participant 038, female, Vitamin D intervention)  
5.4.6.2 Sub theme 4.2: Study retention 
Participants identified a variety of different facilitators to retention within the three-
month pilot intervention study. These included the desire that something beneficial 
may result from the intervention, which may benefit other, interest in the study, not 
wanting to disappoint the researcher and the need to finish the study and see it 
through to the end.  
All I have given up here is my time, you know, everything else 
is…something good might come out of it and like I say if not for 
myself then it might for somebody else. (Participant 033, male, 
Vitamin D intervention) 
Well I was quite happy to do that because I’ve got the time and I 
was just quite interested really (Participant 038, female, Vitamin D 
intervention) 
I saw it through. I didn’t like taking the tablets. I knew they weren’t 
having a beneficial effect on me, but I saw it through. (Participant 
045, male, Vitamin D intervention) 
One participant identified the pain they experienced during the study as a barrier to 
study retention, as they perceived the pain as a result of the Vitamin D supplements 
they were taking as part of the Vitamin D intervention. 
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If I had, I would have...the agony I was in, it didn't seem to be 
improving. That was the real reason why I nearly gave up. I didn't 
think they were doing any good at all[Vitamin D supplements]. 
(Participant 026, female, Vitamin D intervention) 
5.4.6.3 Sub theme 4.3: Facilitators to intervention success 
A number of facilitators to participants remaining in the study were reported. 
Facilitators to study retention varied between individuals, including a need to finish 
what they had started (regarding the study), the feeling of contributing towards 
something potentially beneficial for others, personal interest in the study topic and not 
wanting to disappoint the research team. Interestingly, many of these facilitators to 
remaining in the study were similar to the motivations identified for entering the study 
initially (see section 5.4.3.1). 
“I didn’t want to disappoint you. I knew you’d be heartbroken so I 
thought I’ll keep taking them [Vitamin D supplements] to the end” 
(Participant 045, male, Vitamin D intervention) 
The majority of study facilitators related to participation in the physical activity 
intervention with social support heavily influencing adherence (e.g., having someone 
else there to encourage you to carry on with the intervention, such as a spouse). 
“If it’s just you, you’ll think, oh I’ll not bother going [to exercise], but 
if somebody else wants to go with you, or comes to pick you up or 
jollies you along a little bit, I think it’s easier to do it with someone.” 
(Participant 004, female, Online PA intervention) 
Pets also played a role with encouraging adherence to the physical activity 
intervention by encouraging regular walking (e.g. a dog walking). 
“Oh like I say, my daily activities more or less revolve around my 
dog.” (Participant 041, male, Online PA intervention) 
In addition, anticipated regret played a role in facilitating adherence to the physical 
activity intervention. Some participants reported guilt or fear of ‘not doing enough’ or 
not complying with the intervention as a reason for continuing compliance. 
“…gave me a big push to get going and then I would be so guilt 
ridden if I didn’t do it, I would continue doing it [PA intervention]. 
(Participant 003, female, Vitamin D intervention) 
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Barriers to intervention acceptability, feasibility or adherence related to the disruption 
of the participant’s regular routines, such as staying away from home (e.g. holidays, 
social events and work), environmental factors (e.g., bad weather), and personal 
factors (e.g., injury, illness and lack of time). These factors often made it difficult to 
access study materials (e.g. pill cases and the online PA website) and adhere to the 
intervention. People further reported that other events meant they sometimes did not 
have time to participate in the intervention. 
“I mean sometimes we were doing bed and breakfast and 
sometimes they [pill cases] were packed in the car and so on so I 
couldn’t do them [take Vitamin D supplement] that day.” (Participant 
026, female, Vitamin D intervention) 
If I’m staying in a hotel overnight, they haven’t always got any 
facilities [for activity] (Participant 004, female, Online PA 
intervention) 
5.4.6.4 Sub theme 4.4: Barriers to intervention retention 
A specific barrier to study retention was expressed by one participant relating to the 
level of pain they experienced throughout the study. However facilitators to retention 
included not wanting to disappoint the researcher and eventually feeling an 
improvement with longer term participation.   
“…the agony I was in, it didn’t seem to be improving. That was the 
real reason why I nearly gave up. I didn’t think they were doing any 
good at all…I nearly came in to give it up then too but I was so sorry 
for you doing this wretched study, I thought, “ Well I better hang 
on”. Then it did, in the end, finally kick in to be some use but it got 
worse before it got better.” (Participant 026, female, Vitamin D 
intervention) 
Other barriers to intervention adherence referred specifically to the PA interventions. 
For example, bad weather disrupted and discouraged outdoor based activities such as 
gardening and walking and higher levels of activity in general.  
“So it wasn’t really the weather to garden. That’s why we decided to 
do swimming. It was the easiest option to do because I haven’t got a 
bike…And now that the weathers better and it’s a bit lighter at night, 
especially when the clocks go forward, it will be lighter again, so I 
think we will get out and about a lot more often. It will make us walk 
more often.” (Participant 004, female, Online PA intervention) 
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The importance of sedentary working environments in preventing increased activity 
was also highlighted by one participant. They described how their working 
environment prevented them from being active at work and left little time remaining 
to do more activity outside of work. 
“I just felt I haven’t maybe helped as much as I could if I was only 
working 38 hours a week. Because if I worked 38 hour a week I could 
put in more exercise.” (Participant 022, female, Online PA 
intervention) 
The contribution of periods of illness and other injuries/health conditions on the 
amount of activity the individual was able to undertake was discussed by several 
participants. 
“I was having problems with my neck at the time so the swimming 
was out” (Participant 007, male, both interventions) 
“As I said, there was a complaint, and when my back had gone 
[injured] unfortunately I couldn’t do any real sort of exercise or 
anything additional certainly at that time.” (Participant 043, male, 
Online PA intervention) 
5.4.6.5 Sub theme 4.5 Intervention safety concerns  
Continued participation for both interventions relied on confidence of some 
participants that the intervention was safe. Most of these safety concerns related to 
fear of side effects of taking Vitamin D supplements and injury during increasing PA as 
part of the online PA intervention. 
“Well I did ask you, ‘Can you overdose on this stuff [vitamin D 
supplements]?’ and you reassured me there. (Participant 026, 
female, Vitamin D intervention) 
“I think the day my knee almost locked, I was a bit worried then that 
I was overdoing it [with the PA intervention].” (Participant 004, 
female, Online PA intervention) 
5.4.6.6 Sub theme 4.6: Taking Vitamin D supplements 
In terms of acceptability of the Vitamin D intervention, several improvements were 
recommended by participants. For example, some participants occasionally did not 
take the Vitamin D supplements during the intervention. This was the primary reason 
reported for forgetting to take the supplements. However, if they missed these 
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supplements participants carried on taking supplements for additional days at the end 
of the supplementation period. This ensured all participants took the full dose of 
vitamin D supplements.  
"If I did miss some, I had them the next day but not in double 
quantities, I merely went on for a little bit longer, which is why I've 
got one more lot to do." (Participant 026, female, Vitamin D 
intervention) 
5.4.6.7 Sub theme 4.7: Barriers to POW website usage 
In terms of barriers to engagement with POW, participants, particularly those who did 
not comply with the online component of the PA intervention, reported a preference 
for paper-based resources and little or no experience of using the internet previously. 
“No problem [paper activity sheets], it was part of what I used to do 
at work; I used to fill a log in, I used to write a log, it was all written. 
If I had to write it in, on the computers, I would have, probably, been 
on until twelve o’ clock at night…Yes if it had all been on the 
computer, I wouldn’t have taken part; I would have phoned you up 
and said I don’t want to take part anymore.” (Participant 032, male, 
Online PA intervention) 
Non-compliers to the online PA intervention particularly expressing the perception the 
internet version of the PA intervention as a barrier due to fear of using the internet 
correctly or expressing the perception that being ‘old’ was a barrier to internet use and 
therefore avoided using the POW website. 
“And it’s my generation that never grew up with computers, so we 
often, some of us find it harder than others [using POW]” 
(Participant 022, female, Online PA intervention) 
Some participants began to engage with the website, but subsequently lost confidence 
with it after experiencing functional/technical problems with the POW activity graph 
feature. This meant that imputed steps were not correctly represented on the online 
activity graph. Some participants reported consequently losing confidence in the 
function of the website.  
‘I think it wasn’t transferring the data in the way that you were 
expecting it to, which I lost a bit of confidence in the online part 
then.” (Participant 043, male, Online PA intervention)  
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5.4.6.8 Sub theme 4.8: Facilitators to POW usage 
An important part of continued participation in PA was engagement with the physical 
activity intervention, POW. An important facilitator to compliance with the online PA 
intervention was familiarity with or previous experience of the internet as part of work 
or personal use. 
“I do most things online, even although I work on a computer at 
work, when I come home at night, I check my emails and have a look 
on Facebook and chat to my friends. Then I buy stuff, online 
shopping, I do the ASDA shopping. So I use it a lot. So, for me, it was 
just second nature to go onto the website and have a look at stuff 
on there and input my steps. So I found it really great.” (Participant 
004, female, Online PA intervention) 
5.4.6.9 Sub theme 4.9: Activity monitoring to increase activity 
The importance of monitoring activity in order to increase PA was discussed by the 
Online PA intervention participants. The majority of PA intervention participants 
mentioned at the start of the intervention they conducted a period of monitoring their 
PA, without making any changes to their PA, in order to obtain a ‘baseline’ PA level for 
reference, which they could the subsequently build upon for the rest of the 
intervention period.  
“...didn't set any goals on purpose for the first two or three weeks 
because I just wanted to see how everything was working. I wanted 
to get a picture of where I was at before I started trying to push 
myself further.” (Participant 007, male, both interventions) 
Participants then highlighted the importance of continuously building on their PA by 
competing with themselves. Participants described wanting to achieve the level of PA 
(usually counted in steps using the pedometers provided as part of the intervention) 
they had obtained the day before and feeling disappointed if they were unable to do 
this. It can be inferred from this that the monitoring PA itself was motivation to 
maintain or increase PA. 
Well, as I say, that's the sort of thing that keeps me going; I'm 
checking it all the time, I'm trying to beat yesterdays figures, and, 
when I find out I've been doing my gardening, and I'm nackered, an I 
haven't beaten yesterdays figures, it's a little bit disappointing, but 
it's just a game, isn't it? (Participant 032, male, Online PA 
intervention) 
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5.4.6.10 Sub theme 4.10: Improvements to POW step graph 
When exploring the acceptability of POW, many functionality improvements to the 
website were suggested, mostly regarding the online step graph used to visualise the 
amount of daily activity undertaken by the participant. One participant suggested that 
the graph could visualise the pattern of activity achieved more effectively by including 
a summary of the activity achieved on each day of the week. This would allow 
participants to identify any particular days of the week where their activity was 
particularly low.  
"It was to try and help identify to me, is there a same day, or days in 
the week, when I have less steps, and I look and think 'right is that 
because on the Saturday night, because I go down to the so-and-so, 
and then I'm sick on the Sunday', and that's where I would have 
liked to have seen it, over the week, and then looked at the next 
week and thought, hang on a minute, Sunday was the same last 
week, or, you did better on a Wednesday because that's your day 
off." (Participant 029, female, Online PA intervention) 
It was also suggested that a weekly email notification and summary of the participant’s 
activity would be preferable to visualise activity week to week.  
"I find that, if that side of it could be sorted out [online step graph]. 
Even if you sent the sheets [paper based activity sheets] away and 
they fed them in and put it onto the graph and maybe once a week 
you got an email or something, or 'this is how you've done this 
week', something to look at. I think you do need to have something 
to look at for your progress because there's nothing more 
motivational than looking at something and saying, oh I dipped last 
week, I'll sort it out this week. So I did find the visual side of it could 
be helpful, but I just didn't think it was working properly. Sorry. 
(Participant 007, male, both interventions) 
5.4.6.11 Sub theme 4.11: Use of POW website pages 
Most comments on the use of specific web pages within the POW website mentioned 
the use of the interactive step graph page, where participants could impute their daily 
steps as recorded by the pedometer. 
“Obviously I used the step page on a weekly basis to begin with and 
then more frequently once it went on to day.” (Participant 004, 
female, Online PA intervention) 
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It was mentioned by one participant that the POW page summarising activities 
available in the local area was useful in aiding them to think of different activities that 
were available and which they could try.  
No, it was good, it made you think about different things, that you 
could, perhaps, try, if you haven’t already tried them. (Participant 
029, female, Online PA intervention) 
One participant mentioned they did not like using the POW page allowing the 
participant to set PA goals for the coming week as they felt when they set the goal too 
high, and they were unable to achieve that goal, it was discouraging and when they set 
the goal too low, and they consistently achieved the goal, that there was no point to it. 
Not for me, no, because, if I don't achieve them, I get annoyed and 
irritated with myself, and then, if I'm achieving them every day, I 
think, 'I set those too low', so what’s the good of that? (Participant 
029, female, Online PA intervention) 
One participant also mentioned the POW page summarising possible barriers and 
solutions to increasing PA. They felt the barriers were not applicable to them and the 
solutions provided were not helpful.  
Probably a bit of both. Certainly the answers weren't helpful, but the 
barrier side of it, I think if somebody wants me to do something, 
they'll do it. The barriers, to me, they just didn't apply to me. 
(Participant 007, male, both interventions) 
5.4.6.12 Sub theme 4.12: Continuing the intervention beyond the study period  
When asked about the participant’s capability to continue with their assigned 
intervention beyond a 12 week period. Most responses which indicated a preference 
or capability for continuing with the intervention beyond 12 weeks regarded the PA 
intervention. Most participants involved in the PA intervention stated they would like 
to ‘stick to’ or keep up their increased PA beyond the end of the study. 
Now that I understand it a little bit more, it's probably been life 
changing because I'll stick to it now. I'll stick to what I'm doing. I 
realise how many steps I need to do a day and okay it might be 
chucking it down with rain or blowing a gale, but I know that I still 
need to do something (Participant 007, male, both interventions) 
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5.4.7 Theme 5: Study Experience 
There were many important aspects of the study experience which emerged during 
interviews. These included the importance of the participant’s relationship with the 
researcher, the level of communication between the researcher and participant 
throughout the study and maintaining a professional appearance when conducting the 
study.  
5.4.7.1 Sub theme 5.1: Voluntary nature of involvement 
No financial incentive was offered as part of this study, however when asked 
participants expressed that they would be uncomfortable accepting a monetary 
reward in exchange for study participation, highlighting the voluntary nature of 
participation.  
“That’s not why I did it. I didn’t expect anything back. Actually I’d 
feel uncomfortable with that…because I think if you do something 
like this there shouldn’t be a monetary reward. You’re doing it to 
help yourself, not for what money you can gain out of it.” 
(Participant 003, female, Vitamin D intervention) 
5.4.7.2 Sub theme 5.2: Participants relationship with the researcher 
Some participants viewed it as important that the researcher puts the participant at 
ease during study appointments in order to ‘get the best’ out of the participant. The 
level of familiarity and rapport with the researcher was also important with 
participants preferring to maintain contact with the same researcher throughout the 
study duration. 
“I think it’s been nice having the same person each time. I mean I 
don’t know how other studies particularly work but, you know, so 
that by the time you’ve been more than once you’re coming to see 
someone you’ve already met. I think that’s good.” (Participant 038, 
female, Vitamin D intervention) 
5.4.7.3 Sub theme 5.3: Communication 
The speed and consistency of communication throughout the study was also viewed as 
important. One participant referred specifically to a ‘gap’ between the first 6 weeks of 
their pilot intervention study and the study visit which would begin their second 6 
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weeks of the pilot intervention study. This gap or lag in communication was viewed as 
potentially off putting. 
“Like I said earlier, I think that might have out a lot of people off 
[time delay in responses from researcher], you know, because, I 
don’t know, it might be down to me, but when I commit to 
something, I’m gonna do something. I’m up for it, ready to, you 
know, right, let’s get started! That’s probably down to me more than 
anything else.” (Participant 007, male, both interventions) 
5.4.7.4 Sub theme 5.4: Professional demeanour 
One participant specified the importance of a professionally run study through the 
allocation of appropriately trained staff. One participant spoke about the provision of a 
receptionist rather than fellow students to the study to take study calls and pass on 
messages to the researchers. This kind of professional approach was thought to 
increase the credibility of the study.  
“The people who were answering the phone were hardly what you 
would call receptionists. They were probably fellow students and 
they didn’t know when you were coming in or they might or might 
not take the information. I mean that really was rather poor quite 
frankly because you weren’t put in the mood for believing it to be a 
doctoral student’s piece of work…” (Participant 026, female, Vitamin 
D intervention) 
5.4.7.5 Sub theme 5.5: Hope the study will provide future benefit 
Finally participants reported hope in that the results of the study would provide future 
benefit by informing future healthcare and giving benefit to other patients. It was 
hoped that the results from this study contribute towards medical advancements 
which could be used in the treatment of KOA in the future.  
“I feel as if I’ve helped in some capacity to develop for the future, 
trying to relieve pain in the knees. If I can help in that way, at least 
I’ve tried and done something.” (Participant 037, male, Vitamin D 
intervention) 
I hope that whatever you’ve found can be, in the fullness of time, 
given in advice to the management of the condition of people.” 
(Participant 026, female, Vitamin D intervention) 
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5.5 Discussion and Recommendations 
This qualitative interview study established that participants generally felt the study 
interventions and conduct acceptable and feasible, although some barriers were 
reported and should be considered when planning a future trials. 
5.5.1 Comparison with existing literature and future implications 
5.5.1.1 Recruitment  
Regarding recruitment into the cross-sectional study, the majority of participants felt 
that the method of recruiting through GP surgeries was acceptable. In addition to this 
many participants felt that being identified by their own GP surgery gave the study 
authenticity, as if the study was ‘endorsed’ by the surgery. In support of this, a 2015 
report for the Health Research Authority (HRA) which collected the opinions of 110 
members of the public about their opinions of recruitment into clinical trials 
expressed, when asked about searching of GP records to identify patients for clinical 
trials research, that most people supported the searching of records by research 
nurses and non- clinical NHS doctors, with the caveat that high levels of data security 
and patient anonymity were observed[273]. 
When investigating reasons people had for participating in the study, it was found that 
motivations centred on a desire to improve their overall health and wellbeing by 
improving their KOA or losing weight, and a desire to help others by contributing to 
research. A systematic review of the barriers to participation in clinical trials[220] also 
found the most commonly mentioned motivation for participation in clinical research 
studies was identified as altruism. 
We also identified as part of this study many facilitators to participation such as 
provision of transport and appointment flexibility. It has been previously reported that 
travel related costs were potential reasons for refusing participation or poor retention 
[220] and that making sure study visits take place at convenient times (e.g. after 
participant working hours or weekends) and locations were an important 
facilitator[220]for participation in their study [274]. The importance of addressing 
these ‘patient related barriers’ to participation in clinical studies has been previously 
emphasised as a means to improve study recruitment and retention [275]. 
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Finally, participants identified several potential barriers to participation in the studies. 
One participant described how his family had discouraged his involvement in the study 
due to a distrust of medical research. The influence of ‘important people’ to the 
participant (e.g. family members, spouses and friends) has been previously 
acknowledged, with participation more unlikely if these important people are against 
participation[220].  Mistrust of medical research is a factor which and been linked to 
low participation and retention in research studies [275]. Many participants also 
expressed they found the use of certain terms in the recruitment materials as 
potentially off-putting and offensive, such as the terms ‘obese’ and ‘older’. 
5.5.1.2 Study Measures and Visits 
The majority of participants reported that the hospital was an appropriate setting for 
conduct of the study and felt this location provided the study with credibility and a 
higher level of safety. However, transport to the hospital was identified as an issue, 
with a particular dislike of hospital car parking charges and finding a place to park. 
There were many thoughts on the consenting process, with some participants 
confused about why consent was required while other participants saw it as a normal 
part of participating in a research study. However, a systematic review surmised that in 
general, study participants prefer to sign a consent form even if they don’t fully 
understand the purpose of the consent form [220]. One participant reported concern 
over the consent form rooted in a distrust of medical research, with some fear that 
they may be giving consent to something unpleasant. This may be unsurprising 
considering, in a study examining 732 participants views on the consent process before 
surgery, that 10% participants did not understand what they agreed to on the consent 
form[276]. This suggests that greater time and clarity may be required when the 
researcher reviews the consent form with the participant. Previous literature suggests 
such a strategy would be successful in improving participant understanding of consent. 
A 2004 systematic review assessing interventions to improve participant 
understanding of the consent process showed extending the duration of the consent 
discussion between the researcher and participant significantly improved participant 
understanding [277]. In support of this, a quarter of the participants of this pilot 
intervention study noted they preferred completing the consent form in discussion 
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with the researcher during the study visit as this provided the participant with the 
opportunity to ask questions. 
Most study participants expressed that having blood samples taken during the study 
was acceptable as they were used to having blood taken and had experienced this 
previously in a clinical setting. However, some participants reported a dislike of the 
DBS blood collection method, with the main reason for this being a dislike of the 
associated pain and of giving blood samples. However despite this, (as reported in 
Chapter 4) compliance to DBS measurements across all time points in the pilot 
intervention study was high at 90%. This level of compliance to DBS measurements 
and the concepts expressed regarding issues in providing DBS samples is similar to 
what has been reported in a2009 study, which assessed the use of the DBS 
methodology and resulted in84% participants agreeing to provide DBS samples. The  
main reported reasons for refusal to provide a DBS sample in this study was use of 
medications (e.g. use of blood thinners), dislike of potential pain, blood and needles 
and belief the procedure was unnecessary, invasive or dangerous [278]. 
Many issues regarding the monitoring of participants’ activity post visit using activity 
monitors (accelerometers) were discussed. These issues mostly concerned comfort 
(with some participants commenting that the elastic belt was irritating and itchy), the 
concept of being monitored (with the fear of being seen as lazy when they were not 
moving) and the impact of external factors (such as illness) on the amount of activity 
recorded. There are few studies that have qualitatively assessed the views of 
participants on accelerometer use for clinical trials. One study comparing the 
acceptability of accelerometers, pedometers and questionnaires for assessing PA in 
bronchiectasis patients found the accelerometers (actigraph 9.42) easy to use. 
However, as with this study, participants found the elasticated belt uncomfortable and 
experienced problems with the belt moving or twisting. One of the strategies 
employed by participants to address this problem was by putting the elastic belt 
through belt loops[279]. 
5.5.1.3 Study Materials 
Through the qualitative interview study we also gained insight on the appropriateness 
of study materials regarding their comprehensiveness and clarity. Through this 
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examination of the study materials we were also able to highlight several 
improvements which could be made which could potentially increase participant 
recruitment and understanding of the study, e.g. changing of the terms used to 
describe obesity and age which were thought to be ‘off putting’ and ‘offensive’. 
Sensitivity to terminology used in the way certain treatment conditions are described 
is recommended. It is suggested to avoid use of potentially off putting terminology, 
members of the study population are consulted at the design phase of study 
documents to identify any necessary changes, ensuring the documents are appropriate 
for the target study population [275]. 
Participants stated the intervention instructions were easy to understand. The majority 
of the Vitamin D intervention participants stated that the pill cases containing the 
Vitamin D supplements were easy to use and facilitated compliance by allowing the 
participants to visualise and track which supplements they had taken. One exception 
was a participant who stated that they found it difficult to open the pill cases and open 
the blister packs containing the Vitamin D supplements. The use of pill cases in 
delivering drug interventions is common; [280]however, the effectiveness of their use, 
particularly in nutritional supplementation interventions, has been rarely reviewed. 
One study, the TRACE study delivering daily Vitamin C and E supplements in a 2x2 
factorial placebo controlled design over 2 months, found99% supplements were taken 
without pill organisers and 100% taken with pill organisers (no significant difference) 
[280]. Another study, the VITAL study, a 4 month placebo controlled antioxidant 
supplementation study comparing 7 day pill organisers (n=148) and blister packs 
marked with days of the week (n=149),found adherence significantly (p=0.05) differed 
according to supplement delivery method, with adherence higher in the blister pack 
delivery group in the lowest tertile of pill count (lowest number of pills taken)[280]. 
The pedometer provided as part of the online PA programme was routinely used by 
participants and was seen as a motivator and facilitator to monitoring daily activity. 
The use of pedometers in physical activity interventions is widespread and has been 
seen to significantly increase activity by a mean 2491 steps/day compared to controls 
(p=<0.001) according to a systematic review of 8 RCTs[281].  Pedometers as facilitators 
and motivators for activity has been explored before in a 2016 study of 12 cardiac 
rehabilitation patient provided with a pedometer based tele-rehabilitation PA 
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intervention. Themes which emerged from analysis of qualitative interviews were that 
patients gained awareness of their PA and consequently were able make personalised 
PA goals. This allowed participants to tailor their PA to fit into their daily lives and 
provided them with independence to choose when and how they increased their PA 
[282].  
5.5.1.4 Pilot Intervention Study 
Most importantly, during this study we explored the acceptability of the pilot study 
interventions. This was important to assess as both of these pilot interventions 
(Vitamin D supplementation and online physical activity programme) had not been 
administered in this particular study population (older, obese adults with symptomatic 
KOA) as part of a clinical trial before this PhD project began. It was therefore important 
to determine if these interventions were acceptable and appealing to participants as 
part of a pilot study before conducting a full scale RCT [195]. As part of this qualitative 
interview study, rich data on practical issues which occurred as part of the 
interventions was collected and analysed to provide recommendations on how to 
improve these pilot interventions to make them more acceptable to the study 
population. 
We established many motivations and barriers to intervention retention and 
engagement. The barriers and motivators to PA in KOA patients have been well 
explored in other qualitative studies [243, 246-248, 252, 254, 283]. Many of the 
themes which emerged from our own qualitative study reflected what was found in 
other qualitative studies looking at barriers to exercise interventions in older 
participants with KOA, including lack of suitable environments for activity (due to bad 
weather, lack of facilities and equipment), poor personal health, current injury, fear of 
side effects or ‘pushing oneself too far’ and competing responsibilities and life events 
[243, 248, 252].Themes regarding motivators and facilitators to exercise from this 
study also reflected those found previously on exercise interventions in older adults 
with KOA, including the influence of social support (including friends, family and pets) 
and desire to lose weight [248, 252]. In addition to this, our study identified that guilt 
of not complying or ‘letting down the researcher’ also facilitated adherence to the 
interventions, suggesting the participant’s relationship with the researcher is also an 
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important aspect of the interventions. A less well-explored area of research is the use 
of web based physical activity interventions, particularly in older and KOA populations. 
A recent systematic review [284] of internet based physical activity interventions 
showed 54/72 of the paper intervention identified used health adults. Of the 18/72 PA 
interventions in disease populations, the majority of online PA interventions were 
targeted to Type 2 diabetes populations (7/72 papers) followed by Heart disease 
(3/72) and MS (2/72) populations. Only one online PA intervention was found in an 
arthritic/fibromyalgic population, which provided online PA lessons and self-
assessments to an intervention group and a standard care group. No improvement in 
self-reported PA measures was observed between the online PA and standard care 
groups [285]. Most of these existing studies of online PA interventions were also 
conducted in a younger to middle aged population, with an average age of 40.2years in 
the healthy populations and 51.6 years in disease populations [286]. While there have 
been no studies investigating the use of an online platform for delivery of PA 
intervention to older adults with KOA, studies have been conducted to understand the 
views of older people on internet use. Many of the barriers to internet use we 
identified such as ‘being too old’ and ‘difficulty in using the internet’ have been 
identified in other qualitative studies, suggesting these are prevalent views amongst 
the older population [287]. Considering the gaps identified in the current literature, 
the themes which have emerged regarding the use of our online PA programme in 
older obese adults with KOA is therefore unique data which can be applied to the 
future design and conduct of studies delivering online PA interventions to the same 
study population. 
5.5.1.5 Study Experience 
Regarding study experience, it was concluded the participant’s relationship with the 
researcher, particularly the familiarity and rapport developed throughout the study, 
was an important aspect of the study experience, which meant during the study visits, 
participants were more at ease. This concept of ‘building trust’ has been reported 
previously, specifically in the context of qualitative research. Prolonged engagement 
with participants in studies allows the building of trust and rapport between 
participant and researcher, which means the participant may be more comfortable 
disclosing information about themselves[288]. 
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The appropriateness and effectiveness of providing monetary compensation for 
participation in research studies is unclear [289].  Previous studies have noted that 
participants who express financial incentives as the main motivator for participation in 
studies are more likely to have high attrition. This highlights that although financial 
incentives may trigger interest in a study, it is not the key factor in maintain 
engagement with a study till the end [275]. The views of the participants of this study 
was that they would not be comfortable receiving monetary incentives and that they 
felt participation should be voluntary without the need for payment. However, as no 
financial incentives were offered as part of this cross-sectional or pilot intervention 
studies, beyond compensation for travel, this participant population may be biased as 
a self-selected set individuals who ascribe to this belief (individuals who would prefer 
monetary compensation may not have participated in this study). 
5.5.2 Study Strengths and limitations 
One of the strengths of this qualitative study is that it could be combined with the 
objective data from the cross-sectional and pilot intervention studies to provide a 
mixed methods design, which has allowed us to review the feasibility and acceptability 
of the study measures, materials and interventions. This mixed methods approach is 
important in providing multiple views, approaches to review during our pilot study, as 
a measure or procedure may be accurate, and clinically relevant however, it may be 
affected by factors independent to the study. E.g. within this study accelerometers 
were used as an accurate, objective method of measuring activity however due to 
technical issues (such as monitor placement and movement) and external factors (such 
as injury and illness), the activity data collected may not be representative of the 
participants usual activity at that time point. Therefore piloting the study measures 
helps to identify what the most feasible and realistic outcome measure may be, while 
ensuring accuracy and relevance of the measure to the aims of the study [195]. 
Another strength of this study was the approach to a deviant case which emerged 
within our study sample. To explain why the views of the deviant case differed from 
the rest of the study sample, we drew upon several comments from the participant 
regarding her previous career and experiences. As this particular participant’s previous 
career was within a research environment, many of the views expressed by this 
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participant were contradictory or unique due to the different perspective this 
participant had regarding the research studies they had conducted themselves. The 
participant therefore had very specific views on methodology and quality within the 
study which were unique to their specific experiences and views as a researcher 
themselves. [271] 
There were a number of limitations to our qualitative interview study which should be 
highlighted. Firstly to obtain sufficient data, all participants who took part in the pilot 
intervention study (n=17) were invited to take part in the qualitative interview study 
(of which only 1 refused to participate. Due to the low participant pool for the 
qualitative study we were unable to obtain a purposeful sample of participants and 
instead obtained a convenience sample based availability. Despite this all participants 
had taken part in the pilot intervention study, and therefore were able to provide their 
views on each of the qualitative interview study aims (see section 5.2). Therefore I do 
not believe this alteration in sampling method significantly impacted on the fulfilment 
of the aims and objectives of the study. However ideally a larger sample would allowed 
us to have picked a purposeful sample of participants we believed could have provided 
rich and varied data on each of the study aims.  
Secondly, due to our sampling only pilot intervention participants, we obtained a 
relatively homogenous study population. Therefore the qualitative data collected 
reflects the view of those participants who consented to recruitment and participation 
in the studies. In order to collect a more heterogeneous view of issues such as 
recruitment and compliance, interviews need to be conducted with those people who, 
for example, refused recruitment to the original cross-sectional or pilot intervention 
studies, or who did not adhere to the studies. 
5.5.3 Implications for further research 
We aim for the results from the cross-sectional and pilot intervention studies in 
combination with the context provided by the qualitative interview study to provide 
recommendations for conduct of future trials of vitamin D and online based PA 
interventions in this study population. Below the recommendations based upon the 
results of the qualitative interview study (in the context of the categories explored) are 
summarised. 
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5.5.3.1 Study Recruitment 
 Based on the finding that recruitment from GP surgeries was feasible 
(resulting in recruitment of n=45 participants) and acceptable (with 
participants expressing they felt recruitment from their GP surgery gave the 
study a sense of authenticity and safety), we therefore recommend that 
follow on studies should consider this method of recruitment. 
 Resulting from concerns discussed in the interviews regarding ‘permission 
to be contacted’ for participation in research studies, we suggest that 
future researchers or GPs discuss potential participation in a research study 
with individual participants before study recruitment materials are mailed 
out. 
 The importance of appointment flexibility in facilitating study participation 
has been highlighted in previous literature [220]. In this qualitative 
interview study, we also found that participants felt flexible appointment 
times facilitated study participation. We therefore recommend study teams 
make sure a range of appointment dates and times (morning to evening) 
are available for participants and that appointments are organised by 
telephone so participants can suggest the most suitable time and date for 
themselves. 
5.5.3.2 Study Visits and Measures 
 In this study, participant’s identified several issues regarding accessibility to the 
study site, including difficulty finding parking bays within the hospital site, 
hospital parking charges and difficulty in using public transport. Provision of 
transport (e.g. taxis) or compensation for travel (e.g. reimbursement of bus 
tickets or car journeys) has also been highlighted in previous literature as a 
facilitator to study participation [220]. As it is essential can access the study site 
without difficulty to facilitate participation and retention we therefore 
recommend the provision of travel as part of future studies e.g. provision of 
taxis to take participants to and from study visits, and/or recompensation for 
parking charges, bus fare and mileage if participant choose to travel by car or 
bus to study visits. 
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 As some participants expressed confusion over what the consent form meant 
and why it was required, we recommend extending the consent discussion 
between the researcher and participant, splitting the consent form into simple 
bullet points and providing participants with their own copy of the consent 
form to review later if desired (all strategies previously reported to improve 
participant understanding of the consent process [277]). 
 Some participants expressed a misunderstanding of what the activity monitors 
were able to record and felt it may be recording things which were intrusive. 
We therefore recommend that researchers provide further explanation of the 
activity monitor, how it works and what it records, with a small example of the 
activity monitor output. This information should also be included in the activity 
monitor information sheet so participants can review the information at a later 
date if they wish. 
 Some participants highlighted instances where they felt external factors (e.g. 
illness) affected their activity levels, and therefore they felt the activity levels 
recorded by the activity monitor may not have been representative of their 
usual routine. We therefore recommend extending the activity monitor 
recording period from 5 days to 7 days. 7 days activity monitoring is routinely 
used as the ‘gold standard’ of activity monitoring time in PA research as this 
allows monitoring of all weekdays and weekends, allowing patterns of weekly 
activity to be measured. Increased monitoring time also accounts for greater 
within participant and between participant variation[219]. We also recommend 
participants use of a log to record significant events during activity monitoring, 
e.g. injury preventing activity, to monitor any deviations in regular activity. 
5.5.3.3 Study Materials  
 Some terminology used as part of the recruitment materials, particularly 
regarding obesity and age, was considered insensitive and potentially offensive 
to potential participants. We therefore recommend avoiding use of the terms 
‘older’ and ‘obese’ as part of participant materials and recommend piloting 
materials amongst groups with similar demographics to the  to identify optimal 
terms (prior to study recruitment) regarding weight and age to use within 
materials.   
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 Receiving individual feedback in this study was viewed positively and additions 
to the data included in this feedback were recommended by participants (e.g. 
feedback on how to improve individual health status). Based on this we 
recommend the participant should be sent written feedback on the 
measurements taken as part of the study with a clear explanation of what the 
measures mean. Feedback should also be sent to the participant’s GP surgery if 
participant’s wish it, including recommendations to the GP to follow up any 
abnormal results with the participant.  
 We conclude the mode of delivery (post) of the pilot intervention materials 
employed in this pilot intervention study was acceptable to participants. We 
therefore recommend that future studies use a similar approach by posting 
materials required for the pilot intervention to the participant’s home address 
and therefore reducing burden on the participant. To ensure an accurate 
tracking of materials, the pilot intervention pack should include a receipt to 
confirm correct delivery which should be returned to the study team and we 
recommend the mail out should be followed a phone call by the study team to 
the participant to review instructions and confirm participants understanding 
of the intervention.  
 This study confirmed that delivery of vitamin D supplements in pill cases was 
acceptable for participants of the Vitamin D intervention and facilitated 
compliance to the vitamin D intervention. However previous literature suggests 
use of blister packs labelled with days of the week is more effective in 
facilitating compliance to medication [280], and so we recommend a trial of the 
use of labelled blister packs for delivery of vitamin D supplements/matching 
placebos in future studies. 
 Participants of the online PA intervention felt that provision of pedometers for 
activity monitoring was motivating for participants to increase their PA. We 
therefore recommend pedometers should be provided to all participants as 
part of the online physical activity intervention to allow participants to monitor 
their own PA and as a motivation tool to increase PA. 
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5.5.3.4 Pilot Interventions: Vitamin D supplementation and Online PA Intervention 
 As some participants expressed confusion about the study arm allocation 
process (specifically how participants are allocated to each study arm), we 
recommend in future studies the study arm allocation process should be clearly 
and adequately explained in the PIS and discussed face to face with participants 
during recruitment to the intervention study to ensure understanding. 
 As there were participant concerns over intervention safety in both 
intervention groups(specifically fear of side effects in the Vitamin D 
supplementation group and fear of injury in the online PA group), we 
recommend intervention safety is thoroughly discussed before the participant 
commences the intervention. It should also be made clear that participants can 
contact the research team should there be any issues or concerns over safety 
and that specific signs and symptoms of potential intervention side effects 
should also be assessed during all intervention study visits.  
 As some participants expressed a specific dislike of the online format of the PA 
intervention and a preference for a paper based intervention, we recommend 
an individualised approach to the PA intervention, offering the POW 
programme as both a paper based and an online based intervention, thereby 
providing participants with a choice of intervention format.  
 As during the pilot intervention study there was a lack of confidence regarding 
using the POW website due to technical difficulties with the function of 
websites step graph feature, we recommend full pilot testing the POW website 
(with a subsection of age appropriate pilot testers) before the further studies 
commence to identify any technical or usage problems. 
 We recommend the implementation of some of the recommendation made by 
participants for improving the functionality of the POW website, e.g. changes 
the activity graph output to display individual days of the week so participants 
can identify patterns in activity and the addition of weekly email activity 
summaries to participants. 
5.5.3.5 Study Materials 
 Familiarity and rapport with the researcher was identified as an important 
aspect of the study experience by participants in this study. We therefore 
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recommend the same researcher/staff are maintained for participants 
throughout the duration of future studies. 
 The maintenance of a professional demeanour during the study e.g. by 
allocation of a receptionist rather than students, was highlighted particularly by 
one participant. Therefore, if resources allow, allocations of specialised staff 
e.g. receptions, clinicians and researchers, should be allocated to appropriate 
roles within the study. 
 Speed and consistency of the communication throughout the study was 
highlighted as an issue to participants, with some expressing they felt 
‘forgotten about’ during large gaps in communication with the study team. To 
avoid gaps in communication, we recommend the allocation of dedicated 
research or administrative staff to maintain consistent and timely 
communication with participants during studies.  
5.6 Conclusions 
This qualitative interview has identified participant views on the acceptability and 
feasibility of the whole study process from recruitment to participation in the vitamin 
D supplementation and online PA interventions, as specified in the study aims. We 
believe we obtained a sufficient participant sample from our pilot intervention study 
participants (n-=16) to achieve data saturation (evidenced as no new themes emerged 
within analysis of the final two interview transcripts). During analysis of the qualitative 
interview data, we identified prevalent themes, which have informed the many 
important recommendations for future studies of this kind, including:  
 Recruitment from the screening of GP surgeries in northeast England was 
generally acceptable to participants however concerns regarding ‘permission to 
contact’ for study participation need to be addressed in future studies. 
 Most participants found the study measures and procedures acceptable, with 
only few minor issues identified. Comfort (particularly regarding the elasticated 
belt) and movement of the accelerometer were identified as issues by 
participants, which have been reflected by the results of a previous study [279]. 
We therefore recommend the placement of accelerometers through belt loops 
where possible. 
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 When reviewing written study materials, participants found some of the 
terminology used potentially offensive. We therefore recommend piloting 
when designing study documents to ensure the documents are appropriate for 
the target study population. 
 Pilot intervention participants generally viewed the materials provided as part 
of each intervention as acceptable and useful, and in some instances facilitated 
intervention compliance (e.g. pill cases and pedometers) 
 Several key facilitators (social support and activity monitoring) and barriers 
(disruptions to daily routine, bad weather, illness or injury and sedentary work 
environments) to increasing physical activity were identified and could be 
addressed to provide a more effective interventions. 
 Lack of compliance to the POW programme depended on a preference for a 
paper based intervention and a fear of using the internet 'incorrectly' while 
compliance was mediated by previous experience with using the internet. More 
flexibility in mode of physical activity intervention delivery according to 
participant’s preferences is recommended to increase intervention compliance. 
  
 238 
Chapter 6. General Discussion 
6.1 Main Findings and Relation to the Literature 
This PhD project aimed to explore relationships between vitamin D status, physical 
activity and KOA symptoms as part of cross-sectional study and to pilot an intervention 
study designed to deliver Vitamin D supplementation and an online physical activity 
intervention in older, obese people with symptomatic KOA. The project had several 
distinct, but inter-related, objectives which are summarised in Table 6.1. 
Study Design and Date 
Conducted 
Study Objective 
Cross-sectional study 
(April 2015, October-December 
2015) 
To explore relationships between circulating 
concentrations of Vitamin D, objectively 
measured PA and KOA symptoms in older obese 
adults with symptomatic KOA. 
Pilot intervention study 
(January-July 2016) 
To design and implement a pilot intervention 
study to assess the acceptability and feasibility of 
a vitamin D supplementation intervention and/or 
a web-based PA intervention in older obese 
adults with symptomatic KOA. 
Qualitative interview study  
(March-July 2016) 
To assess participant's views on the acceptability 
and feasibility of key aspects of the intervention 
study including procedures for recruitment, 
intervention modalities and outcome measures. 
Table 6.1: Summary of the objectives and specific studies conducted in this PhD project 
The three studies were set up and conducted from September 2013-July 2016. During 
this time participants were recruited and screened against the study eligibility criteria. 
Eligible participants were invited to take part in a single 90 minute cross-sectional 
study at NTGH. In addition, cross-sectional study participants were screened against 
the pilot interventional study criteria. Eligible participants were invited to take part in 
 239 
the 3 month pilot intervention study, which included an initial study pack mail out, and 
a midpoint (6 week) and end point (12 week) study visit at NTGH. The qualitative 
interview study took place directly after the 12 week pilot intervention study visit. 
The main findings from these three studies were: 
1. That recruitment of older obese patients with symptomatic KOA though a 
clinical route is best achieved using primary care (North East GP surgeries) sites 
rather than secondary care sites (Liverpool hospital outpatient clinics). The 
availability of formal support mechanisms, including specialist recruitment 
staff, (through CRN and the local NHS commissioning group), aided with 
recruitment of primary care sites (GP surgeries). Recruiting from primary care 
enabled the screening of large numbers of North East population (n=57,229) 
across 8/153 GP surgeries. From those screened, n=791 (1.38% people 
registered to the recruited GP practices) met our study eligibility criteria. When 
these data are compared with the prevalence data for individuals with KOA in 
the North East (using the closest available filters to our study inclusion criteria. 
aged 45-74 and BMI >30kg/m2) reported by ARUK [202], this showed that I 
identified and contacted 4.3% of potentially available potentially eligible 
participants in Northumberland, Newcastle Upon Tyne and North Tyneside. 
However, for this pilot study, I recruited only 8 of the 153 GP practices in the 
North East. These 8 practices are responsible for 7.2% of Northumberland, 
Newcastle upon Tyne and North Tyneside (areas where recruitment took place 
in this study) so, extrapolating to all GP practices, these data suggest that this 
recruitment strategy has the potential to identify 55.2% (n=11,155) of the total 
potentially eligible patients in this region. 
2. Recruitment from secondary care sites (Liverpool UHA outpatient clinics) was 
unsuccessful in recruiting any potential participants for this study. To 
determine the reasons for this failure, I undertook a post hoc analysis in which I 
reviewed the case notes for n=2202 hospital referrals sent to UHA outpatient 
clinics between November 2015 and February 2016. This revealed that the two 
most common reasons for potential participant exclusion during referral 
screening were the non-reporting of patient BMI on referrals (1780/2202) and 
low number of patients diagnosed with KOA (171/2202). As a result only n=8 
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potential participants, who met all study eligibility criteria, were identified from 
hospital referral screening of 2202 referral notes. Additionally there was no 
formal support processes, unlike primary care recruitment, to aid with 
recruitment in the outpatient clinics. Also as referral documents sent to the 
outpatient clinics were paper based, this meant referrals had to be screened 
manually, which was both labour and time intensive. Lastly, most KOA patients 
are managed in primary care (according to NICE guidelines [10]), and those 
referred to secondary care clinics for specialist services, e.g. physiotherapy and 
manual therapy, or for more advanced treatment, e.g. joint surgeries and 
procedures, are likely to be the more difficult/ advanced cases. The latter may 
also have more concurrent disease which would make them ineligible for my 
study. 
3. The cross-sectional study confirmed that objectively measured activity levels in 
older, obese people with KOA were low in comparison with the general UK 
population. In summary, 41% of my participants were classed as physically 
inactive (<30mins moderate activity/week) and only 27% met the UK 
Department of Health (DoH) PA guidelines[217]. This compares with the 
general UK population in which 26-27% were classed as inactive and 55% met 
the UK guidelines(based upon PA data compiled by the BHF)[163]. A 2013 
meta-analysis of 2 studies (n=1250) in KOA populations which reported only 
13% participants met the DoH PA guidelines (>150mins MPA per week) and the 
total sample  had a  weighted mean average of MVPA at 50mins/week[162].It 
has been suggested that this disparity in PA amongst KOA and non-KOA groups 
is due to both disease related (e.g. pain, dysfunction and disease severity) and 
non-disease related factors (e.g. age, sex and BMI) [223, 224, 290]. The low 
levels of activity seen in people with KOA in comparison to the general UK 
population as defined by DoH PA recommendations highlight the need to 
increase PA in this clinical population, not only as a means to managing their 
disease [10] but also because of the positive effects of greater PA on many 
aspects of physical and mental health [291]. Closing the PA gap between 
people with KOA and the general population by increasing levels of moderate 
activity, may improve both KOA symptoms and overall health. In the cross-
sectional study, it was observed that time to complete the timed up and go test 
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was a mean 1.9 seconds longer in the inactive participants compared to 
participants which met PA guidelines. This suggests that the participants who 
met PA guideline had better physical function than those who were classed as 
inactive. This observation has been reported previously in a cross-sectionals 
study of160 older overweight and obese adults with KOA  in which there was a 
significant correlation between Short Physical Performance Battery Score 
(SPPB) (a 10 minute battery of test designed to measure lower extremity 
function [292]) and time (mins) spent in MVPA (r=0.315, p=<0.001) [225]. 
4. In this cross sectional study, there was little observable differences in KOA 
symptoms by vitamin D status. In the literature, the previous evidence 
regarding relationships between serum 25OHD concentrations and KOA 
symptoms is limited. A systematic review [93] concluded that there is limited 
evidence (only 2 cross-sectional studies) which have reported the relationship 
between symptomatic KOA and 25OHD concentrations. However a more recent 
cross-sectional study of 256 adults aged 45-85 years with ACR defined 
symptomatic KOA showed a significant negative correlation between self-
reported KOA pain (WOMAC pain scale 0-20) and serum 25OHD concentrations 
(r=-0.25, p<0.01) and significant differences in WOMAC pain score observed 
between participants with adequate (>75nmol/L) Vitamin D concentrations and 
participants with deficient (<50nmol/L) (p<0.001) and insufficient (51-
74nmol/L) (p= <0.016) Vitamin D concentrations[293]. However another cross 
sectional study of 148 patients explored the association between 25OHD 
concentrations and presence of diagnosed symptomatic KOA by age and found 
a positive relationship in those <60 years (OR: 2.26, 95%CI: 1.15-4.4, P=0.018) 
but not in those >60 years old (OR: 1.01, 95% CI: 0.48-5.9, P=0.96)[229].  
Several theories about how 25OHD status may relate to knee pain in KOA have 
been proposed including : i) the increased bone turnover which occurs during 
KOA leads to increased sensitivity to normal mechanical forces [294] and ii) that 
decreased 25OHD promotes a chronic pro-inflammatory state which increases 
pain sensitivity [295-297].  
5. During this pilot intervention study we were able to test the feasibility of 
randomisation and study arm allocation. We found that given our study 
eligibility criteria for the Vitamin D supplementation and web-based PA 
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programme, there were very few of our cross-sectional study cohort who met 
both of these criteria, 6/45 (13%), and were therefore able to be randomised to 
one of the 4 originally planned study intervention arms (standard care, vitamin 
D supplementation, web-based PA programme, or both interventions). This 
suggests you would need to screen and invite very large numbers of people to 
achieve a RCT design. E.g. if we extrapolate our pilot study recruitment and 
retention data to the number of participants estimated to be eligible for our 
study in north eastern England by ARUK[17], from a pool of 9619 potential 
participants (who have been screened for eligibility and sent study information) 
we could expect 72 participants to be eligible for and recruited to a RCT study. 
It is therefore clear that conducting a RCT study would be a large undertaking 
and may involve the collaboration of several study teams as part of a multisite 
study approach.   
6. The 12 week pilot interventional study demonstrated that Vitamin D 
supplementation and Online PA interventions were feasible and effective in 
their intended purpose. Supplementation with 2000IU (50µg) of D3/day 
increased 25OHD concentrations by 51(±23.1) nmol/L(95% CI 33.2, 68.8) and 
compliance to the Vitamin D intervention was high (99.1% i.e. 1499/1512 
supplements taken). In contrast, compliance with the web-based PA 
programme was lower (66.6%; (6/9)) participants logged onto the online PA 
programme beyond the registration. The amount of time that participants 
spent using the online PA programme was highly variable with an average total 
97 (±78) minutes and a mean interval of 4 days (±2.1) between visits. From 
baseline to week 12 of the PA intervention, % time sedentary decreased and 
time spent in moderate intensity activities increased by 5.8% and 1.0% 
respectively. Change in average daily time spent in sedentary activity 
throughout the 3 month intervention increased from baseline to week 12 in 
non-compliers (participant who did not utilise the POW website) (+17 (±80.3) 
mins) while sedentary time reduced in compliers (participants who did utilise 
the POW website) by -170 (±215.3) mins. Interestingly non-compliers achieved 
greater increases in average daily time in moderate activity from baseline to 
week 12 of the pilot intervention study of +9 (±7.3) mins compared to +2 
(±10.4) mins in compliers. Evidence of the effectiveness of 72 web-based PA 
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programmes was summarised in a 2013 systematic review [286]. This review 
found that 37 studies targeted PA as the sole intervention outcome and only 1 
paper was conducted in an arthritic population. Only 7 studies assessed PA 
objectively using accelerometers or pedometers and significant improvements 
in PA were seen in 86% (6/7) of these studies [286]. The sole RCT reporting the 
use of a web-based PA intervention in an osteoarthritic populations tested the 
use of a 9 week web-based intervention ("Join2move" intervention) in 100 
older (50-75 years) KOA/HOA participants. Engagement with this PA 
programme resulted in no improvement in PA at 3 months but there was 
evidence of improvement in subjective (+ 21.2 points, 95% CI 3.6-38.9) and 
objective (+24 mins Light/Moderate/Vigorous PA, 95% CI 0.5-46.8) measures of 
PA after 12 months [262]. 
7. In the pilot intervention study, there was no evidence that increasing 25OHD 
status changed any self-reported KOA symptom. However, it is important to 
note that this was a pilot study designed to investigate acceptability and 
feasibility and was not powered to detect effects of the intervention modalities 
on KOA symptoms. Evidence from RCTs of the effects of vitamin D 
supplementation on KOA symptoms is very limited. A 2013 RCT delivering 
2000IU (50µg) (with subsequent dose adjustment) Vitamin D over 2 years in a 
symptomatic KOA population found although knee pain (WOMAC, 0-20 points) 
decreased in both the Vitamin D supplementation (-2.31, 95% CI -3.24, -1.38) 
and placebo group (-1.46, 95% CI -2.33, -0.60), this was not significant and 
there was no significant difference in change in knee pain between the 2 
treatment groups at 2 years (p=0.17). A more recent 2016 UK randomised, 
double blinded multisite study [146] recruited 474 patients >50 years and 
supplemented them with 800IU (20µg)/day cholecalciferol or a placebo over 3 
years. The authors found no significant change in KOA symptoms (WOMAC 
pain, stiffness and function, scale 0-100) with Vitamin D supplementation and 
no significant differences between the Vitamin D and placebo groups [146]. The 
fact that both of these intervention studies did not observe any relationships 
between 25OHD concentrations and KOA symptoms may be due to a major 
limitation of all currently published Vitamin D supplementation studies in that 
they did not recruit those with low 25OHD concentrations exclusively. Vitamin 
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D supplementation would be more likely to benefit those with low baseline 
25OHD concentrations, therefore supplementing those with sufficient 25OHD 
concentrations is unlikely to demonstrate any effect. This may be supported by 
the fact that sub analysis of participants in the 2013 RCT Vitamin D 
supplementation study [92] showed that change in WOMAC Pain (baseline to 
22 months) in participants with low baseline 25OHD were greater than the 
whole sample, however not significantly so (change in pain −2.7 vs. −1.0, [95% 
CI of difference, −5.3, 1.9], p = 0.36, effect size = 0.4). The advantage of this 
pilot study is that an exclusively 25OHD insufficient population participated in 
the Vitamin D intervention, therefore testing supplementation in the 
population most likely to demonstrate any potential effect. 
8. The pilot intervention study showed several significant changes in KOA 
symptom measures from baseline to week 12 in the Online PA intervention 
group, particularly in WOMAC pain (0-20) (mean difference -3.0 [95% CI: -5.2, -
0.8])and activities of daily living (0-64) (mean difference -7.3 [95% CI: -13.7, -
1.0]). The only other web-based PA programme in KOA participants [262] 
showed no significant difference in self-reported KOA symptoms in response to 
the intervention. However results from a systematic review of home-based or 
supervised aerobic or strengthening exercises in KOA patients concluded that 
there were positive effects on pain  and on self-reported disability [103].  
9. Finally my qualitative study in which I interviewed participants (n=16) who took 
part in the pilot intervention study provided insights into what did or did not 
work well from the participants’ perspective. Many of the barriers and 
facilitators to recruitment reported here had been reported in previous studies, 
such as a dislike of travel and travel related costs and a distrust of medical 
research [220]. The primary motivation for participation in clinical research 
studies was identified as altruism [220], which we also identified as part of this 
study as well as a desire to improve personal health. 
10. The qualitative interview study revealed that the terminology used in some of 
the study materials was insensitive to this particular audience and requires 
revision. Terms relating to weight, specifically ‘obese’ and ‘obesity’, and age, 
specifically ‘older’, were considered insulting by some, who felt the use of such 
language may be enough to ‘put people off’ participating in the study. The 
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importance of using the correct terminology in study documents for the study 
target population has been highlighted previously and the involvement of the 
study population at the document design stage, to ensure their 
appropriateness for that population, is a strategy to ensure this [275]. Some 
participants expressed they felt surprised at being identified as obese or older 
as they had not previously considered these terms applicable to them. This 
highlights the importance of piloting studies and of the involvement of the lay 
public in the development of study materials.  
11. The interviews with participants showed that the Vitamin D intervention was 
acceptable and the way it was delivered (e.g. via a pill case) facilitated 
compliance with the intervention. The effectiveness of use of pill cases and 
blister packs to increase compliance have also been demonstrated in previous 
vitamin supplementation studies [280]. Most participants took the Vitamin D 
supplements with their other prescribed medication, and so it became part of 
their ‘daily routine’. This is reflected in the excellent compliance with this 
intervention modality (99.1%). Minor concerns regarding potential side effects 
of Vitamin D supplementation were expressed by some participants but they 
were reassured after discussions with the researcher.  
12. Qualitative data suggested reasons why some participants did not engage with 
the web-based PA programme through the different themes which emerged 
from POW programme compliers (participants who demonstrated use of the 
POW website beyond the initial visit) and non-compliers (participants who did 
not log on to the POW website beyond an initial visit), with previous experience 
and confidence in using the internet expressed as key factors relating to the 
compliance with the POW programme. This highlights the need for a more 
personalised and multifaceted (using paper and online based interventions) 
approach to PA interventions and that a ‘one size fits all’ approach is unlikely to 
be successful in maximising compliance [298]. 
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6.2 Study strengths and limitations 
6.2.1 Study Strengths 
The pilot design of this study was important to test our study aims (to test the 
feasibility and acceptability of measuring Vitamin D and PA and providing Vitamin D 
supplementation and online PA intervention studies in this study population), 
especially as these interventions were being applied in a novel way. By exploring issues 
of study design, study management, and feasibility and acceptability of study 
recruitment, measures and interventions, I was able to provide useful 
recommendations (see section 7.4 below) for the effective conduct of a full scale study 
with the potential to save time and money and to reduce participant burden in 
subsequent studies of these interventions in this study population. The mixed methods 
design allowed me to produce quantitative data which can be used practically to 
estimate expected recruitment rates (55% of potentially eligible population), pilot 
intervention study recruitment numbers (n=234) adherence and outcomes for a north 
eastern England population, while the qualitative information provided insight into the 
context and reasons for my findings, particularly in regards to participants views on 
acceptability. Both of these data collection methods provided useful information which 
can be used to provide recommendation for future studies. 
Another major strength of this study was the development and implementation of an 
evidenced-based set of inclusion and exclusion criteria. By focussing on older people 
with obesity, I attempted to maximise the ability to recruit participants with 
symptomatic KOA who would have inadequate Vitamin D status and low PA [133, 299]. 
Recruitment of this sub-population for the cross-sectional study potentially increased 
the number of participants eligible for the subsequent intervention study. Additionally, 
application of these criteria meant that we targeted individuals who may benefit most 
from a Vitamin D supplementation and PA intervention to improve KOA symptoms. By 
recruiting those with symptomatic (and not radiographic diagnosed) KOA, we could 
test the effect of the effect of Vitamin D and PA interventions on symptoms more 
effectively. Not everyone with radiographic KOA has symptoms and not everyone with 
symptomatic KOA will have evidence of radiographic KOA [300].  
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Another study strength is that I recruited participants from primary (and attempted to 
recruit from secondary) care NHS sites using ACR defined symptomatic KOA criteria 
and excluded any other arthritic condition (e.g. Rheumatoid Arthritis). By using a 
healthcare based recruitment strategy rather than advertising to the general public, I 
hoped to prevent contamination of our participant sample with those with alternative 
or undiagnosed arthritic conditions and those who self-report KOA but may not have 
the condition. While this may make the recruitment strategy more complicated and 
time-consuming initially, in the long run I expect it to save time and resources by 
ensuring that non-eligible participants are not invited to a study visit. 
This pilot intervention study is novel in that, in contrast to previous Vitamin D 
supplementation studies, it was the first which has attempted to deliver a Vitamin D 
supplement people with symptomatic KOA who were known to be 25OHD insufficient. 
I recruited into the intervention study pre-screened participants who were defined as 
25OHD insufficient (25OHD 25-50nmol/L) (deficient participants, 25OHD <25nmol/L, 
were referred back to their primary care provider for medical treatment for ethical 
reasons). Previous vitamin D supplementation studies have included participants, 
regardless of baseline 25OHD status [90, 92]. This problem with this approach is that 
participants who are deficient in 25OHD potentially may benefit from an increase in 
25OHD. Indeed, a case could be made that those already sufficient in 25OHD may be 
unresponsive to supplementation. This is supported by the results of subgroup analysis 
of one Vitamin D supplementation study in KOA [92] in which participants with  low 
25OHD concentrations (<38nmol/L) at baseline had slightly greater, but non-
significant, improvements in KOA pain at two years (measured by WOMAC 
Questionnaire, 0-20 scale) (-2.7 [95%CI -5.3, 1.9], p=0.36, ES=~0.4) compared with the 
total treatment group (-2.31 [95%CI -3.24, -1.38], p=0.17, ES=~0.2)[92]. 
Another strength of this study is the use of objective measures, specifically 
accelerometry, to measure PA at baseline, half way point (6 weeks) and end point (12 
weeks) of the pilot intervention study. Previous studies comparing the use of 
accelerometry and self-reported questionnaires for measuring PA have shown that 
participants self-report significantly less sedentary intensity activity and higher 
vigorous intensity activity than was measured objectively [301, 302].However despite 
the clear advantages in using objective PA measures, the use of objective measures to 
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monitor PA during previous web-based PA intervention studies are sparse. A 2013 
systematic review of internet based PA interventions concluded, that from 72 studies, 
only 16 studies measured PA using an objective PA method and only 4 of the studies 
used accelerometers [284]. Further, the only other published internet-based 
intervention study in a KOA population [262] used a self-report PA questionnaire 
(n=199) to measure PA with only a subset of participants provided with accelerometers 
(n=83). The latter paper did not provide any statistical comparison between the self-
reported and objective measures used. 
6.2.2 Study Limitations 
The first limitation of this study is that due to administrative problems we were unable 
to adhere to the timelines originally laid out this study. This pilot study was originally 
designed so the cross-sectional and pilot interventional studies would take place 
during the annual ‘winter’ period (October-April [110]) when Vitamin D cannot be 
synthesised in the skin in the UK. This would ensure there would be no confounding 
effect of additional cutaneous synthesis of Vitamin D throughout the intervention 
period. However, due to the time required for an ethical amendment application to 
update and amend the eligibility criteria for the pilot intervention study, some 
participants were delayed from entering into the pilot intervention study. This meant 
that the last participant started the pilot intervention study on 02-04-2016 and 
therefore finishing the 3 month intervention on 25-06-2016. This means that 
cutaneous synthesis of Vitamin D may have occurred in some participants. This is 
confirmed by evidence that the Online PA intervention group increased mean 25OHD 
concentrations by 14.9nmol/L over the 3 month intervention, without any Vitamin D 
supplementation. However there were no significant differences in median 25OHD 
concentrations (nmol/L) Vitamin D supplemented participants who finished the 
intervention before or after April (end of ‘winter’ period) at baseline (34.5 [95%CI 86-
155] and 38 [95%CI 30-46] respectively) and week 12 (81 [95%CI -40-201] and 84 
[95%CI 73-107] respectively). 
The original study design included the piloting of a randomised 2x2 factorial 
intervention study. However the lower than anticipated numbers of participants 
recruited to the cross-sectional study and, of those, meeting both eligibility criteria for 
the intervention study (low 25OHD concentrations and low activity levels) meant that I 
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had to alter the design of the pilot study. Since the focus was on acceptability and 
feasibility of the study interventions, the decision was made to amend to study design 
to a unrandomised design allowing those eligible for only the Vitamin D intervention 
(having low 25OHD concentrations) to be assigned to the Vitamin D supplementation 
intervention and those eligible for the online PA intervention (low PA levels) to the 
online PA intervention. This change allowed us sufficient numbers of participants in 
each intervention group to assess the interventions acceptability and feasibility. 
However, the limitations of changing the study design to an unrandomised design 
means we were unable to obtain data on participant acceptance and retention rates 
when randomised according to a 2x2 randomised design. We have only obtained data 
on the acceptance of each intervention individually and not a standard care or 
combined intervention arm. We therefore cannot, as a result of this unrandomised 
pilot study, inform a power calculation for a full scale RCT study of Vitamin D 
supplementation and Online PA interventions in this study population. We can 
however estimate the numbers of participants required for each individual 
intervention based on previously published studies  e.g. McAlindon calculated for their 
Vitamin D supplementation study [92] that in order to detect a change of 2.2 units 
(effect size 0.54) in WOMAC Pain (scale 0-20) detectable to 80% power, 114 
participants are needed. Based on the screening and recruitment rates obtained for 
this pilot intervention study, 387,786 would need to be screened to obtain 114 
participants for a full scale RCT Vitamin D and Online PA intervention with similar 
power to previous full scale Vitamin D supplementation RCTs [92]. 
Another limitation of this study was the lack of success of our secondary care 
recruitment strategy which resulted in no recruitment of participants from the 
Liverpool study site. The failure of the recruitment strategy to recruit reduced 
participant numbers and resulted in some of the study design amendments discussed 
above. This also meant we were unable to explore the acceptability of recruitment 
from secondary care in participants. However large amounts of resultant feasibility 
data were collected from the secondary care site at Liverpool which allowed me to 
determine why this strategy was unfeasible in this study.  
Lastly, as the pilot intervention study was 3 months (12 weeks) in duration, it can only 
give us data on the feasibility of running and maintenance of the study interventions 
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over a short time period and not on feasibility and maintenance in the long term. This 
is important to establish, particularly regarding the PA intervention, as it has been 
reported that long term adherence to PA programmes (12 months) by older people 
(aged 55-70 years) lead to significant improvements in PA which are likely to improve 
overall health and to reduce risk of age-related diseases [175]. 
6.3 Recommendations and Future Research 
6.3.1 Recommendations from this PhD Project 
The results of this study are intended to inform the design of future trials of the 
interventions investigated. In light of the results from this pilot study, it may be more 
practically feasible to recommend a three arm RCT design, with a Vitamin D 
supplementation, Online PA intervention and control arm, where the effectiveness of 
intervention can be compared to controls. This design would require fewer 
participants and could estimate based on power calculations from existing studies of 
Vitamin D supplementation [90, 92] and Online PA interventions [262] in this study 
population and by incorporating recommendations from this pilot study. 
Recommendations based on the results of this study are summarised in Table 6.2.  
Future Study Recommendations 
Study Design - Providing the Vitamin D supplementation intervention 
during the winter period (October-April) would be ideal 
to avoid the confounding effect of cutaneous synthesis 
of Vitamin D from sunlight.  
Study Recruitment - Recruitment from primary care sites allows easy and 
quick screening of large numbers of people resulting in 
sufficient numbers of eligible study participants and is 
an acceptable form of recruitment for most participants. 
- Recruitment can be boosted using follow up mail outs or 
phone calls from the study team.  
- Assistance from the local commissioning group (North 
East Commissioning Service) was essential in the 
recruitment of GP practices in this study. Therefore 
obtaining the support of the local healthcare authority, 
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or commissioning group, should be sought when 
recruiting from primary care. 
Study Materials  - Completion of the consent form during the study visit 
was preferable to participants, giving participants the 
opportunity to ask questions and the researcher to 
check participant understanding of the study 
requirements.  
- Terminology regarding obesity and age should be 
presented with care to avoid offense to participants. 
Conducting a focus group with target population to 
select acceptable terms may be useful before finalising 
study materials.  
- Make the study design and allocation process simple, 
clear and understandable within the patient information 
sheet (PIS).  
- Delivery of study intervention materials by post was 
convenient and acceptable to participants. This should 
be followed up by a phone call from the researcher to 
talk through the study intervention instructions, to 
check participant understanding and to answer any 
participant questions. 
- Receipt of personal feedback on study outcome 
measures was important to participants. Participants 
recommended that in addition to information on study 
measures there should be information on how to 
continue improving their health after the intervention 
and that GPs are sent a copy of their feedback for 
review. 
Study Measurements - There were some minor issues raised by participants 
regarding accelerometers which included;  
o Comfort of the elastic belt used to attach 
accelerometer to trunk: advise participants to 
wear the device above clothing where possible. 
o Movement of the accelerometer and belt with 
activity: advise participants to pull belt through 
clothing belt loops, where possible, to keep belt 
in place. If this is not possible, provide 
alternative accelerometer attachment options 
(belt clips or watch straps).  
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o Concern of being monitored and what activities 
the monitor can record: during the study visit, 
the researcher should explain the nature of the 
device and what data are collected. In addition, 
include this information of the written 
instructions. 
o Concern that injury or illness reduces ‘normal’ 
activity at time of monitoring: provide 
participants with a log where they can note 
down any important occurrence such as illness 
or injury if they feel this would affect their 
activity results. 
Study Arm allocation/ 
Randomisation 
- Participants expressed a dislike of the idea of being 
allocated to a standard care group in this intervention 
study. Therefore, if resources allow, a placebo group 
should be used for the vitamin D intervention. 
Vitamin D 
intervention 
- As participants expressed concerns over side effects and 
intervention safety during the intervention, care should 
be taken to reassure participants of intervention safety 
and potential risks. Therefore all reported medical 
incidences and suspected side effects should be 
recorded carefully and reviewed by a clinician during the 
study. Serum 25OHD and Calcium should also be 
monitored throughout the study to ensure toxicity is not 
experienced.  
Web-based PA 
intervention 
- Provide training sessions before commencement of the 
pilot intervention study on the use of the POW 
Programme as well as written instructions and 
materials. 
- A subset of participants disliked the web-based format 
of the PA intervention. Therefore a multimodal method 
of intervention delivery should be considered with a 
web-based and paper based PA intervention formats 
offered to boost intervention engagement. 
- Concerns over potential injury and intervention side 
effects were mentioned by participants, such as flare up 
of symptoms by increasing activity. Therefore, as in this 
pilot study, researchers and study materials should 
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clarify the importance of gradually increasing activity to 
avoid injury and recommendation of appropriate types 
or activity for those with KOA. All side effects and 
injuries should be carefully recorded and reviewed by a 
clinician, with adjustments in PA adjusted during the 
study if necessary. 
- A part of the qualitative interview study participants 
suggested a range of improvements to the POW system 
which should be applied to future studies, including; 
improvements in the ease of use/clarity of the website's 
design and layout, reformatting of the online activity 
graph to display total activity per day rather than total 
activity per week, allowing participants to identify 
patterns of activity and setting up email updates on 
weekly activity for participants.  
Study Resources and 
Management 
- Study recruitment is labour and time intensive and 
therefore, if resources permit, specific study staff should 
be allocated to recruitment and assistance from 
research (e.g. CRN) and local authorities (e.g. 
commissioning groups) sought. 
- If study is conducted across different study sites, a study 
manager should be appointed at each site, with 
responsibility for promoting and running the study at 
that site. This splits the burden of study management 
amongst staff, reducing burden and improving study 
recruitment and outcomes.  
Table 6.2 Recommendations for improvements to protocols when conducting full-scale 
intervention studies based on pilot study findings 
6.3.2 Intervention applications and Scalability 
Our final recommendation for future work is to test these interventions in a large 
population in order to assess the intervention's appeal and scalability amongst the 
older, obese population with KOA. The is important to establish in full scale studies if 
there are potential beneficial effects of our pilot interventions on KOA symptomatic 
outcomes, as it is important to determine if these interventions can be delivered on a 
large scale. 
The advantage of the web-based PA intervention is that the online delivery means it is 
practically scalable to a large number of people simultaneously, cheap and easy to 
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deliver. It may also be possible to expand this intervention further to include a module 
within the web-based intervention regarding weight loss. This would be particularly 
relevant to our study population (identified as obese) and was a topic many pilot study 
participants expressed interest in during the qualitative interviews. It was remarked by 
some participants they had hoped to lose weight by participating in the PA 
intervention and so I surmise that adding a weight loss aspect to the intervention 
would be appealing to study participants. Additionally despite existing evidence that 
weight loss is beneficial in reducing risk of [303] and improving KOA progression and 
outcomes[107, 157, 304, 305], no web-based weight loss specific programme has been 
trialled amongst obese KOA participants with this aim of improving symptoms. This is a 
research gap which needs addressing and could potentially form part of a web-based 
self-help programme including a PA and weight loss intervention.  
Scaling out Vitamin D interventions may be more difficult to achieve as provision of 
supplements and medical monitoring (for clinical safety reasons) will be required, 
resulting in associated costs. Approaches which could be considered include prompts 
for GPs and clinics to perform regular serum 25OHD screening in KOA populations and 
provision of information regarding how to maintain sufficient Vitamin D levels 
throughout the year and the importance of this regarding health. 
As part of further pilot testing of these interventions I suggest a co-design approach 
with involvement and input from different user groups, e.g.  
 PPI to provide a participant centred input, particularly regarding materials and 
processes directly affecting participants in the study 
 Clinical management organisations, e.g. commissioning groups and CRN to 
suggest appropriate pathways for patient recruitment and to provide 
assistance in access to potential participants. 
 Clinical teams to suggest how the study may designed to successfully engage 
clinicians in research and identify which member of the clinical team may have 
capacity to engage with research 
By collating input from different potential user groups, it may be possible to provide 
further recommendations to refine and design an effective complex intervention to 
assess the effectiveness of vitamin D and online based PA in obese older KOA patients.   
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